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Abstract 
 
Cancer is expected to rank as the most significant global public health problem 
and a leading cause of death and illness in the world in the 21st century. The burden 
of cancer is rapidly increasing globally, including Australia. The responses to this 
growing burden of cancer have been limited owing to a poor understanding of the 
long-term burden of cancer and its consequences. The overarching aim of this 
thesis is to investigate the burden of cancer on patients, households, as well as on 
society over time. This thesis also aims to generate evidence for health 
policymakers, who make nationwide cancer control and management decisions on 
cancer prevention (e.g., cancer vaccination) and cancer treatment programs. This 
thesis has examined the burden of cancer using a geographical lens, including 
regional, rural, and remote areas in Australia. To accomplish this aim, five 
empirical studies for assessing the impact of the cancer burden in terms of long-
term cancer outcomes (an incidence-based approach); health status burden, 
chronic comorbid conditions, productivity-related work disability (mixed-
longitudinal approach); and the economics of cancer vaccination (economic 
evaluation) have been conducted.  
 
This thesis is constructed using three main themes of study including 
‘understanding the challenges of cancer outcomes’, ‘the long-term cancer burden 
(i.e., health status burden, chronic comorbid conditions, productivity-related work 
disability, and its consequences)’, and ‘evaluation of cancer vaccination’ in the 
context of Australia. These inter-related studies result in a thesis by publication. 
These studies are constructed based on a quantitative approach, using health 
economic evaluation and advanced statistical modelling. The thesis is based on six 
articles, national health data sets are utilised for the first article, three of them 
(Articles 2 to 4) being mixed-longitudinal nature survey-data driven from the 
Household Income and Labour Dynamics in Australia survey, and two of them 
(Articles 5 and 6) based on national and international contexts and published data 
sources related to cancer and health economics modelling.  
 
The findings of this thesis have been theorised inductively, which means the 
analytical exploration has been data-grounded, rather than theory-dictated. In this 
thesis, every finding is underpinned by a suitable theoretical framework. Three 
inductively generated theories are adopted: social conflict theory, stress-coping 
theory, and portfolio theory perspectives.  
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The thesis revealed that all of these factors (e.g., cancer incidence, hospitalisation, 
cancer-related mortality, and burden of cancer) increased significantly over the 
period. Furthermore, survival inequality was most pronounced for cervix, prostate, 
melanoma, Non-Hodgkin Lymphoma, and breast cancers. Additionally, socio-
economically disadvantaged people were more likely to bear an increasing cancer 
burden in terms of incidence, mortality, and death. The findings of the thesis 
showed that approximately 36% of cancer patients had an initial high health status 
burden in 2013, which had declined significantly to 21% by 2017. Adequate levels 
of sleep, physical activity, social support, and higher economic status were 
significantly associated with improving health status.  
 
This thesis revealed that 61% of cancer patients experienced at least one chronic 
condition over the period, and 21% of patients experienced three or more chronic 
conditions. An inadequate level of physical activity, patients who suffered from 
extreme health burden or moderate health burden, and patients living in the poorest 
households were significantly associated with a higher risk of chronic comorbid 
conditions. This research also found that approximately 50% of cancer patients 
had experienced with long-term productivity-related work disability, 18% of 
patients had experienced extreme work disability, which was more pronounced 
with the magnitude of their health status burden. Finally, cancer prevention 
program (cancer vaccination) demonstrated ‘good value for money’, if the adopted 
vaccination strategies could accomplish a high vaccination coverage and provide 
protection. With a continued assessment of the potential vaccine properties as well 
as vaccine delivery and scale-up strategies, the two-dose 9vHPV vaccine would 
provide significant health and economic benefits for preadolescents and society.  
 
This thesis provides a better understanding of the challenges of cancer outcomes 
and long-term consequences on health status burden, chronic comorbid conditions, 
and productivity-related work disability, and has provided an evaluation of cancer 
vaccination for preventing cancer-related infections, along with contributing to the 
ongoing debate of cancer research. The findings are also significant for health care 
providers, including physical therapists and oncologists, who must manage the 
unique problems that challenge this population and who should advocate for 
prevention and evidence-based interventions that incorporate comprehensive 
social supports. The findings of this thesis will contribute to the decision-making 
process regarding the prevention of cancer illness, better outline the management 
of a sequelae course of treatment for cancer survivors, both of which aim to reduce 
the long-term burden in Australia.  
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Chapter 1: Introduction 
1.1 Introduction 
   
The overarching aim of this thesis is to investigate the burden of cancer on 
patients, households, as well as on society over time. This thesis also aims to 
generate evidence for health policymakers, who make nationwide cancer 
control and management decisions, though, for example, the introduction of 
early cancer prevention programs (e.g., cancer vaccination). This thesis has 
examined the burden of cancer using a geographical lens, including regional, 
rural, and remote Australia. The thesis has also further examined the impact 
of the cancer burden in terms of long-term cancer outcomes, health status 
burden, chronic comorbid conditions, work-related disability and the 
economics of cancer vaccination. A quantitative approach is adopted in this 
thesis. This is a thesis by publication. In this introduction section, the cancer 
background context is explained as a public emergency, and the ongoing 
debate about cancer research is discussed, as well as the rationale of this 
thesis in the Australian context explained. It concludes with a conceptual 
framework which underpins this thesis. 
 
1.2 Background and rationale   
 
Noncommunicable diseases (NCDs) are accountable for the majority of 
global deaths (World Health Organization, 2019). Cancer is expected to rank 
as the most significant global public health problem and a leading cause of 
death and illness in the world, including Australia, in the 21st century (Bray, 
Ferlay, & Soerjomataram, 2018; Fitzmaurice et al., 2018; GBD 2015 
Mortality and Causes of Death Collaborators, 2016; Niessen et al., 2018; 
Yabroff et al., 2011; AIHW, 2019c). In 2019, it was estimated that almost 
145,000 new cases of cancer would be diagnosed in Australia, and that 35% 
of these individuals will eventually die from the disease (AIHW, 2019a). 
Cancer accounts for the highest burden of disease of any illness, at 
approximately 18%, followed by cardiovascular disease (14%), 
musculoskeletal disorders (13%) and mental health (12%) (AIHW, 2019b). 
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Despite tremendous progress made over the last couple of decades in terms of 
cancer survival and mortality rates, the cancer incidence rate has increased by 
58% between 1982 and 2019 (AIHW, 2019a). The burden of cancers (e.g., 
lung, bowel, prostate and pancreatic) increases significantly with remoteness 
from treatment sources and for those individuals living in depressed socio-
economic circumstances (Valery et al., 2006; Coory et al., 2013; Teng et al., 
2017).  
 
In Australia, approximately 40% of cancer patients are of working age 
(AIHW, 2019a). Among those in employment, 46% are unable to return to 
work after an episode of cancer (Bates et al., 2018), and 67% on their return 
to employment or change their job (Paul et al., 2016). The majority of cancer 
survivors depend on family, relatives and friends for physical and economic 
support during their treatment and/or in the last stages of the disease (Doran 
et al., 2015; Paul et al., 2016; Bates et al., 2018; CanTeen Australia, 2018).  
 
The costs of advanced cancer treatment are a growing concern globally 
(Luengo-Fernandez et al., 2013), including in Australia (Sullivan et al., 2011; 
OECD, 2013; Karikios et al., 2014; Vogler et al., 2016). Spending on cancer 
constitutes approximately 5% of health-care costs in Organisation for 
Economic Co-operation and Development (OECD) countries, and this 
number is increasing (OECD, 2013). This surge is attributable to increasing 
incidence and prolonged survival, but also to the high costs of new drugs and 
technologies (Sullivan et al., 2011; Kelly and Smith, 2014). In Australia, 
public pharmaceutical expenditure on cancer drugs increased significantly 
from A$65 million in 1999–2000 to A$466 million in 2011–2012, with an 
average increase of 19% per year (Karikios et al., 2014). Access to cancer 
medicine remains a major public health challenge, even in high-income 
countries such as Australia (Vogler et al., 2016). The increasing costs 
associated with cancer treatment are not driven exclusively by higher demand 
for services (Sullivan et al., 2011). This nevertheless creates major 
challenges for healthcare systems, particularly those like Australia’s that are 
publically funded. However, the ability to deliver affordable cancer care is 
problematic due to a volatile mixture of demographics (ageing and expanding 
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populations), rapid development of new technologies (such as medicines and 
surgery), and increasing health care expenditure which is driving cancer-care 
costs upwards (Karikios et al., 2014; Kelly and Smith, 2014; Vogler et al., 
2016).   
 
As the overall cancer burden increases, the economic loss due to premature 
cancer-related illness and associated mortality poses the main challenges to 
poverty alleviation efforts. Furthermore, cancer-related illness results in a 
number of patients and their households experiencing economic hardship due 
to high out-of-pocket expenses, lost productivity, loss/reduction of household 
income, and other induced expenditure (Doran et al., 2015; Paul et al., 2016; 
Bates et al., 2018; Gordon et al., 2018). Catastrophic healthcare expenditure 
has been found to occur in more than 60% of diagnosed cancer patient’s 
households (Jan et al., 2018).  
 
The economic burden of cancer is of growing concern for policymakers, 
healthcare practitioners, physicians, employers, and society overall (Doran et 
al., 2015; Paul et al., 2016). Considerable progress has been made in recent 
decades in terms of cancer survival and reduced mortality rates (Tiwari and 
Roy, 2012; Allemani et al., 2018) through the introduction of primary 
preventive strategies (e.g., vaccination) and effective collaboration with non-
government organisations and other potential stakeholders, including 
community groups. Therefore, a reduction of cancer incidence, along with 
improvements in cancer treatments and survival rates, is essential to reduce 
the burden of the disease. 
 
The increased burden of cancer-related illnesses, together with advanced 
treatment procedures (including technological innovation) and intensified 
patient, community, and provider expectations, impose challenges to the 
affordability as well as affability of health care services for households and 
governments alike. As a chronic condition, cancer-related illnesses can lead 
to a devastating, long-term health and economic burden for individuals and 
their households, particularly in resource-constrained settings. Many patients 
with cancer-related illness are confronted with the choice of either opting for 
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treatment, thereby reducing resources available for their families possibly 
leading to poverty, or declining treatment, which also has adverse health and 
economic consequences for the individual and their household. For example, 
21% of the Australian population with diagnosed cancer  have ‘skipped’ 
health care services due to the high health care costs (Callander et al., 2017).  
 
Health systems that protect individuals and their households from the 
economic circumstance of NCDs, including cancer, are pivotal if the United 
Nation’s Sustainable Development Goals (SDGs) of ineqalities reduction is 
to be achieved. However, health and economic outcomes are associated with 
social disadvantage, increases an individual’s risk of chronic disease, and 
pre-disposes them and their households to illness-related poverty and 
economic hardship through loss of employment and high out-of-pocket costs 
(Callander et al., 2017, 2019; Jan et al., 2018). This association between 
NCDs and poverty is identified in the SDGs, and some of the goals relate 
directly to measures that reduce the burden of NCDs (e.g., reducing 
premature deaths from NCDs by 30%), and strengthening access to essential 
medicines and universal health coverage. In Australia, the number of cancer 
patients (due to the demographic transition such as an ageing population) will 
increase, and course of treatment protocols will be more complex, and 
therefore more expensive. The challenge of the health system is how to 
collectively deliver reasonably priced cancer health care services to all 
exposed citizens i.e., make cancer care affordable for individuals and society 
alike. This is needed to inform and guide this essential public debate amongst 
leading members of the cancer community, from patient advocates to 
economists and health-care professionals. 
 
1.3 The ongoing debate on cancer research 
The ongoing debate about cancer research in Australia has been extended to 
include issues such as over-diagnosis, accessibility, prevention, and societal 
benefits, with a particular focus on the burden of the cancer disease for 
patients, households and society. Over-diagnosis is an extremely vexing 
issue. It can lead to over-treatment of cancer patients (Bleyer and Welch, 
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2012) and confers short- and long-term risks (Bach, 2008). Consequently, 
cancer patients often experience other chronic comorbid conditions (Bach, 
2008; Braithwaite et al., 2016) and it imposes a higher physiological burden 
of disease (Stairmand et al., 2015). The presence of specific severe 
comorbidities or psychiatric disorders is associated with delayed cancer 
diagnosis (Sogaard et al., 2013). Furthermore, patients with chronic diseases, 
who have regular medical consultations and follow-up, have their cancer 
detected at an earlier stage. Thus, any amount of over-diagnosis increases the 
overall treatment costs (Carter and Barratt, 2017). 
 
Similarly, equitable access to health services (e.g., access to new cancer 
medicine) is also highly contentious in the context of Australia (Vitry et al., 
2016). Moreover, there is an equity concern across regional Australia because 
cancer patients they have less opportunity to receive health care services than 
patients in urban areas (Deloitte Access Economics, 2013; Vitry et al., 2016). 
In the perception of most stakeholders, the ongoing debates about cancer 
research are challenging and inevitably emotive from the perspective of 
patients, family, and society (Deloitte Access Economics, 2013). In addition, 
this debate draws attention as to how Australian society should value the 
advantages of cancer prevention and control innovations, and how to best 
facilitate equitable patient access to health care through fair and transparent 
resource allocation mechanisms, which is a priority concern of cancer 
research in Australia.  
 
1.4 Emerging risk of cancer 
The World Health Organization (WHO) has reported that approximately 30-
50% of all cancer cases are preventable (WHO, 2019a). There is also a 
number of avoidable risk factors which contribute to an increasing incidence 
of cancer. In addition, prevention and early detection of cancer, supported by 
national policies and programs, are the most cost-effective long-term 
strategies for the control of cancer. These should be implemented to increase 
public awareness, to reduce exposure to cancer risks and to ensure that 
people are provided with the relevant information and support they need to 
adopt healthier lifestyles. 
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(a) Tobacco use 
The harmful use of tobacco is one of the leading avoidable risk factors for 
cancer incidence and cancer-related mortality. Worldwide, approximately 
6 million people die each year from cancer and other NCDs (WHO, 
2019a). Tobacco smoking contributes to the development of several types 
of cancer (e.g., cancers of the lungs, larynx, mouth, throat, kidneys, 
bladder, pancreas, stomach, cervix, and oesophagus). A recent study 
conducted in Australia found that approximately 13% of all cancers were 
attributable to exposure to tobacco smoking, including 81% in lungs, 
60% in oesophagus, 59% in oral cavity and pharynx, and 6% in colorectal 
cancers (Pandeya et al., 2015). Cancer Australia reported that more than 
one in eight cancers are attributed to tobacco smoking, and could be 
avoided if nobody smoked (Cancer Australia, 2014a). Strategies to reduce 
the prevalence of smoking remain a high priority for cancer control 
authorities (WHO, 2013; Cancer Australia, 2014a). 
 
 
(b) Alcohol use 
The harmful use of alcohol is a serious health burden. Health problems 
from excessive alcohol use arise in the form of acute and chronic 
conditions, and adverse social consequences are common. Alcohol 
consumption is a dominating risk factor for developing many cancer 
types (e.g., cancer of the liver, colorectal, oral cavity, pharynx, larynx, 
oesophagus, and breast) (Meyer et al., 2019; Wilson et al., 2019). The 
risk of cancer increases with the amount of alcohol consumed (Chu et al., 
1990; Grevers et al., 2019; Meyer et al., 2019; Wilson et al., 2019). For 
several types of cancer, heavy drinking of alcohol, combined with the use 
of tobacco, predominantly increases the high risk of cancer (Chu et al., 
1990; Grevers et al., 2019; Meyer et al., 2019; Wilson et al., 2019). To 
combat alcohol abuse, most global strategies focus on key areas of policy 
regulation and enforcement (WHO, 2013, 2018a, 2019a; Cancer 
Australia, 2014a). Through public health advocacy and partnerships, 
national interventions focus on resource mobilisation, the provision of 
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technical support and capacity building, and knowledge dissemination 
(WHO, 2013, 2018a, 2019a; Cancer Australia, 2014a). 
 
(c) Physical inactivity, dietary factors, and obesity 
Dietary modification is another significant mode of controlling cancer-
related illness. There is a significant association between obesity and 
many types of cancer (e.g., oesophagus, colorectal, breast, endometrium 
and kidney cancer). For example, diets high in meat and reduced fibre are 
associated with colon cancer. Fruits and vegetables may have an 
independent protective effect against many cancers (Ambrosini et al., 
2008; Lee et al., 2017; Afshin et al., 2019; WHO, 2019b). Furthermore, 
an adequate level of physical activity and the maintenance of a healthy 
body weight, along with a healthy and balanced diet, reduces cancer risk 
significantly (Loprinzi et al., 2012; Afshin et al., 2019; Lacombe et al., 
2019). Therefore, healthy eating practices that prevent the development 
of diet-related cancers will also lower the risk of other NCDs. Improved 
prevention strategies are needed to encourage individuals to implement 
improved lifestyle habits. 
 
(d) Infections 
A number of human oncogenic infectious agents, for instance human 
papillomavirus (HPV), helicobacter pylori, hepatitis B and C, and the 
Epstein-Barr virus, are significantly attributed in 15% of all cancers 
worldwide (WHO, 2019a). Persistent infections with HPV are a key 
cause of cervical cancer and it is an established carcinogen of cervical 
cancer (Forman et al., 2012). HPV is predominantly transmitted to 
reproductive-aged women through sexual contact (CDC, 2015). Most 
HPV infections are transient, and individuals are cured within a short 
duration of time, usually within a few months after their acquisition. 
However, HPV infections can continue and evolve into cancer without 
treatment. There are more than 100 types of HPV infections that have 
been identified so far and they can be divided into low- and high-risk 
types in terms of developing into cervical cancer (Mennini et al., 2017). 
Thirteen high-risk HPV types are known to be predominantly responsible 
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for malignant and premalignant lesions of the anogenital area (Guan et 
al., 2012), and they are the leading cause of the most aggressive cervical 
cancers (Li et al., 2011). Furthermore, HPV is also responsible for the 
majority of anogenital cervical cancers, such as anal cancers (88%), 
vulvar cancers (43%), invasive vaginal carcinomas (70%), and all penile 
cancers (50%) (Mennini et al., 2017). Cervical cancer is preventable 
through implementation of a primary prevention strategy such as 
vaccination (Jit et al., 2014; Patel et al., 2018). 
 
Helicobacter pylori (HP) is a gastric pathogen that colonises 
approximately 50% of the world's population (Wroblewski et al., 2010). 
Infection with HP causes chronic inflammation and significantly 
increases the risk of developing duodenal and gastric ulcer disease and 
gastric cancer. Infection with HP is the strongest known risk factor for 
gastric cancer, which is the second leading cause of cancer-related deaths 
worldwide. Once HP colonizes the gastric environment, it persists for a 
lifetime in the host, suggesting that the host immune response is 
ineffective in clearing this bacterium (Wroblewski et al., 2010). 
 
The viral hepatitis pandemic takes a heavy toll on lives, communities and 
health systems (Orlando et al., 2015). Cancer caused by infection with 
the Hepatitis B virus (HBV) is a major global health problem (WHO, 
2019c). It is estimated that approximately 257 million people are infected 
with HBV, which is defined as hepatitis B surface antigen-positive–
HBVsAgþ (WHO, 2019c). As a consequence, HBV resulted in 887,000 
deaths, predominantly from cirrhosis and hepatocellular cancer, in 2015 
(WHO, 2019c). The virus is highly infectious and abundantly found in 
blood and body fluids of infected persons, many of whom are 
asymptomatic and unaware of their disease (Orlando et al., 2015). 
Furthermore, HBV is transmitted via the parenteral route, infusion of 
infected blood or blood products, needle sharing, penetration of micro-
wounds on skin or mucosae. (Orlando et al., 2015; WHO, 2016a, 2019c).   
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Since 1982, HBV infection has been preventable by vaccination. The 
HBV vaccine is one of the most effective vaccines of neonates and 
infants, resulting in decreased rates of new infections and chronic liver 
disease, including cancer and hepatocellular carcinoma (Mikaeloff et al., 
2001). Currently, 130 countries, including Australia, implement the 
hepatitis B vaccine in their routine vaccination schedules for infants 
and/or adolescents (Goldstein and Fiore, 2001). In Australia, vaccination 
against hepatitis B was introduced in the early 1980s and targeted those at 
most risk of infection (AIHW, 2018a). Free infant vaccination was 
implemented in 1990 in the Northern Territory and was eventually rolled 
out nationally in 2000 (AIHW, 2018a). The Australian National 
Immunisation Program now provides vaccination against hepatitis B at 
birth and during infancy. Vaccination is also recommended for some 
adults who are at higher risk, for instance, people who have had organ 
transplant, people with certain liver or kidney problems, and people who 
travel to countries where hepatitis B is common. In 2017, 95% of 
Australian one-year-olds were fully vaccinated against hepatitis B 
(AIHW, 2018a; Ioannides et al., 2019). The current strategies for 
controlling HBV infection include active immunization, passive 
immunization and chemoprophylaxis with antiviral drugs (Orlando et al., 
2015; WHO, 2016a). Passive immunization and chemoprophylaxis can 
also contribute to the control of HBV infection. 
 
1.5 Australian health care system 
As a national goal, the Australian’s health system (AHS) provides quality and 
affordable health care services for all Australians. All three levels of 
government are involved: federal (financing), state and territory (funding and 
service delivery), and local (service delivery) (Australian Government, 
2019a). The foundation of AHS is the publically funded national universal 
health insurance scheme, Medicare, and its predecessor Medibank, which 
commenced in the 1970s to promote universal health care by providing safe 
and affordable health care services for Australians. Through Medicare, 
patients are able to access free or subsidised medical services, treatment in 
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public hospitals free of charge, and receive subsidises with respect to some 
procedures provided in private hospitals. Through the pharmaceutical 
benefits scheme, patients are also able to receive a subsidy for medicines. 
Those eligible to access health care services through Medicare include 
Australian and New Zealand citizens, permanent residents of Australia, and 
individuals who have applied for a permanent visa (Department of Health, 
2019). Patients are provided with a rebate benefit for health care services for 
out of hospital services. However, overseas student health cover (OSHC) is 
mandatory for all international students, to ensure that they and their 
dependents can access affordable healthcare whilst living and studying in 
Australia.  
 
The rebate amount is case-dependent. For example, for a consultation with a 
General Practitioner, specialist or consultant physician, with a duration of at 
least 10 minutes for a cancer patient to develop a multidisciplinary treatment 
plan, the scheduled payment was $81.50 in 2019, and the benefit was 100% 
of the scheduled fee; hyperbaric oxygen therapy associated with treatment of 
localised non-neurological soft tissue radiation injuries had a scheduled fee of 
$254.75 and the benefit was 75% of the schedule fee, or $191.10 
(Department of Health, 2019). While public hospitals are free of charge, the 
majority of out of hospital health care services are provided by private health 
providers. The actual amount of fees for service is set by the providers 
themselves and are not regulated, meaning that private healthcare providers 
can have fees above the scheduled payment. Any difference between the 
amount of the provider's fee for a service and the amount of rebate is paid by 
the patient from their out-of-pocket (OOP) expenses. For example, if the 
actual amount charged by the provider is $81.50 for a diagnostic (e.g., blood) 
test, Medicare would provide a rebate of $61.10 (75% of the schedule fee), 
leaving the patient to pay $20.40. Medicare has additional policies to protect 
patients from catastrophic OOP healthcare payments. In this context, health 
care cards are provided to welfare recipients and low-income earners, and 
other eligible patients who pay a lower OOP payment for prescription 
medicines (Department of Human Services, 2019a).  
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The ‘Medicare Safety Net’ and ‘Extended Medicare Safety Net’ programs 
also provide higher rebates if an individual or family group reaches a certain 
level of total expenditure on OOP fees within a calendar year. Any 
subsequent services or prescriptions will have a higher proportion of subsidy 
for the rest of that calendar year (Duckett and Willcox, 2015). Under the 
‘Medicare Safety Net’, once the threshold has been reached then 100% of the 
schedule fee for all health care services is rebated; and under the ‘Extended 
Medicare Safety Net’ 80% of the actual OOP payments is rebated 
(Department of Human Services, 2019b).  
 
1.6 Existing studies  
1.6.1 Unequal distribution and emerging burden of cancer outcomes 
Cancer is a life-threatening disease that leads to a huge health and economic 
burden during the treatment and oncology follow-up periods. However, 
certain groups (e.g., those affected by disability, remoteness, and 
disadvantaged socioeconomic status) of the population are more prevalent in 
bearing a disproportionate burden of cancer outcomes (e.g., incidence, 
mortality, hospitalisation) compared with other more advantaged groups 
(Heathcote and Armstrong, 2007; Elwood et al., 2016; Bergin et al., 2018; 
Goodwin et al., 2018; Arnold et al., 2019; Khan; et al., 2019). The 
magnitude of comorbid conditions (during course of treatment and follow-up 
periods) among cancer patients in Australia is also more pronounced for 
people aged 65 years and over (87%) compared with people aged 0-44 
(35%); people from a deprived socioeconomic background (55%) compared 
with their more advantaged counterparts (47%); and people living in regional 
and remote areas (54%) compared with those in the major cities (48%) 
(AIHW, 2016a).  
 
In Australia, economic disparities between socio-economically advantaged 
and disadvantaged individuals and groups are increasing as a result of the 
growing burden of cancer (Coory et al., 2013). There are several reasons that 
might contribute to this disparity, directly or indirectly. The paucity of 
appropriate health care services is significantly worse in resource-constrained 
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settings, including geographically underprivileged locations compared to 
privileged people and communities with easier access to a greater range of 
cancer services, improved knowledge and awareness of cancer prevention 
strategies, and better and more easily accessible health facilities and 
resources (Blinman et al., 2012; Coory et al., 2013; Cancer Australia, 2014). 
Other common reasons for such disparities include limited affordability and 
accessibility of cancer care services for population of socio-economically 
underprivileged groups (Valery et al., 2006), and their inadequate utilisation 
of healthcare services (Bernardes et al., 2012). This imbalance contributes to 
an increasing burden of cancer outcomes and leads to a greater burden for the 
individual, family and society, which is exacerbated for the more 
underprivileged. 
 
In the recent past, disparities related to cancer outcomes have become the 
subject of an international focus and new service initiatives (Yabroff et al., 
2011; Fitzmaurice et al., 2018). In 2016, the WHO Executive Board 
recommendation was to strengthen health systems to ensure early detection 
and diagnosis, as well as enable accessible, affordable, and appropriate and 
quality healthcare services for all patients with cancer (WHO, 2016b). Only a 
few studies have focused explicitly on socio-economic inequality of cancer 
care and healthcare utilisation in Australia. In recent decades, the incidence 
of cancer has increased (Baade et al., 2010; Adama et al., 2018; Allemani et 
al., 2018; Bray et al., 2018; Luo et al., 2019), which has been more 
pronounced among adolescents and young adults (Roder et al., 2018), and 
older adults (Feletto et al., 2019), yet cancer-related mortality rates have 
slightly dropped (Carioli et al., 2018). In Australia, some types of cancer 
have the highest rates in the world: melanoma (Roder et al., 2018), 
keratinocyte, and melanocyte (Lai et al., 2018). Australia and New Zealand 
together have the highest rates for merkel cell carcinoma (Stang et al., 2018; 
Lee et al., 2019). Some of these studies have focused on geographical or 
socioeconomic disparities in cancer care and survival (Fox and Boyce, 2014; 
Baade et al., 2016; Stanbury et al., 2016; Tervonen et al., 2016a, 2016b, 
2017b, 2017a).  
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1.6.2 Long-term health status burden of cancer patients 
Studying health status among cancer survivors is warranted, and has attracted 
considerable attention in the public health domain. Even with advanced 
treatment of side effects, cancer survivors undergo experiences that often 
reduce their capacity to conduct their usual activities, which in turn may 
affect their overall health status. In recent decades, measuring health status 
has been integrated into the examination of treatment impacts on quality of 
life (Tan et al., 2019). Health status assessments have become routine and are 
used to evaluate health status in terms of treatment outcomes (Arraras et al., 
2018; Su et al., 2019; Tan et al., 2019). Despite this, very little attention has 
been paid to measuring the longitudinal health status burden of diagnosed 
cancer survivors during the oncology follow-up period. 
 
Some studies have focused on the impact of treatment or surgical outcomes 
in relation to health status, and access to palliative care in different national 
settings (Elliott et al., 2004; Dunn et al., 2013; Thomas et al., 2014; Garvey 
et al., 2016; Haugland et al., 2016; Arraras et al., 2018). The health status of 
cancer survivors can be adversely affected by side effects (Shin et al., 2017), 
such as compromised nutritional status (Capuano et al., 2010), and eating 
problems (Spielman, 1998). Moreover, engaging in physical activities can 
lead to improved health status outcomes among cancer survivors (Shin et al., 
2017). Similarly, cancer survivors who engage in less sedentary behaviour 
enjoy a better quality of life, and this can also significantly contribute to 
reducing the risk of chronic comorbid conditions (AIHW, 2017). 
Furthermore, the comorbid condition of cancer survivors is an important 
parameter to predict poor health status (Der-Martirosian et al., 2013; Banham 
et al., 2018).   
 
 
1.6.3 Long-term chronic comorbid conditions of cancer patients 
Most cancer patients suffer from multiple chronic diseases or conditions, 
commonly referred to as comorbidity. Comorbidity has a well-documented 
detrimental effect on cancer survival (Sarfati et al., 2016a) and it describes 
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the existence of a long-term health condition or disorder in the presence of a 
primary disease or illness (Sarfati et al., 2016b). A number of studies have 
confirmed that comorbid chronic conditions were more pronounced among 
cancer patients (Gross et al., 2007; Sarfati et al., 2009; Sogaard et al., 2013; 
Lindhagen et al., 2015; Siegel and Wisnivesky, 2017; Cuthbert et al., 2018; 
Ng et al., 2018). The most prevalent risk factors are amongst older 
population groups (aged 65 years or more) (Yancik et al., 2001; Yun et al., 
2007), tose with unhealthy behaviours (e.g., alcohol consumption and 
smoking tobacco) (Grimmett et al., 2009; Ezzati and Riboli, 2013), obesity 
(Loprinzi and Cardinal, 2012) and inadequate diet (Ezzati and Riboli, 2013). 
These factors are significantly associated with a higher risk of developing 
cancer along with chronic comorbid conditions (Ezzati and Riboli, 2013; 
Stairmand et al., 2015; AIHW, 2018b). The ongoing evidence shows that 
modifying or avoiding risk factors can significantly reduce the burden of 
chronic comorbid conditions among cancer patients (WHO, 2018b). 
 
The risk of having comorbidity increases during treatment as well as 
oncology follow-up periods (AIHW, 2018b, 2019c; WHO, 2018c), which can 
adversely influence treatment choices and health outcomes. Chronic 
comorbid conditions of cancer patients contribute to major clinical 
challenges, including diagnosis, ill health, treatment, long-term health 
conditions and disease management (Stairmand et al., 2015). In 2014-15, 
more than 11 million Australians (50%) reported having at least one chronic 
disease, while approximately 1 in 4 (23%) Australians had two or more 
chronic conditions (AIHW, 2016a). The severity of comorbidity contributes 
significantly to an increased risk of hospitalisation, reduced health status, 
increased risk of mortality, and increased financial burden on the healthcare 
system (Carstensen et al., 2012; Sogaard et al., 2013; Sarfati et al., 2016a). 
The chance of improving health status and completing cancer treatment 
protocol in the presence of comorbid conditions is considerably lower among 
cancer patients (Elliott et al., 2004; Sarfati et al., 2009; Gurney et al., 2015; 
Cuthbert et al., 2018; Ng et al., 2018). There is a significant association with 
a higher rate of mortality depending on the severity of the disease and 
associated comorbidity (Sogaard et al., 2013). For instance, the mortality rate 
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is substantially higher among cancer patients with comorbidities (47%) 
compared with cancer patients without comorbidities (34%) (Van Hemelrijck 
et al., 2016).  
 
1.6.4 Impact on long-term productivity of cancer patients 
Internationally, some studies have focused on cancer survivors’ 
characteristics and work participation, including those in the United States of 
America (USA) (Feuerstein and Harrington, 2006; Short et al., 2008; Oberst 
et al., 2010; Mehnert, 2011; Mehnert et al., 2013; Tangka et al., 2013; 
Chrischilles et al., 2019), Canada (Lauzier et al., 2008; Jones et al., 2016), 
South Korea (Park et al., 2009), the Netherlands (Muijen et al., 2013a, 
2013b, 2014), and Belgium (Sullivan et al., 2004; Kiasuwa Mbengi et al., 
2018).  
 
Several factors adversely influencing work participation of patients with 
cancer have been determined in different settings, such as poor economic 
position (Muijen et al., 2013a, 2013b, 2014; Chrischilles et al., 2019), 
disease-related factors (e.g., tumour site, advanced tumour stage), side effects 
of advanced treatment (e.g., chemotherapy) (Muijen et al., 2013a; Yokota et 
al., 2015; Jones et al., 2016; Chrischilles et al., 2019), and work-related 
factors (e.g., physical work demands) (Mehnert, 2011; Muijen et al., 2013b). 
The severity of diseases and the presence of comorbid conditions in cancer 
patients create a higher likelihood of work-related disability (Jones et al., 
2016). A previous study conducted in the Netherlands found that cancer 
survivors who had experienced hormone therapy to treat metastatic disease, 
had limited physical strength, and limited workability was strongly and 
adversely associated with a higher risk of work disability (Muijen et al., 
2013a, 2014). The poor perceptions of cancer survivors, in terms of their 
health and workability (Muijen et al., 2013a), their unhealthy behaviours 
(e.g., alcohol consumption), and their clinical-stage (Vartanian et al., 2006) 
were also significant predictors in determining independent effects on their 
work disability levels. In the context of Australia, some studies among cancer 
patients have examined the psychological effects of current treatment or level 
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of disability (Banks et al., 2010), association with work-related stress and 
chronic illnesses, including cancer (Renzaho et al., 2013), and lost 
productivity due to cancer (Bates et al., 2018).  
 
 
1.6.5 Economic of cancer prevention (vaccination) in Australia 
Early prevention mechanisms include vaccination, diagnosis, effective 
screening, adequate referral and advanced course of treatment procedures. In 
this context, HPV vaccinations (i.e., bivalent and quadrivalent) have been 
introduced in many countries in the past decade (Jit et al., 2014). Currently, 
available HPV vaccines can promote herd immunity against cancer-causing 
types of HPV, which helps to reduce the high-risk of the cervical cancer 
burden. These vaccines have played a significant role in preventing HPV 
infection types 16 and 18 (Jit et al., 2014), which cause more than 70% of 
cervical cancers in Australia (Li et al., 2011).  
 
In 2007, Australia was the first country to implement a publicly-funded 
National HPV Immunisation Program (NHIP), starting with pre-adolescent 
girls, using the quadrivalent Gardasil® vaccine (4vHPV; Merck & Co., 
Kenilworth, NJ, USA) (Georgousakis et al., 2012). This program for 
adolescents employed a three-dose schedule of the 4vHPV vaccine 
(Australian Government, 2019b). The 4vHPV vaccine provides protection 
against HPV infection types 6, 11, 16, and 18 (Smith and Canfell, 2017). 
Later in 2018 in Australia, the 4vHPV vaccine was replaced by the two-dose 
nonavalent Gardasil®-9 vaccine (9vHPV; Merck Sharp & Dohme) (Office of 
the Prime Minister of Australia, 2017). According to the underlying 
distribution of HPV infection types of cervical cancers, the 9vHPV vaccine 
builds population-level strong immunity against HPV-6, 11, 16, 18, 31, 33, 
45, 52, and 58 infections (Guan et al., 2012) that cumulatively contribute to 
approximately 89% of all cervical cancers globally (Serrano et al., 2012) and 
93% in Australia (Brotherton et al., 2017). Considering the primary 
prevention of HPV infection, the 9vHPV vaccine is anticipated to reduce, by 
10%, the lifetime risk of a diagnosis of cervical cancer in immunised cohorts 
 
Chapter 1: Introduction 
 
18 
 
compared to the 4vHPV vaccine, and by 52% compared to non-vaccinated 
cohorts (Simms et al., 2016).  
 
With the availability of vaccines for the different HPV infection types, there 
are good opportunities for primary prevention to add to continuing efforts 
related to secondary prevention strategies. However, the decision for any 
country to add a new vaccine to national immunisation programs requires 
careful assessment of the relative value of the vaccine compared with 
alternative uses of the required resources (i.e., cost-effectiveness) and its 
affordability (i.e., budgetary impact).  
 
There is considerable evidence that attest to the cost-effectiveness of the 
9vHPV vaccine in different country settings. In Canada, the 9vHPV was 
found to be highly cost-effective compared with the 4vHPV vaccine, taking 
into consideration the shorter duration of protection (9vHPV = 20 years vs. 
4vHPV = lifelong), along with a lower vaccine efficacy (85% vs. 95%) 
(Drolet et al., 2014). In other studies conducted in the USA, the 9vHPV 
vaccine was also found to be very cost-effective compared to the 4vHPV 
vaccine (Chesson et al., 2018). However, findings of cost-effective 
evaluations differ based on study settings, funding, perspectives and coverage 
of vaccination.  
 
For example, in the USA, Chesson et al. (2016) found that the 9vHPV vaccine 
was not cost-effective, with an incremental cost-effectiveness ratio (ICER) of 
$146,200 per quality-adjusted life-year (QALY) gained, which exceeded the 
cost-effectiveness threshold ($100,000) (Chesson et al., 2016). Some cost-
effectiveness evaluations were performed using the same vaccine (i.e., 9-
valent) in the USA to capture the different dimensions of its economic 
viability (Brisson et al., 2016; Chesson et al., 2016; Laprise et al., 2016; 
Markowitz et al., 2016). These studies incorporated different study 
participants, designs, perspectives, vaccine delivery routes and model 
specifications.  
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A recent study conducted in both Australia and Canada focused on the 
9vHPV vaccine in terms of screening scenarios (Simms et al., 2016) and they 
found that 9vHPV had a significant impact on reducing cervical cancer 
incidence. Furthermore, they claimed that the incremental cost per dose for 
girls should not exceed a median of A$35.99. However, this study 
emphasised the impact of vaccines to prevent cervical cancer rather than their 
economic viability. Significantly, sufficient evidence did not arise for health 
policymakers to use the findings to develop cost-effective intervention 
strategies. In Germany, universal immunisation with 9vHPV was suggested, 
as it had an ICER of €22,987/QALY gained, which was below the threshold 
(Largeron et al., 2017). In Spain, a recent study evaluated a vaccine program 
in adolescent girls, as part of which the 9vHPV vaccine was found to be 
highly cost-effective, with an ICER of €7,718 per QALY compared to the 
4vHPV vaccine (Fuente et al., 2019). In Kenya and Uganda, a study 
recommended that the 9vHPV vaccine was highly cost-effective in both 
countries, as the additional cost of the 9vHPV vaccine did not exceed I$8.3 
per immunised girl (Kiatpongsan and Kim, 2014).  
 
 
1.7 Research gap  
 
The themes for this research have been developed based on the academic 
literature and grey literature and anecdotal evidence as well as ongoing 
public and policy debates about cancer research. Most studies pay little 
attention to analysing the long-term health and economic impacts with 
analytical rigour. Thus, their evidence is not sufficient for health 
policymakers to develop effective or conclusive strategies in relation to the 
levels of the burden of cancer. Empirical evidence in the Australian context is 
also limited, in terms of long-term cancer outcomes, to measure the trends, 
associated determinants and magnitude of socio-economic inequalities of 
cancer outcomes (e.g., incidence, mortality, hospitalisation, and burden of 
cancer) over time. Therefore, national-level trends, differential socio-
economic inequality of cancer outcomes, as well as influential factors 
associated with the cancer burden in Australia are unclear.  
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The first study of this thesis examines the national level cancer outcomes in 
Australia and considered an incidence-based approach in terms of trends, 
determinants and inequality over the last three decades (see Figure 1). 
Furthermore, the main intention of the majority of previous studies (by 
conducting a cross-sectional, clinical or randomised control trial) was to 
investigate the impact of treatment or surgical outcomes on health status, 
while adjusting for a limited range of confounders. Most studies pay little 
attention to examining the long-term health status burden of cancer survivors 
over time. Therefore, it is significant for routine oncology follow-ups to 
explore how cancer survivors’ characteristics impact on their health status 
outcomes over an extended period.  
 
The second study of this thesis focuses on quantifying the long-term health 
status burden and associated risk factors (e.g., lifestyle, life satisfaction, 
associated chronic diseases) of cancer survivors using a longitudinal 
approach. The longitudinal effect was captured using generalized linear 
mixed model (GLMM), which estimated changes in health status burden 
influenced by socio-demographic, lifestyle, life conditions and location-
specific variables.   
 
Given the clinical significance of comorbidity and its prevalence in cancer 
survivors, it is essential to have a measure to quantify the likely effects on 
cancer outcomes (Pule et al., 2018). However, understanding more about 
comorbidities among cancer patients can also generate possible evidence as 
well as provide direction for prevention, management, and treatment of 
chronic diseases. The primary intention of the existing studies was to 
examine the distribution, trend, pattern, and disparity in comorbidity status 
among cancer patients when considering a limited range of variables. The 
majority of studies pay little attention to examining the long-term impact of 
chronic comorbid conditions for cancer survivors over time, and which is 
unclear in Australia. Therefore, routine oncology follow-ups should explore 
how cancer survivors’ characteristics impact on the number of chronic 
comorbid conditions they experience. The third study addresses this gap by 
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examining the longitudinal nature of chronic comorbid conditions of cancer 
patients using health economics analytics and a fixed-effect negative 
binomial regression model and employing a longitudinal design to analyse 
Household, Income and Labour Dynamics in Australia (HILDA) survey data.   
 
Considering the economic burden, few studies have examined the health 
burden in relation to the work-related disability of cancer survivors. The 
potential factors associated with work disability of cancer survivors are 
poorly explored. This may be partially accounted for by the variety in study 
designs, analytical rigour and follow-up periods. For instance, many 
international studies have used a limited number of predictors. A number of 
previous studies have been cross-sectional in nature in terms of their clinical 
and treatment perspectives. Thus, a study to examine the impact of the health 
burden in relation to the magnitude of work disability for a long-term sequela 
of patients with cancer is relevant. There is increased interest in cancer 
survivorship, leading to efforts to identify and manage treatment-related 
sequelae, enhance the quality of life, and improve the overall functioning of 
people who are receiving long-term follow-up care after cancer treatment.  
 
The fourth study therefore, aims to investigate the distribution, potential 
predictors and associated burden of chronic comorbid conditions among 
cancer patients by using a longitudinal data set for Australia. The longitudinal 
effect was captured using a fixed effect multinomial logistic regression 
model, which predicted changes in the relationship between cancer burden 
and work disability level, while controlling for socio-demographic, lifestyle 
and life conditions predictors. 
Finally, some limitations have been identified in the existing findings of 
cancer preventative and control programs with regards to their economic 
viability, due to the hypothetical programs and populations used. Previous 
cost-effective evaluations have only considered one perspective usually 
related to the health system or societal, or both perspectives, along a single 
vaccine delivery route. In Australia, the 9vHPV vaccine was introduced in 
2018. However, there is no current comprehensive evidence concerning the 
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economic viability of the 9vHPV vaccine in Australia across delivery 
strategies (e.g., school-based, health facility-based and outreach-based) from 
the health system and societal perspectives. In this context, comprehensive 
evidence with regard to the economic viability of new cancer vaccines is 
significant for determining the optimal pricing of delivery strategies in the 
vaccination program in order to maximise the societal benefits of the 
introduction of the vaccines in Australia.  
 
The fifth study evaluates the cost-effectiveness of the 9vHPV vaccine from 
both the health system and societal perspectives across three delivery routes. 
Before conducting this cost-effectiveness evaluation of the 9vHPV 
vaccination, a systematic review was conducted to update and investigate 
general trends as part of an ongoing cost-effectiveness evaluation with regard 
to the economic viability of HPV vaccination within a global context.   
 
 
1.8 Research aim and research questions 
The main aim of this thesis is to measure the burden of cancer and examine 
the longitudinal impact on cancer survivors, their households, as well as on 
society generally. This thesis has examined the burden of cancer across 
geographical distribution, including regional, rural, and remote Australia. The 
study has also examined the impact in terms of long-term cancer outcomes, 
health status burden, chronic comorbid conditions, and productivity related 
work disability. While an economics of cancer vaccination study could 
potentially have been conducted in this setting, a quantitative approach was 
adopted based on the research questions, modelling framework, the expertise 
of the student and the supervisors. To achieve the research goals outlined 
above, five studies (Studies 1-5) were conducted. The following table (Table 
1) lists the objectives and research question of each publishable paper written 
for this thesis. 
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              1.9 Study design and perspective 
The present research work has evolved based on the aims of the thesis, and 
has been focused within the ongoing debates around cancer. All these studies 
were quantitative in nature, utilising health economic methods and advanced 
statistical techniques. This thesis is based on five studies using different but 
established study designs and approaches. All studies had a national and 
international context, and used published data sources related to cancer. This 
thesis is constructed based on three main themes including ‘understanding of 
the challenges of cancer outcomes’, ‘long-term cancer burden (i.e., health 
status burden, chronic comorbid conditions, productivity-related work 
disability and its consequences)’, and ‘evaluation of cancer prevention 
program’ in the context of Australia (Figure 1). 
 
Study 1 used an incidence-based approach restricted to the publicly accessible 
AIHW database, which extended understanding the challenges of cancer 
diseases in terms of incidence, mortality, hospitalisation and associated 
burden of diagnosed cancer patients in Australia. Studies 2-4 used a 
longitudinal study design, using HILDA datasets that examined the long-term 
impact on health status burden, comorbidities, associated work-disability, and 
their consequences related to cancer. Study 2 focused on the impact of health 
status burden and its consequences on cancer patients (Figure 1).  
 
A longitudinal exploration concerning the burden of cancer on chronic 
comorbid conditions was examined in Study 3, whereas the long-term impact 
of cancer burden on chronic comorbid conditions and work-related disability 
were elucidated in Study 4. Concerning the burden of cancer, Study 5 related 
to the primary prevention of cancer and focused on the economics of cancer 
vaccination using economic evaluation technique. This study assessed the 
cost-effectiveness of the new 9vHPV vaccination used in Australia while 
considering a broader societal perspective.  
 
As cancer incidence and associated mortality rates still remain a devastating 
public health concern in Australia, these studies are anticipated to contribute 
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to generating new knowledge, particularly in the context of the ‘economic of 
cancer vaccination’, and could bring added value to ongoing research and 
exploration in this field (Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Five studies of the thesis: the interlinkages 
 
 
 
Theme-I 
Theme-II 
 
Theme-III 
Study 1  
(RQ 1-3) 
Understanding the challenges 
of cancer outcomes  
Study-V 
(RQ 11 & 12) 
Evaluation of cancer 
preventive program 
(Economic of cancer 
vaccination) 
Long-term cancer burden 
Study 2  
(RQ 4 & 5) 
Long-term health status 
burden and consequences 
Study 3  
(RQ 6 & 7) 
Long-term chronic 
comorbid conditions and 
consequences 
Study 4 
(RQ 8-10) 
Long-term productivity- 
related work disability and 
consequences 
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Table 1. Summary facts about different studies objectives, research questions and conceptual issues
Study 
Published 
paper(s) Objective(s) 
Research questions  
(RQs) 
Conceptual 
issues 
Study design/ 
approach/ 
perspective 
Data 
sources 
Outcome parameters 
Study 1 Article-I 
i) To examine the trends of 
cancer outcomes and 
associated burden over an 
identified periods. 
RQ1: What is an emerging 
trends of cancer outcomes in 
terms of incidence, mortality, 
hospitalisation and associated 
burden over identified 
periods? 
Extend of the 
challenges of 
cancer 
outcomes: 
Incidence, 
mortality, 
hospitalisation 
and associated 
burden. 
Incidence-
based 
approach, 
health system 
perspective 
AIHW 
 
Cancer incidence, cancer-
related mortality, 
hospitalisations, cancer 
burden (e.g., YLL, YLD, 
DALYs). 
ii) To measure the magnitude 
of socioeconomic inequalities 
in terms of cancer outcomes 
and cancer burden. 
RQ2: What is the magnitude 
and direction of the cancer 
outcomes and associated 
burden in terms of 
socioeconomic inequalities? 
iii) To investigate associated 
determinants on cancer burden 
over an identified period. 
RQ3: What factors associate to 
health burden of cancer over 
an identified period? 
Study 2 Article-II 
i) To examine the longitudinal 
nature of health status burden 
among cancer patients. 
RQ4: What is the longitudinal 
nature of health outcomes and 
the extent of health status 
burden among cancer patients 
in Australia? 
Impact of long-
term health 
status cancer 
burden and 
consequences. 
Mixed 
longitudinal 
design 
 
HILDA 
Health status burden and 
associated determinants 
of health status burden. ii) To determine the factors 
that predict their health status 
burden over an identified 
period. 
RQ5: How does life style 
factors impact on health status 
burden of cancer survivors in 
Australia? 
(Continued) 
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AIHW = Australian Institute of Health and Welfare, HILDA = Household, Income and Labour Dynamics in Australia, CEA = Cost-effectiveness analysis, YLL = Years life lost, YLD= Years lost due to disability, DALYs = Disability adjusted life 
years, ICER= Incremental cost-effectiveness ratio 
Study 
Published 
paper(s) Objective(s) 
Research questions  
(RQs) 
Conceptual issues 
Study design/ 
approach/ 
perspective 
Data sources Outcome 
parameters 
Study 3 Article-III 
i) To investigate the longitudinal 
distribution of chronic comorbid 
conditions among cancer survivors 
over an identified period. 
RQ6: What is the longitudinal distribution 
and changes of chronic comorbid 
conditions with cancer survivors over 
times? 
Impact of long-term 
burden of chronic 
comorbid conditions 
among cancer 
survivors and 
consequences. 
Mixed 
longitudinal 
design 
 
HILDA 
Burden of 
chronic 
comorbid 
conditions and 
associated 
predictors 
 
ii) To identify the potential 
predictors of chronic comorbid 
conditions over an extended 
period. 
RQ7: What factors influence the chronic 
comorbid exposure of cancer patients 
over an extended period of 2007 to 2017? 
Study 4 Article-IV 
To examine the longitudinal 
impact of health burden on the 
magnitude of work-related 
disability of cancer survivors in 
Australia over an extended period 
of 2003-2017. 
RQ8: What is the magnitude of work 
disability levels among cancer patients in 
Australia? 
Impact of long-term 
productivity-related 
work disability and 
Consequences 
Mixed 
longitudinal 
design 
HILDA 
Disability 
status and 
severity of 
disability and 
influencing 
determinants. 
 
RQ9: What is the longitudinal association 
between health burden and the magnitude 
of work disability among cancer patients 
in Australia over 2003-2017? 
RQ10: What are the potential predictors 
associated with the magnitude of work 
disability for cancer patients in Australia 
over this extended period? 
Study 5 
Article-V 
i) To extend and mapping of the 
general trends on the ongoing 
cost-effectiveness evaluation of 
the 9-valent HPV vaccination 
within a global context. 
RQ11: To what extent of the ongoing cost-
effectiveness evaluation of the 9-valent 
HPV vaccination performs in the global 
context? 
To investigate the 
current evidence on the 
economic viability of 
HPV vaccination, from 
the global context  
Systematic 
review 
Relevant 
academic 
published 
articles 
ICER per cancer 
cases averted, 
life saved, life 
year saved, 
DALYs averted. 
Article-VI 
ii) To assess the cost-effectiveness 
of adding a nonavalent new 
Gardasil-9® (9vHPV) vaccine to 
the national immunisation 
schedule in Australia across three 
different delivery strategies. 
RQ12: Is cancer vaccination economically 
viable to prevent cervical cancer in 
Australia? 
To evaluate the cancer 
prevention strategy in 
terms of economically 
viable of cancer 
vaccination in Australia.  
CEA from 
Health system 
and societal 
perspectives 
National and 
international 
sources, 
relevant 
published 
articles 
ICER per cancer 
cases averted, 
life saved, life 
year saved, 
DALYs averted. 
Table 1. Summary facts about different studies objectives, research questions and conceptual issues (Continued) 
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1.10 Data sources and study population 
 
In the context of Australia, the study population was ethnically, 
geographically, and socio-economically diverse. The first study was restricted 
by the availability of various cancer-related national-level data sources. Data 
on cancer incidence, mortality, and hospitalisation were extracted from the 
publicly accessible Australian Institute of Health and Welfare (AIHW) online 
data sources (AIHW, 2019a), and cancer-related published reports (AIHW, 
2016b, 2019b). Cancer burden-related data was collected from the Australian 
Burden of Disease Study (ABDS). Data were retrieved from the published 
reports of ABDS-2011 and ABDS-2015, the last two reports that explicitly 
included cancer (AIHW, 2016b, 2019b). Study I used these national level 
accumulated data in its analytical exploration. A total of 2,784,148 registered 
cancer cases was accessed, based on data from 1982 to 2014 in Australia (see 
published article-I).  
 
In Studies 2-4, data were accessed from the HILDA survey dataset 
(Summerfield et al., 2018), which is a nationally representative longitudinal 
study of Australian households. Survey waves were selected based on the 
availability of data related to cancer and conceptual issues (Table 1). For 
example, Study 2 used data from HILDA wave-13 in 2013 (n = 517) and 
wave-17 in 2017 (n = 576) to measure the longitudinal health status burden 
(see article–II). In Study 3, data were restricted to four waves (e.g., wave-7, 
wave-9, wave-13 and wave-17) based on the availability of data related to 
cancer (see published article-III). However, wave-3 was excluded from the 
analysis due to the limited data related to comorbidity status. A total of 2,066 
diagnosed cancer patients were potential participants from the four waves: 
wave-7 in 2007 (n = 557), wave-9 in 2009 (n = 416), wave-13 in 2013 (n = 
517) and wave-17 in 2017 (n = 576). Study 4 was focused on productivity-
related work disability among diagnosed cancer patients, and data were 
generated from five HILDA waves (505 patients from wave-3 in 2003, 557 
patients from wave-7 in 2007, 416 patients from wave-9 in 2009, 517 
patients from wave-13 in 2013 and 576 patients from wave-17 in 2017) (see 
published article-IV).  
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Finally, Study 5 was constructed based on a full economic evaluation (i.e., 
cost-effectiveness analysis) of the cancer prevention program (new 9vHPV 
cancer vaccination), from the global context (i.e., to investigate the current 
evidence on the economic viability of 9vHPV vaccination; see published 
article-V) and Australia (i.e., to evaluate the cancer prevention strategy in 
terms of economically viable of 9vHPV vaccination; see published article-
VI). Data were derived from published original articles, secondary national 
and international data sources, and anecedotal evidence based on economic 
model input assumptions. 
 
 
 1.11 Theoretical underpinning  
The essence of cancer burden is that it can be seen as a social dynamic, which 
can be explained with relevant theories and models. The findings of this 
thesis have been theorised inductively, which means the analytical 
exploration has been data-grounded, rather than theory-dictated. In this 
thesis, every finding was underpinned by a suitable theoretical framework. 
This theorising stage was not straightforward, but rather a reflexive process 
and the relevant theory was selected based on compelling arguments of the 
researchers. As a result of the response to reviewers’ comments (the peer 
review process), however, the theoretical perspective was excluded from 
some of the papers in order to address the reviewers’ comments. In this 
thesis, three inductively generated theories were adopted: social conflict 
theory (Study 1), stress-coping theory (Studies 2-4) and portfolio theory 
perspectives (Study 5). The following section outlines the reasons for 
selecting those theories.   
 
1.11.1 Social conflict theory 
One of the studies (Study 1) was performed to examine the national level 
cancer outcomes in terms of trends, determinants and inequality over the last 
three decades, through the prism of social conflict theory (Marx and Engels, 
1848), which was used to explain the phenomenon of socioeconomic 
inequality as a driving force behind cancer outcomes. Social conflict theorists 
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argue that social classification emanates in a society from the conflict 
between and amongst social groups. In the mid-19th century Karl Marx was 
one of the principal social theorists who claimed that the attributes of the 
capitalist economy underpin upper-class domination of the socio-economic 
stratum (Marx, 1887). One of the striking themes in social conflict theory is 
that socioeconomic inequality is magnified owing to inequalities in age, race, 
wealth, gender, and geographical distribution. In this research (Study 1), 
social conflict theory fits into two dimensions. First, Australia has significant 
geographical differentiation, which indicates a deep divide among people in 
different localities in terms of their social capital, income, wealth, and class. 
This might generate systematic social conflict between the ‘haves’ and ‘have 
nots’. Second, urban patients can more easily access health care services than 
those in remote areas. Other researchers have also used this theory to study 
different dimensions of social and health service provision (Sage Editors, 
1957; Azar and Farah, 1981; Cornfield, 1991; Scambler, 2001; Hammack et 
al., 2018).  
 
1.11.2 Stress-coping theory 
The theoretical framework of stress-coping theory was designed by Lazarus 
and colleagues (Lazarus and Folkman, 1984; Lazarus, 1999) to investigate 
which antecedent factors may be aligned with long-term cancer health status 
burden (Study 2), chronic comorbid conditions (Study 3), and productivity-
related work disability (Study 4). The longitudinal study perspective was 
underpinned by a stress-coping theory in order to determine if it could predict 
long-term health status burden (Dunn et al., 2013), chronic comorbid 
conditions (Hermsen et al., 2016), and work-related disability (Martz and 
Livneh, 2007; Livneh, 2015) over an extended period. They investigated 
individuals who faced the burden of life-threatening cancer and examined the 
magnitude of the cancer burden associated with its initial appraisal as well as 
their ability to manage the secondary stage of treatment and progression. In 
terms of secondary appraisal, individuals reconsidered their health status 
based on the magnitude of the burden (as either more or less). The theory of 
stress-coping is that the burden which extends over an extended period of 
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time adversely affects health outcomes, including cancer outcomes (Lazarus, 
1999). Furthermore, the theory holds that the magnitude of burden related to 
the disease is contextual, meaning that it involves a transaction between the 
individual and the management of disease, and it is a process, meaning that it 
changes over time.  
 
To examine the longitudinal effects of the model, it is hypothesised that 
several antecedent variables (e.g., individual characteristics, social factors, 
and disease-related factors), measured at the symptom-level, might predict 
outcome factors (appraisal of disease with comorbidities, course of treatment, 
caregiving, life condition, uncertainty, disability). Moreover, the combination 
of factors (e.g., antecedent and outcomes) was assumed to predict patients’ 
health burden. In this context, the stress-coping theory fits with two adaptive 
tasks common across situations that threaten physical well-being managing 
the burden of disease and coping with a changing reality. 
 
1.11.3 Portfolio theory 
Portfolio theory, as applied in health economics, highlights the trade-offs that 
exist between the returns on investment in healthcare interventions or 
programs (e.g., cancer vaccination) and the risk associated with the outcomes 
(both costs and effects) (Markowitz, 1952). This theory also suggests a 
means to improve the risk-return characteristics of investments in healthcare 
interventions or programs (e.g., cancer vaccination) through change when 
costs and outcomes are uncertain. The foundation of this theory is based on 
the potential assumption that the investment proportions are not subject to 
uncertainty and that the budget can be invested in healthcare interventions or 
programs. Furthermore, a portfolio approach allows one to evaluate a 
combination of healthcare interventions or associated programs, focusing on 
their returns (e.g., health benefits) and risk related to outcomes. While 
various methods have been suggested for incorporating risk in the evaluation 
of costs and outcomes in health economic evaluations (Zivin and Bridges, 
2002), these techniques remain dependent on the specification of a threshold 
incremental cost-effectiveness ratio for decision-making from the health 
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system and societal perspectives. In this thesis, Study 5 is underpinned by the 
essence of Portfolio theory, whereas previous researchers have employed this 
theory to study healthcare interventions through economic evaluation 
approaches (Zivin and Bridges, 2002; Sendi et al., 2003, 2004; Bridges and 
Terris, 2004; Gafni, 2006).   
    
1.12 Conceptual framework of the thesis  
  
The conceptual framework (Figure 2) of the thesis explains the proposed 
hypotheses, which have explored the direct or indirect relationships that exist 
between individual, demographic, environmental and other associated 
factors, and cancer outcomes. These factors have a fundamental relationship 
with the risk of developing cancer. Consequently, cancer leads to a huge 
health and economic burden. Different factors may be contributing, at 
different levels, to the degree of inequality of cancer outcomes. These 
relationships have been examined in the proposed model, and the burden of 
cancer was considered as a consequence of the disease. Different dimensions 
of health status have previously been shown to influence health-related 
behaviour. As a result, cancer patients are exposed to adverse events leading 
to reduced health status. Cancer leads to a huge economic burden on the 
individual and households, as well as society.   
 
The distribution of comorbidity varies by patient-level factors. Like cancer 
itself, comorbidity increases with age. Functional status, a measure of 
patients’ ability to perform everyday activities, is related to both the presence 
and the consequences of chronic comorbid conditions. Health status burden is 
associated with increased vulnerability to stressors that result from decreased 
health status as well as physiological strength (Fried et al., 2004). 
Furthermore, health status burden is strongly associated with increased age 
and the severity of the disease. In the context of comorbidity experiences, 
patients assess their health status depending on the severity of disease (as 
either ‘better’ or ‘worse’) (Lazarus, 1999). Despite strong associations 
between them, comorbidity, functional status, and health status burden are 
separate entities, and each has an independent effect on outcomes (Fried et 
al., 2004). To investigate the longitudinal effects, it was assumed that several 
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predictors (e.g., individual background characteristics, social factors, and 
disease-related symptomatic factors), measured at the symptom-level, might 
predict outcome factors (e.g., appraisal of disease severity levels, utilisation 
of advanced treatment, life satisfaction, and uncertainty). Moreover, the 
combination of predictors was expected to predict patients’ health outcomes 
(e.g., chronic comorbid conditions, long-term health problems or disability, 
and adverse events). 
 
Considering the economic burden, the long-term impacts include out-of-
pocket payments, catastrophic expenditure, work-related disability, lost 
productivity, reduced income, and increased costs to the health system 
(Figure 2). The benefit of developing this structure for analytical assessment 
resides in the establishment of a logical model that indicates potential causal 
relationships among factors, thus enabling the implementation of specific 
policies related to cancer. A positive feature of the framework is the 
opportunity to investigate the costs and societal benefits of cancer prevention 
programs (e.g., cancer vaccination) (Figure 2). To examine the degree of 
inequality in relation to cancer, this study employed inequality related 
techniques referencing social conflict theory.  
 
To inquire into the magnitude of long-term cancer burden and consequences 
on cancer outcomes and current challenges (Figure 2) in the Australian health 
system (Study 1), health status burden (Study 2), chronic comorbid condition 
(Study 3), and productivity-related work disability (Study 4), this research 
employed a mixed-longitudinal approach using advanced inequalities related 
techniques and statistical models (e.g., generalized linear mixed models, 
fixed-effect negative binomial regression model and fixed-effect multinomial 
logistic regression model), underpinned by stress-coping theory. Finally, to 
evaluate a cancer control program (cancer vaccination), in terms of its 
societal benefits and associated costs, a full economic evaluation (e.g., cost-
effectiveness analysis) was performed, which is also aligned with portfolio 
theory (Study 5). 
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socioeconomic characteristics) 
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macronutrients (e.g., total 
energy, fiber, fat, protein, 
sodium chloride) 
  
Environmental Factors 
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radiation, chemicals, alcohol) 
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(e.g. predisposing, facilitating, 
reinforcing) 
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Figure 2. Conceptual framework of the thesis 
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           1.13 Thesis organisation  
This thesis is composed of an introduction that highlights the research theme, 
a review of the literature that identifies the gap in the existing evidence, five 
major studies that cover the objectives, a discussion and conclusions as well 
as future research, which summarises the findings and contributions of this 
study. A total of six (Quartile Q1) journal articles produced from this research 
are presented below: 
 
Article from study 1: 
 Article I 
Rashidul Alam Mahumud*, Khorshed Alam, Jeff Dunn, Jeff Gow. 
Emerging cancer incidence, mortality, hospitalisation, and associated 
burden among Australian cancer patients, 1982-2014: An incidence-
based approach in terms of trends, determinants and inequality. BMJ 
Open 2019; 9(12): e031874. (Quartile-1 ranked; Impact Factor: 2.376; 
SJR = 1.321; SNIP = 1.145; Publisher: BMJ Publishing Group).  
DOI: http://dx.doi.org/10.1136/bmjopen-2019-031874 
Article from study 2: 
 Article II 
Rashidul Alam Mahumud*, Khorshed Alam, Jeff Dunn, Jeff Gow. 
The impact of lifestyle risk factors, life satisfaction and chronic 
exposure on changing in longitudinal health status burden among 
Australian cancer patients, 2013-2017. BMJ Open (under review) 
(Quartile-1 ranked; Impact Factor: 2.376; SJR = 1.321; SNIP = 1.145; 
Publisher: BMJ Publishing Group). 
            Ref. No.: bmjopen-2019-036675 
Article from study 3: 
 Article III  
Rashidul Alam Mahumud*, Khorshed Alam, Jeff Dunn, Jeff Gow. 
The burden of chronic diseases among Australian cancer patients: 
Evidence from a longitudinal exploration, 2003-2017. PLoS ONE 
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2020; 15(2): e0228744. (Quartile-1 ranked, Impact Factor: 2.392; SJR 
= 1.100; SNIP = 1.123; Publisher: Public Library of Science). 
            DOI:  https://doi.org/10.1371/journal.pone.0228744 
 
Article from study 4: 
 Article IV  
Rashidul Alam Mahumud*, Khorshed Alam, Jeff Dunn, Jeff Gow. 
The changing relationship between health burden and work disability 
of Australian cancer survivors, 2003-2017. BMC Public Health 2020; 
20 (548): 1-14 (Quartile-1 ranked, Impact Factor: 2.567; SJR = 1.382; 
SNIP = 1.342; Publisher: Springer Nature). 
DOI: https://doi.org/10.1186/s12889-020-08710-9 
 
Articles from study 5: 
 Article V  
Rashidul Alam Mahumud*, Khorshed Alam, Syed Afroz Keramat, 
Gail M Ormsby, Jeff Dunn, Jeff Gow. Cost-effectiveness evaluations 
of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from 
a systematic review. PLoS ONE 2020; 15(6): e0233499. (Quartile-1 
ranked, Impact Factor: 2.392; SJR = 1.100; SNIP = 1.123; Publisher: 
Public Library of Science). 
DOI: https://doi.org/10.1371/journal.pone.0233499 
 Article VI  
Rashidul Alam Mahumud*, Khorshed Alam, Jeff Dunn, Jeff Gow. 
The cost-effectiveness of controlling cervical cancer using a new 9-
valent human papillomavirus vaccine among school-aged girls in 
Australia. PLoS ONE 2019; 14(10): e0223658. (Quartile-1 ranked, 
Impact Factor: 2.392; SJR = 1.100; SNIP = 1.123; Publisher: Public 
Library of Science).  
DOI: https://doi.org/10.1371/journal.pone.0223658. 
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For a better understanding of the link among the studies and articles, the flow 
of the thesis is graphically presented in Figure 3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                
Figure 3. Flow diagram of the thesis structure 
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2.1 Study 1 
Challenges of cancer diseases: Incidence, mortality, 
hospitalisation and associated burden 
 
The first study of this thesis examined the national level cancer outcomes in Australia 
and considered an incidence-based approach in terms of trends, determinants and 
inequality over the last three decades. Study 1 provides evidence of understanding the 
challenges of cancer outcomes, which is significant for routine oncology follow-ups 
to explore how cancer survivors’ characteristics impact on their health status outcomes 
over an extended period.  
Article I: Emerging cancer incidence, mortality, hospitalisation and associated 
burden (years lost life, years lost due to disability, disability-adjusted life years) 
in Australia, 1982-2014: Evidence from an incidence-based study in terms of 
trends, determinants and inequality 
The objective of Study 1 was to understand the trends, determinants and magnitude of 
socioeconomic inequality associated with cancer incidence, hospitalisation, mortality 
and its burden over the period 1982 to 2014 in Australia using an incidence-based 
approach. This study found that cancer incidence, hospitalisation, cancer-related 
mortality, and burden of cancer all increased significantly over the period. 
Furthermore, survival inequality was most pronounced for cervix, prostate, melanoma, 
Non-Hodgkin Lymphoma, and breast cancers. Furthermore, socio-economically 
disadvantaged people were more likely to bear an increasing cancer burden in terms 
of incidence, mortality, and death. This study concludes that significant differences in 
the burden of cancer persist across socio-economic strata in Australia. Policymakers 
should therefore introduce appropriate cancer policies to provide universal cancer care, 
which could reduce this burden by ensuring curable and preventive cancer care 
services are made available to all people.   
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AbstrACt
Objective Cancer is a leading killer worldwide, including 
Australia. Cancer diagnosis leads to a substantial burden 
on the individual, their family and society. The main aim 
of this study is to understand the trends, determinants 
and inequalities associated with cancer incidence, 
hospitalisation, mortality and its burden over the period 
1982 to 2014 in Australia.
settings The study was conducted in Australia.
study design An incidence- based study design was used.
Methods Data came from the publicly accessible 
Australian Institute of Health and Welfare database. 
This contained 2 784 148 registered cancer cases over 
the study period for all types of cancer. Erreygers’ 
concentration index was used to examine the magnitude 
of socioeconomic inequality with regards to cancer 
outcomes. Furthermore, a generalised linear model was 
constructed to identify the influential factors on the overall 
burden of cancer.
results The results showed that cancer incidence (annual 
average percentage change, AAPC=1.33%), hospitalisation 
(AAPC=1.27%), cancer- related mortality (AAPC=0.76%) 
and burden of cancer (AAPC=0.84%) all increased 
significantly over the period. The same- day (AAPC=1.35%) 
and overnight (AAPC=1.19%) hospitalisation rates also 
showed an increasing trend. Further, the ratio (least- most 
advantaged economic resources ratio, LMR of mortality 
(M) and LMR of incidence (I)) was especially high for 
cervix (M/I=1.802), prostate (M/I=1.514), melanoma (M/
I=1.325), non- Hodgkin's lymphoma (M/I=1.325) and 
breast (M/I=1.318), suggesting that survival inequality was 
most pronounced for these cancers. Socioeconomically 
disadvantaged people were more likely to bear an 
increasing cancer burden in terms of incidence, mortality 
and death.
Conclusions Significant differences in the burden of 
cancer persist across socioeconomic strata in Australia. 
Policymakers should therefore introduce appropriate 
cancer policies to provide universal cancer care, which 
could reduce this burden by ensuring curable and 
preventive cancer care services are made available to all 
people.
bACkgrOund
Non- communicable diseases (NCDs) are 
accountable for the majority of global deaths.1 
Cancer is expected to rank as the most signif-
icant global public health problem and a 
leading cause of death and illness in the world 
in the 21st century2–6 including Australia.7 In 
2019, it is estimated that almost 145 000 new 
cases of cancer will be diagnosed in Australia, 
and 35% of these individuals will eventually 
die from the disease.7 Cancer accounts for 
the highest burden of disease of any illness, at 
approximately 18% (19% for males; 17% for 
females), followed by cardiovascular disease 
(14%), musculoskeletal (13%) and mental 
health (12%).8 Approximately 40% of cancer 
patients are of working age in Australia.7 
Among those in employment, 46% are unable 
to return to work after an episode,9 and 67% 
return to employment or change their job 
after being diagnosed.10 The majority of 
strengths and limitations of this study
 ► This study examined the trends, determinants and 
inequality in terms of incidence, mortality, hospital-
isation and associated burden of cancer (eg, years 
life lost, years lost due to disability and disability- 
adjusted life years) in the Australian context over a 
33 year period.
 ► This study was not captured in details inequalities 
regarding the cancer survivorship in terms of stage, 
treatment procedures and utilisation of healthcare.
 ► Although we have limited understanding of what is 
driving these changes in cancer outcomes as report-
ed here they may reflect random variation or chang-
es in unknown risk factors, and therefore highlight 
the need for more research into the aetiology of 
cancer.
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cancer survival patients depend on family, relatives and 
friends for physical and economical support during their 
treatment and/or in the last stages of the disease.9–12 
Cancer- related illness results in a substantial number of 
patients experiencing economical hardship due to high 
out- of- pocket expenses (eg, medicines and treatments, 
including diagnostics), lost productivity, loss/reduc-
tion of household income and other induced expendi-
ture.9 10 12 13 The economic burden of cancer is of growing 
concern for policymakers, healthcare practitioners, physi-
cians, employers and society overall.10 12 Furthermore, the 
magnitude of the cancer burden increases significantly 
with remoteness from treatment sources and those indi-
viduals in depressed socioeconomic circumstances.14–16 
Considerable progress has been made in recent decades 
in terms of cancer survival and reduced mortality rates17 18 
through several initiatives including introducing primary 
preventive strategies and effective collaboration with 
non- government organisations and other stakeholders. 
Therefore, a reduction of cancer incidence, along with 
improvements in cancer treatments and therefore survival 
rates, are essential to reduce the burden of the disease.
Economic disparities between socioeconomically advan-
taged and disadvantaged individuals and groups are wors-
ened by the increasing burden of cancer in Australia.15 
The lack of appropriate services are significantly worse 
in resource- poor settings, including geographically disad-
vantaged areas compared with more advantaged people 
and communities with easier access to a greater range 
of cancer services, increased knowledge and awareness 
of cancer prevention and better and more easily acces-
sible health facilities and resources.15 19 20 Other common 
reasons for such disparities include limited affordability 
and accessibility of cancer care services for individuals 
from socioeconomically disadvantaged groups,16 and their 
inadequate utilisation of healthcare.21 Thus, increased 
cancer incidence leads to a higher overall burden for the 
individual, family and society, which is exacerbated for 
the more disadvantaged.
In the recent past, disparities related to cancer 
outcomes have become the subject of international focus 
and new service initiatives.2 6 In 2016, the WHO Executive 
Board recommendation was to strengthen health systems 
to ensure early detection and diagnosis, as well as acces-
sible, affordable and appropriate and quality healthcare 
services for all patients with cancer.22 Only a few studies 
have focused explicitly on socioeconomic inequality of 
cancer care and healthcare utilisation in Australia. This 
study therefore purposes to provide data and analysis on 
trends in cancer incidence, mortality rates, hospitalisation 
and associated burden (years life lost, YLL; years lost due 
to disability, YLD and disability- adjusted life years, DALYs) 
for the most prevalent malignancies among Australians, 
by sex, state, remoteness and socioeconomic status, using 
routinely collected health data for the period of 1982 to 
2014.
There is an extensive body of research on the many 
different dimensions of cancer. In recent decades, the 
cancer incidence has increased,5 17 23–25 which has been 
more pronounced among adolescents and young adults,26 
and older adults,27 yet cancer- related mortality rates have 
slightly dropped.28 Some types of cancer in Australia are 
the highest in the world: melanoma,26 keratinocyte and 
melanocyte.29 Australia and New Zealand together have 
the highest rates for Merkel cell carcinoma.30 31 A number 
of studies have focused on geographical or socioeconomic 
disparities in cancer care and survival.32–38 These have 
usually been conducted in small settings at the Austra-
lian state level. No previous studies have attempted to 
measure the trends, associated determinants and magni-
tude of socioeconomic inequalities of cancer outcomes 
(eg, incidence, mortality, hospitalisation and burden of 
cancer - YLL, YLD, DALYs) over time. Therefore, national 
level trends, the differential socioeconomic inequality of 
cancer outcomes, as well as influential factors associated 
with the cancer burden in Australia are unclear.
Furthermore, the study’s findings will provide authori-
ties with national evidence about the trends and magni-
tude of the inequalities in cancer burden and hopefully 
assist in developing low- cost interventions to reduce this 
burden. This study thus aims to examine the trends, asso-
ciated determinants and magnitude of socioeconomic 
inequality as related to incidence, mortality, YLL, YLD 
and DALYs, as a result of cancer.
MethOds
study design
An incidence- based approach was used to examine the 
trends and socioeconomic inequalities associated with 
adverse cancer outcomes in Australia. A health system 
perspective was adopted and cancer- related data were 
accessed from organisations that are committed to 
promote, restore or maintain health and well- being.39 40 
The study population represented different population 
subgroups using characteristics such as sex, geographical 
distribution and economic circumstances.
Australian health system
Australian health system (AHS) provides quality and 
affordable healthcare services for all Australians. It is oper-
ated by three levels of government: federal (financing), 
state and territory (funding and service delivery) and 
local (service delivery).41 The foundation of AHS is the 
publically funded national universal health insurance 
scheme, Medicare and its predecessor Medibank which 
commenced in the 1970s to promote universal health-
care by providing safe and affordable healthcare services 
for Australians. Through Medicare, patients are able to 
access medical services, treatment in public hospitals free 
of charge, receive subsidised out of hospital treatment and 
medicines. Those eligible to access healthcare services 
through Medicare include: Australian and New Zealand 
citizens, permanent residents of Australia and individuals 
who have applied for a permanent visa.42 On the other 
hand, overseas student health cover is mandatory for all 
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international students, to ensure they and their depen-
dents can access affordable healthcare while living and 
studying in Australia. Patients are provided a rebate 
benefit for healthcare services for out of hospital services.
The rebate amount is case dependent. For example, for 
a consultation with a general practitioner (GP), specialist 
or consultant physician of at least 10 min duration on a 
patient with cancer to develop a multidisciplinary treat-
ment plan, the schedule payment is $A81.50 in 2019, 
and the benefit is 100% of the schedule fee; hyperbaric 
oxygen therapy associated with treatment of localised 
non- neurological soft tissue radiation injuries has a 
schedule fee of $A254.75 and the benefit is 75% of the 
schedule fee, or $A191.10.42 While public hospitals are 
free of charge, the majority of out of hospital healthcare 
services are provided by private health providers. The 
actual amount of fees for service is set by the providers 
themselves and are not regulated, meaning that private 
healthcare providers can make their fees above the 
schedule payment. Any difference between the amount of 
the providers fee for a service and the amount of rebate 
is paid by the patient from their out- of- pocket (OOP). 
For example, if the actual amount charged of a provider 
is $A81.50 for a diagonostic (eg, blood) test, Medicare 
would provide a rebate of $A69.30 (75% of the schedule 
fee), leaving the patient to pay $A12.20. Medicare has 
additional policies to protect patients from catatrophic 
OOP healthcare payments. In this context, healthcare 
cards are provided to welfare recipients and low income 
earners, and other eligible patients who pay a lower 
OOP payment for prescription medicines.43 The ‘Medi-
care Safety Net’ and ‘Extended Medicare Safety Net’ 
Programmes also provide higher rebates if an individual 
or family group reaches a certain level of total expendi-
ture on OOP fees within a calendar year. Any subsequent 
services or prescriptions will have a higher proportion 
subsidised for the rest of that calendar year.44 Under the 
‘Medicare Safety Net’, once the threshold is reached then 
100% of the schedule fee for all healthcare services is 
rebated; and under the ‘Extended Medicare Safety Net’ 
80% of the actual OOP payments are rebated.45
data sources
Various cancer- related national data sources were 
accessed. Data on cancer incidence, mortality and hospi-
talisation were extracted from the publicly accessible 
Australian Institute of Health and Welfare (AIHW) online 
database7 and cancer- related published reports.8 46 AIHW 
accumulates data from the Australian Cancer Database 
(ACD), National Mortality Database (NMD) and National 
Hospital Morbidity Database (NHMD). ACD accumulates 
and manages all sorts of cancer data from each Austra-
lian state and territory under legal mandate since 1982. 
Different types of hospitals (eg, government and non- 
government), clinics, laboratories other organisations and 
institutions are required to report all cancer cases to the 
central cancer registry (CCR). The CCR data is delivered 
to the AIHW on an annual basis, where it is accumulated 
into the ACD. The NMD includes information supplied 
by the registries of births, deaths and marriages and the 
national coronial information system. These data are 
then coded by the Australian Bureau of Statistics (ABS) 
and are incorporated into the NMD. The NHMD is an 
accumulation of episode- level records of hospitalised 
patient morbidity data collection systems (eg, all acute 
and psychiatric hospitals, freestanding day hospital facil-
ities and alcohol and drug treatment centres). Further, 
cancer burden- related data is collected via the Australian 
Burden of Disease Study (ABDS). Data were retrieved 
from the published reports of ABDS-2011 and ABDS-
2015, the last two that explicitly included cancer.8 46 Death 
caused by cancer was considered as the fatal burden (eg, 
YLL) and this data was sourced from the NMD. The non- 
fatal cancer burden related data emanated from different 
administrative sources including NHMD, ACD, NMD and 
some epidemiological studies. ABDS amassed data on 
some other parameters from the Global Burden of Disease 
studies of 2010 and 2013 that covered the standard life 
table for fatal burden (YLL), health status and disability 
weights for the non- fatal burden (YLD) and relative risks 
and the risk factor attribution.8 46 The present study used 
these national level accumulated data in the analysis.
study population
A total of 2 784 148 registered cancer cases (male=1 
537 882; female=1 246 265) were accessed, based on 
data from 1982 to 2014 in Australia (table 1). In addi-
tion, to revealing the trends of cancer- related mortality 
over the same period, a total of 1 165 552 cancer- related 
deaths (male=6 59 105; female=5 06 447) were consid-
ered. Due to the paucity and availability of data related 
to cancer outcomes, a total of 591 631 registered cancer 
cases during the period from 2008 to 2012 and a total 
of 217 349 cancer- related deaths during 2010 to 2014 
were used to examine inequality in cancer incidence and 
cancer- related mortality in Australia.
Measurement of cancer parameters
The age- standardised cancer incidence, or mortality rate, 
was measured using the number of new cases diagnosed 
or deaths for a specific age group, divided by the mid- 
year population of the same age group and year. Simi-
larly, cancer incidence or mortality rate was estimated 
from the total number of new cases diagnosed or deaths 
across all age groups combined, divided by the mid- year 
population. These rates were interpreted as the number 
of new cases of cancer or deaths per 100 000 population. 
Cancer related burden estimation was undertaken using 
the burden of disease methodology.8 46 In the ABDS, the 
burden of cancer was calculated through the DALY by 
summing up the fatal burden (ie, YLL) due to premature 
cancer- related mortality and the non- fatal burden (ie, 
YLD) for patients surviving the condition.
 DALY = YLL + YLD  (1)
 YLL =
N
r (1− e
−rL) (2)
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Table 1 Characteristics of the study parameters
Parameters Conceptual issues Sample population Period Data sources
Cancer incidence To examine the trends of 
cancer outcomes
2 784 148 1982–2014 ACD
Cancer- related mortality 1 165 552 1982–2014 NMD
Cancer burden (eg, YLL, 
YLD, DALYs)
ABDS population 2011–2015 ABDS
Number of cancer- related 
hospitalisations
13 213 340 2000–2015 NHMD
Cancer incidence To measure the magnitude 
of socioeconomic 
inequalities in terms of 
cancer outcomes and 
cancer burden
591 631 2008–2012 ACD
Cancer- related mortality 217 349 2010–2014 NMD
Cancer burden (eg, YLL, 
YLD, DALYs)
ABDS population 2011–2015 ABDS
Cancer burden (eg, YLL, 
YLD, DALYs)
To investigate associated 
determinants on cancer 
burden over the period
ABDS population 2011–2015 ABDS
ABDS, Australian Burden of Disease Study; ACD, Australian Cancer Database; DALYs, disability- adjusted life years; NHMD, National Hospital 
Morbidity Database; NMD, National Mortality Database; YLD, years lost due to disability; YLL, years life lost.
 
YLD = I × DW× L
(
1−e−rL
r
)
 
(3)
Where, n=number of deaths; L (YLL)=standard life 
expectancy at the age of death in that year; I=number of 
people with each type of cancer cases; DW=disability wt; 
r=discount rate; L (YLD)=duration of disability in years.
definition of some potential factors
 Index of economic resources
The magnitude of inequality in cancer outcomes was 
examined using an index of relative socioeconomic 
disadvantage (IRSD). The IRSD was developed by the 
ABS using potential factors like average household 
income, education level and unemployment rates.47 It is a 
geographical area- based estimate of socioeconomic status 
where small geographical settings of Australia are catego-
rised from economically disadvantaged to wealthy. This 
index is employed as a proxy for the socioeconomic status 
of the people living in different geographical settings in 
Australia. The cut- offs value for each of the quintiles are 
as follows: Q
1
 (IRSD ≤927.0), Q
2
 (927.0> IRSD ≤965.8), 
Q
3
 (965.8> IRSD ≤1001.8), Q
4
 (1001.8> IRSD ≤1056.0) or 
Q
5
 (IRSD >1056.0).47 The most disadvantaged socioeco-
nomic quantile (Q
1
) corresponds to geographical settings 
covering the 20% of the population with least advantaged 
socioeconomic areas, and the fifth quintile (Q
5
) refers 
to the 20% of the population with the most advantaged 
socioeconomic areas.
 Remoteness
Remote locations exist in each state and territory of 
Australia and are based on the accessibility to services and 
Remoteness Index of Australia, which is constructed by 
the Australian Population and Migration Research Centre 
at the University of Adelaide.48 Remoteness was classi-
fied into six groups: major cities, inner regional, outer 
regional, remote, very remote and migratory. Migratory 
was excluded from the current analysis due to the paucity 
of information. The category of the major cities included 
Australia’s capital cities, except Darwin and Hobart, 
which were treated as an inner regional.
data analysis
 Trend analysis
Trend analysis of cancer incidence, cancer- related 
mortality rates, hospitalisations and burden of cancer 
were performed using the ACD (from 1982 to 2014), 
NMD (1982 to 2014), NHMD (2000 to 2015) and ABDS 
(2011 to 2015) population data sets, respectively. Trend 
analyses were done across sex, state and socioeconomic 
status over these periods. To identify changes in cancer 
parameters trends, joinpoint regression analysis was 
performed using the Joinpoint Regression Programs, 
V.4.5.0.1.49 The annual percentage change (APC) in rates 
between trend- change points (ie, joinpoint segment) 
was calculated, and it also estimated the average annual 
percentage change (AAPC) in the whole study period. 
A negative APC indicates a decreasing trend whereas a 
positive APC indicates an increasing trend. Furthermore, 
increased or decreased APC of cancer- related outcomes 
were examined by the magnitude of cancer’s impact over 
the period.
To measure the APC, the following model was used:
 log(Yx) = b0 + b1x  (4)
where, log (Y
x
) is the natural logarithm of the rate in 
year x. Then, the APC from year ‘x’ to year ‘x+1’ was:
 
APC = eb0+b1
(x+1)
−eb0+b1x
eb0+b1x × 100 =
(
eb1 − 1
)
× 100
 (5)
Then, AAPC was estimated as a weighted average of 
the estimated APC in each segment by using the segment 
lengths as weights.
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AAPC =
(
e
∑(Si×APCi
)
∑ Si − 1
)
× 100
 
(6)
where, S
i
=i th segment lengths (i=1, 2, 3, …, n), APC
i
=i th 
annual percentage change.
 Measuring socioeconomic inequality
Index of Economic Resources (IER) was measured in 
quintiles, with the first quintile (Q
1
) representing the 
lowest 20% of the total population living in the most 
impoverished socioeconomic areas, and the fifth quin-
tile (Q
5
) representing the top 20% of the total popula-
tion living in the most prosperous socioeconomic areas. 
Inequality analyses were constructed for cancer incidence, 
cancer- related mortality and DALYs across the different 
IER quintiles. The absolute and relative differences (eg, 
least advantaged- most advantaged difference, LMD and 
least advantaged- most advantaged ratio, LMR) in cancer 
incidence, cancer- related mortality, YLL, YLD and DALY 
were calculated to examine the magnitude and direction 
of the cancer outcomes across different socioeconomic 
groups. A high value of the LMR and LMD represents 
a high degree of socioeconomic inequality.16 The ratio 
of cancer mortality and incidence (M/I) was measured 
to capture the survival inequality of cancer patients. The 
measures of the concentration index (CI) (Erreygers’ CI) 
was used to examine the magnitude of socioeconomic 
inequality and the trends in adverse cancer outcome 
changes during the period.50
 Multivariate analysis
The fatal cancer burden (eg, YLL) was considered as the 
outcome variable in the analytical exploration. YLL is 
characterised by a large cluster of data and a right- skewed 
distribution, but the zero values were excluded from the 
analysis. The natural logarithm of YLL was used to reduce 
the effects of the skewed nature of the burden of cancer 
data. In the multivariate analysis, natural logged YLL was 
predicted using different patients’ characteristics related 
to demographics (eg, sex), state, socioeconomic position 
and geographical distribution (eg, remoteness). A gener-
alised linear model (GLM) was constructed to examine 
these associations. The model was tested for sensitivity by 
including and excluding specific variables and estimating 
the robust SEs. A series of diagnostic tests were performed, 
such as tests on the presence of heteroscedasticity, multi-
collinearity and omitted variables. The Breusch- Pagan/
Cook- Weisberg test was used to check the presence of 
heteroscedasticity in the model. Variance Inflation Factor 
test was performed to examine the presence of multicol-
linearity. The Ramsey Ramsey Regression Equation Spec-
ification Error Test (RESET) test was to check if there is 
any omitted variable bias in the model. The outcome of 
the GLM analysis is presented as adjusted regression coef-
ficients with robust SEs along with 95% CIs. Data manage-
ment and all statistical analyses were performed using 
Stata/SE 13.0 (StataCorp, College Station, Texas, USA). 
A p value <0.05 was considered statistically significant.
ethics
This study was conducted using the publicly accessible 
AIHW online data sources and cancer- related published 
reports. Ethical approval was not required from an insti-
tutional review board because the patient information 
was de- identified.
Patient and public involvement
Patient and public were not involved in the design or 
planning of this study.
results
 trends in cancer incidence and cancer-related mortality
The overall incidence of cancer among males significantly 
increased from 1982 to 1994, and then increased expo-
nentially until 2014 (figure 1). The rate of cancer inci-
dence among females also showed an increasing trend 
from 1982 to 2014. The cancer incidence rate increased 
from 1984 (2507 cases) to 1991 (3896 cases) in South 
Australia, after which the rate increased slightly during 
the period 1992 (3994 cases) to 2002 (4127 cases), and 
then increased again until 2014 (5392 cases). A similar 
trend was observed for males in New South Wales and 
Western Australia. A sharp reduction of cancer inci-
dence was seen during 1994 (1333 cases) to 1997 (1100 
cases), and the overall rate increased during 1998 to 2008 
(1124 cases to 1889 cases) in Tasmania. In the Northern 
Territory and Australian Capital Territory, the incidence 
of cancer increased exponentially for both males and 
females throughout the period. The overall cancer- 
related mortality rate also increased for both males (eg, 
5000 cases in 1982 to 8470 cases in 2014) and females (eg, 
3952 cases in 1982 to 6490 cases in 2014) in New South 
Wales from 1982 to 2014. Further, a similar trend was 
observed for male and female in Victoria, Queensland, 
Western Australia, South Australia and Tasmania during 
the period 1982 to 2014 (figure 2). However, in the 
Northern Territory and Australian Capital Territory, little 
change from the trend was observed.
 distribution of average annual percentage change in cancer 
incidence and cancer-related mortality
Cancer incidence was measured as an AAPC over the 
period 1982 to 2014 (figure 3). Cancer incidence 
increased by an AAPC of 1.33% over the period 1982 
to 2014, with the AAPC slightly higher for males 1.38% 
compared with females 1.29%. The highest AAPC was 
found in Northern Territory (2.57%), followed by 
the Australian Capital Territory (1.78%) and Western 
Australia (1.65%). In NewSouth Wales (NSW), the rate 
of cancer incidence increased steadily from 1982 to 1994 
and then oscillated until 2013. Similarly, the percentage 
change of cancer incidence rate increased among females 
over time. Cancer mortality rate rose 0.76% from 1982 
to 2014, and the mortality rate among females (0.78%) 
was slightly higher compared with males (0.73%). In 
the Northern Territory, cancer- related mortality rate was 
comparatively very high among males (1.98%), while 
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Figure 1 Trends of cancer incidence by sex and state, Australia, 1982 to 2014. ACT,Australian Capital Territory; NSW, New 
South Wales; NT, Northern Territory;QLD, Queensland; SA, South Australia; WA, Western Australia.
cancer- related mortality rates were found to be compara-
tively highest among females in Queensland (1.21%) and 
Australian Capital Territory (1.13%).
 trends in cancer-related hospitalisation
A total of 13 213 340 cancer- related hospitalisation cases 
were observed, of which 66.91% were for same- day 
treatment and 33.09% were overnight hospitalisations 
(figure 4). The AAPC of overall cancer- related hospital-
isations increased by 1.27% as a whole, wherein same- day 
and overnight were 1.35% and 1.19%, respectively, 
higher over the period. The overnight hospitalisation 
rate fell over the period with a comparative increase in 
the same- day hospitalisation rate.
 trends in fatal cancer burden
An upward trend of the fatal burden of cancer was 
observed over the 2011 to 2015 period (figure 5). Males 
experienced a relatively higher burden (AAPC=0.89%) 
compared with females (AAPC=0.78%). The magnitude 
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Figure 2 Trends of cancer mortality by sex and state, Australia, 1982 to 2014. ACT,Australian Capital Territory; NSW, New 
South Wales; NT, Northern Territory;QLD, Queensland; SA, South Australia; WA, Western Australia.
of the burden also varied across the states. For example, 
the rate of years of life lost increased by 9950 YLL 
(AAPC=1.16%) in Queensland, 2612 YLL (AAPC=0.22%) 
in NSW, 5838 YLL (AAPC=1.42%) in WesternAustralia, 
2034 YLL (AAPC=0.63%) in SouthAustralia and 1253 
YLL (AAPC=2.57%) in the AustralianCapital Territory. A 
major reduction in the fatal burden of cancer occurred 
among females (11 339 YLL, AAPC=−1.53%) in Tasmania 
and for males (3532 YLL, AAPC=−0.72%) in Victoria.
 the magnitude of socioeconomic inequality for cancer 
patients
Cancer incidence was highest among the poorest quin-
tile (table 2). Similarly, the age- specific cancer incidence 
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Figure 3 Distribution of cancer outcomes in Australia, 1982 to 2014.
Figure 4 Distribution of cancer- related hospitalisations by same- day and overnight status in Australia, 2000 to 2015. 
AAPC, average annual percentage change; ACT, AustralianCapital Territory; NSW, New South Wales; NT, Northern Territory; 
QLD,Queensland; SA, South Australia; TAS, Tasmania; VIC, Victoria; WA, WesternAustralia.
was marginally highest among the poorest group. 
Furthermore, the poorest were 1.083 times more likely 
to be exposed to cancer than the richest and the poor/
rich difference amounted to an additional 9873 cases 
per year. The cancer- related mortality rate difference 
was even starker with the LMR (1.513 times) and LMD 
(17 770 cases/100 000 persons). The overall ratio of 
(LMR of mortality) and (LMR of incidence) was high 
(M/I=1.276). Again, it has been revealed that nearly 
34% more least advantaged group of people experienced 
cancer- related mortality compared with most advantaged 
economic resources of people. The overall magnitude of 
cancer incidence (CI=−0.029, p<0.01) and cancer- related 
mortality rate (CI=−0.011, p<0.05) were highest in the 
least advantaged group.
This skewed distribution was also true for the individual 
types or sites of cancer (table 3). The highest contribu-
tors to the socioeconomic inequality- mortality gap were 
colorectal (LMR=1.327 times), pancreas (LMR=1.336 
times), lung (LMR=1.965 times), cervix (LMR=1.363 
times), kidney (LMR=1.344 times), bladder (LMR=1.433 
times) and unknown primary cancer (LMR=1.660 times). 
Further, the ratio (LMR of mortality) and (LMR of 
incidence) was especially high for cervix (M/I=1.802), 
prostate (M/I=1.514), melanoma (M/I=1.325), non- 
Hodgkin's lymphoma (M/I=1.325) and breast (M/
I=1.318), suggesting that survival inequality was most 
pronounced for these cancers. The high value of the 
concentration index (CI) of different cancers, such 
as lung (CI=−0.060), melanoma (CI=−0.087), breast 
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Figure 5 Trends of fatal burden of cancer across states, Australia, 2011 to 2015.
(CI=−0.104), prostate (CI=−0.076) and non- Hodgkin's 
lymphoma (CI=−0.078), indicates that cancer inci-
dence was disproportionately distributed in the least 
economic resources quintile. In addition, a high degree 
of inequality in cancer related- mortality occurred across 
the different economic resources quintiles. Significant 
negative CI of mortality by different types of cancer, 
such as lung (CI=−0.066), melanoma (CI=−0.034), breast 
(CI=−0.048), cervix (CI=−0.095) and unknown primary 
cancer (CI=−0.043), reflected that mortality due to these 
types of cancers was more highly concentrated among the 
least advantaged economic resources group. Likewise, 
the number of deaths related to all types of cancer was 
highest among the least advantaged group. As a result, 
LMR is more than 1, and LMD is positive for all types of 
cancer- related mortality.
The magnitude of the fatal burden of cancer increases 
with a decline of the socioeconomic status of cancer 
patients (table 4). A notable difference was observed in 
the distribution of the fatal burden of cancer between 
the least advantaged and most advantaged quintiles. In 
2011, people in the least advantaged quintile experi-
enced high YLL (LMR=1.50 times, LMD=62.00 YLL/1000 
persons) compared with the richest quintile, and it 
had increased again slightly by 2015 (LMR=1.57 times, 
LMD=66.00 YLL/1,000 persons). The annual rate of 
years of life lost declined constantly (AAPC=−0.87%) 
across different quintiles over the period, and the rate 
of reduction was greatest in the most advantaged quin-
tile (AAPC=−1.69%) compared with the least advantaged 
quintile (AAPC=−0.63%). The fatal burden of all cancers 
was found to be highest in the least advantaged quintile 
(table 5). The annual reduction rate of cancer burden 
was highest in the most advantaged quintile compared 
with the least advantaged quintile. People diagnosed with 
cancer from the least advantaged economic resources 
areas bear a significant share of the total fatal burden 
(25%) compared with people from the most advantaged 
quintile (15%) (online supplementary appendix figure 
A1). However, a reduction in the share of fatal burden of 
cancer has been observed across all quintiles except the 
second quintile (AAPC=0.65% for Q
2
).
 Factors influencing the fatal burden of cancer
The regression coefficients were interpreted as the effect 
of a 1% change in the characteristics of cancer patients on 
the 1% change in YLL (table 6). These results show that 
a 1% increase in the proportion of male cancer patients 
slightly increased the YLL from 3.87% to 4.19%. In very 
remote areas the YLL increased by 32.05% in 2011 but 
reduced in 2015 by 22.75%.
However, the cancer burden was significantly increased 
for those who lived in remote, inner or outer regional 
areas during the period. In terms of geographical distribu-
tion, patients from New South Wales (32%) experienced 
a significantly higher burden, followed by Victoria (30%) 
and Queensland (25%), but the changes were stable 
during this period. In Western Australia and Tasmania, 
the burden of cancer significantly increased, by 15.72% 
to 20.80% and 6.29% to 7.90%, respectively. However, 
the burden of cancer declined for others, including the 
Northern Territory from 3.77% to 2.43%, and South 
Australia from 18.65% to 16.65%. Similarly, the magni-
tude of the cancer burden increased for those in the least 
advantaged economic resource quintiles.
disCussiOn
This study aimed to reveal the trends in cancer inci-
dence, related mortality and cancer burden, as well as 
measure the magnitude of inequality in cancer mortality, 
incidence and DALYs during the period of 1982 to 
2014 in Australia. The study design was an incidence- 
based on from a health system perspective. Overall inci-
dence and mortality showed an upward trend over the 
period and the highest average increase in incidence 
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Table 2 Socioeconomic inequality of cancer incidence and mortality in Australia
Index of socioeconomic resources
Cancer incidence* Cancer mortality†
Age- standardised 
mortality rates/ 
incidence rates (M/I)
Number of 
new cases 
(N)
Per cent 
(%)
Average 
number of 
new cases ASIR
Number of 
deaths
(N)
Per cent 
(%)
Average 
number of 
new cases ASMR
Q
1
 (least advantaged) 128 553 21.60 25 711 508.50 52 418 24.12 10 484 190.00 0.374
Q
2
128 472 21.58 25 694 507.70 49 353 22.71 9871 178.70 0.352
Q
3
118 500 19.91 23 700 494.30 43 572 20.05 8714 168.30 0.340
Q
4
108 053 18.15 21 611 487.60 37 358 17.19 7472 158.60 0.325
Q
5
 (most advantaged) 118 680 19.94 22 336 488.20 34 648 15.94 6930 142.90 0.293
Total 595 258 100.00 119 303 498.90 217 349 100.00 43 566 168.80 0.338
(Q
1
/Q
5
) 1.083 1.083 1.151 1.042 1.513 1.513 1.513 1.330 1.276
(Q
1
- Q
5
) 9873 1.659 3375 20.300 17 770 8.176 3554 47.100 2.320
(Q
1
- Q
3
)/Q
1
0.078 0.078 0.078 0.028 0.169 0.169 0.169 0.114 4.071
(Q
3
- Q
5
)/Q
3
−0.002 −0.002 0.058 0.012 0.205 0.205 0.205 0.151 12.583
(Q
1
- Q
5
)/Q
1
0.077 0.077 0.131 0.040 0.339 0.339 0.339 0.248 6.201
CI (SE)
Probability value (p value)
−0.029 (0.001)
0.001
−0.011 (0.002)
0.047
Qi=i th index of economic resources (i=1, 2… 5; higher i represents a quintile with most advantaged economic resources), Q
1
- Q
5
=least most advantaged economic resources difference (LMD), 
Q
1
/Q
5
=least most advantaged economic resources ratio (LMR).
*Incidence reported from 2008 to 2012.
†Mortality rate reported from 2010 to 2014.
ASIR, Age- standardised incidence rates; ASMR, Age- standardised mortality rates; CI, concentration index; SE, SE error.
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Table 3 Distribution of cancer cases (2008 to 2012) and cancer- related mortality (2010 to 2014) by cancer site/type and socioeconomic status in Australia
Cancer cases by 
selected cancer 
site/type
Index of economic resources Degree of inequality
Q
1
Q
2
Q
3
Q
4
Q
5
Q
1
/Q
5
Q
1
- Q
5
(Q
1
- Q
3
)/Q
1
(Q
3
- Q
5
)/Q
3
(Q
1
- Q
5
)/Q
1
Concentration 
index
(LMR of mortality)/
(LMR of incidence)
Colorectal 16 746 16 446 14 770 12 941 12 620 1.327 4126 0.118 0.146 0.246 −0.014 –
Pancreas 3176 2980 2715 2438 2377 1.336 799 0.145 0.124 0.252 −0.015 –
Lung 14 142 12 310 10 488 8556 7196 1.965 6946 0.258 0.314 0.491 −0.065** –
Melanoma 10 998 12 155 11 681 10 721 12 170 0.904 −1,172 −0.062 −0.042 −0.107 0.087* –
Breast 13 504 14 363 14 075 13 959 15 735 0.858 −2,231 −0.042 −0.118 −0.165 0.104* –
Cervix 938 894 756 752 688 1.363 250 0.194 0.090 0.267 −0.014 –
Prostate 20 657 22 087 20 793 19 057 21 636 0.955 −979 −0.007 −0.041 −0.047 0.076** –
Kidney 3272 3158 2829 2568 2434 1.344 838 0.135 0.140 0.256 −0.014 –
Bladder 2881 2672 2508 2129 2011 1.433 870 0.129 0.198 0.302 −0.002 –
Non- Hodgkin's 
lymphoma
4653 4659 4564 4482 4654 1.000 -1 0.019 −0.020 0.000   0.001** –
Unknown primary 
site
3264 3016 2525 2172 1966 1.660 1298 0.226 0.221 0.398 −0.031 –
Others 34 322 33 732 30 796 28 278 28 193 1.217 6129 0.103 0.085 0.179 −0.063 –
All cancers 
combined 128 553 128 472 118 500 108 053 111 680 1.151 16 873 0.078 0.058 0.131 −0.079** –
Cancer- related 
mortality by selected 
cancer site/type
Index of economic resources Degree of inequality
Q1 Q2 Q3 Q4 Q5 Q1/Q5 Q1- Q5 (Q1- Q3)/Q1 (Q3- Q5)/Q3 (Q1- Q5)/Q1
Concentration 
index)
(LMR of mortality)/
(LMR of incidence)
Colorectal
Pancreas
Lung
Melanoma
Breast
Cervix
Prostate
Kidney
Bladder
Non- Hodgkin's 
lymphoma
Unknown primary site
Others
4780
2906
10 935
1638
3064
334
3714
1109
1225
1594
3414
17 705
4426
2709
9749
1664
3013
267
3676
1037
1173
1608
3181
16 850
4037
2509
8248
1543
2780
207
3234
968
1057
1458
2587
14 944
3620
2247
6483
1367
2631
190
2651
769
869
1262
2228
13 041
3334
2105
5430
1367
2709
136
2568
707
827
1201
1937
12 327
1.434
1.381
2.014
1.198
1.131
2.456
1.446
1.569
1.481
1.327
1.763
1.436
1446
801
5505
271
355
198
1146
402
398
393
1477
5378
0.155
0.137
0.246
0.058
0.093
0.380
0.129
0.127
0.137
0.085
0.242
0.156
0.174
0.161
0.342
0.114
0.026
0.343
0.206
0.270
0.218
0.176
0.251
0.175
0.303
0.276
0.503
0.165
0.116
0.593
0.309
0.362
0.325
0.247
0.433
0.304
 ► 0.004
 ► 0.011
 ► 0.066*
 ► 0.034**
 ► 0.048**
 ► 0.095*
 ► 0.007
 ► 0.017
 ► 0.009
 ► 0.014
 ► 0.043*
 ► 0.001
1.081
1.034
1.025
1.325
1.318
1.802
1.514
1.167
1.033
1.327
1.062
1.180
All cancers combined 52 418 49 353 43 572 37 358 34 648 1.513 17 770 0.169 0.205 0.339 −0.011** 1.315
Qi=i th index of economic resources (i=1, 2… 5; higher i represents a quintile with most advantaged), Q
1
- Q
5
=least advantaged- most advantaged difference (LMD), Q
1
/Q
5
=least advantaged- most advantaged ratio (LMR). *p<0.01, §p<0.05.
*p<0.01, **p<0.05.
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Table 4 Burden of cancer (YLL, YLD and DALY/1000) across socioeconomic groups, 2011 to 2015
Associated 
burden of cancer 
and annual 
percentage 
change
Index of economic resources Degree of inequality
Q
1
Q
2
Q
3
Q
4
Q
5
Q
1
- Q
5
Q
1
/Q
5
(Q
1
- Q
3
)/Q
3
(Q
3
- Q
5
)/Q
3
(Q
1
- Q
5
)/Q
5
Australian burden of diseases study − 2011
  Fatal burden
  (1) YLL 187.00 175.00 161.00 136.00 125.00 62.00 1.50 0.14 0.22 0.50
  (2) ASR 38.10 34.60 32.40 29.50 26.30 11.80 1.45 0.15 0.19 0.45
  (3) Rate ratio 1.40 1.30 1.20 1.10 1.00 0.40 1.40 0.14 0.17 0.40
  Non- fatal burden
  (4) YLD 10.00 10.00 10.00 10.00 10.00 0.00 1.00 0.00 0.00 0.00
  (5) ASR 2.10 2.00 1.90 2.10 2.10 0.00 1.00 0.10 −0.11 0.00
  (6) Rate ratio 1.00 1.00 0.90 1.00 1.00 0.00 1.00 0.10 −0.11 0.00
  Total burden
  (7) DALY 197.00 185.00 171.00 146.00 135.00 62.00 1.46 0.13 0.21 0.46
  (8) ASR 40.20 36.60 34.30 31.60 28.40 11.80 1.42 0.15 0.17 0.42
  (9) Rate ratio 1.40 1.30 1.20 1.10 1.00 0.40 1.40 0.14 0.17 0.40
Australian burden of diseases study − 2015
  Fatal burden
  (10) YLL 186.60 184.03 166.63 139.97 124.22 62.38 1.50 0.11 0.34 0.50
  (11) ASR 34.00 32.70 30.80 27.70 24.10 9.90 1.41 0.09 0.28 0.41
  (12) Rate ratio 1.60 1.40 1.30 1.20 1.10 0.50 1.45 0.19 0.18 0.45
  Non- fatal burden
  (13) YLD 12.97 13.31 12.58 12.32 12.98 −0.01 1.00 0.03 −0.03 0.00
  (14) ASR 2.30 2.30 2.30 2.40 2.50 −0.20 0.92 0.00 −0.08 −0.08
  (15) Rate ratio 1.04 1.00 0.91 1.00 1.00 0.04 1.04 0.13 −0.09 0.04
  Total burden
  (16) DALY 199.57 197.34 179.21 152.29 137.20 62.37 1.45 0.10 0.31 0.45
  (17) ASR 36.30 35.00 33.10 30.10 26.60 9.70 1.36 0.09 0.24 0.36
  (18) Rate ratio 1.40 1.30 1.20 1.10 1.00 0.40 1.40 0.14 0.20 0.40
Annual percentage change
  YLL −0.04 1.01 0.69 0.58 −0.13 0.12 0.03 −5.23 9.19 0.09
  YLD 5.34 5.89 4.70 4.26 5.35 – −0.02 – – –
Continued
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was found in the Northern Territory, Australian Capital 
Territory and Western Australia. Also, the proportion of 
cancer- related hospitalisation has increased and is domi-
nated by same- day hospitalisations. Further, the survival 
inequality in terms of LMR of mortality and LMR of 
incidence was especially high for prostate, cervix, mela-
noma, non- Hodgkin's lymphoma and breast, suggesting 
that survival inequality was most pronounced for these 
cancers. Overall, the fatal burden of cancer exhibited an 
increasing trend over the period.
The study’s findings support a growing body of 
research evidence that has found the incidence of cancer 
and cancer- related mortality to be increasing in other 
country settings.14 51–54 These increasing trends have been 
pronounced in the last couple of decades globally.6 52 53 The 
WHO55 and the Sustainable Development Goals56 have 
outlined the increasing burden of non- communicable 
diseases that include cancer, and have promoted initia-
tives to control and prevent future increases through 
action plans. Still, the burden of cancer has been growing 
in Australia over the last decades.24 Four driving forces 
have contributed to this: first, increased exposure to risk 
factors (for example, unbalanced and industrialised- type 
diets)57 as well as a high prevalence of obesity58 59; second, 
improved health outcomes (eg, life expectancy)4 and 
demographic transition (eg, ageing and growth of popu-
lation)5 has reduced death rates compared with other 
causes of death; third, widespread urbanisation (respon-
sible for the change in lifestyles),60 exposure to smoking61 
and alcohol consumption60 are contributing to devel-
oping higher cancer risk60 62 and fourth, overdiagnosis is 
considered another potential driving force for increasing 
cancer incidence and related mortality. It is evident from 
past studies that overdiagnosis has played a significant role 
in increasing the burden of cancer63 but that the rising 
magnitude of cancer burden among Australians may 
not be entirely explained by overdiagnosis.64 Therefore, 
further research that explores the potential risk factors 
may contribute to a deeper understanding of the reasons 
behind the increasing burden of cancer in Australia.
This study found that survival inequality was most 
pronounced for prostate cancers and consistent with 
previous studies.65 66 Evidence about underlying causes 
to explain inequalities in prostate cancer. Some possible 
explanations can be considered such as factors associated 
with the tumour (eg, stage at diagnosis, biological char-
acteristics), the patient (comorbidity, health behaviour, 
psychosocial factors) and the healthcare (treatment, 
medical expertise, screening).65–67 Furthermore, the util-
isation rate of screening services is lower among pros-
tate cancer patients with disadvantaged socioeconomic 
status.68 69 Moreover, patient factors as comorbidity or 
health behaviour can interact with treatment modalities 
or disease stage and additionally have a potential impact 
on inequalities in survival.70 71 Further, an increased 
likelihood of surveillance as treatment among patients 
with severe comorbidity while radical prostatectomy was 
significantly less likely to be offered.65 66 69 70 Some studies 
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Table 6 Association of fatal cancer burden (natural logged of years of life lost) with sex, remoteness, location and 
socioeconomic resources
Variables
Model 1 Model 2
Coefficient
(SE) P value 95% 
Coefficient
(SE) P value 95% 
Sex
  Male 0.038 (0.034) 0.01 (0.014 to 0.088) 0.041 (0.026) 0.010 (0.011 to 0.091)
  Female (ref) ref – – ref – –
Remoteness
  Major cities (ref) ref – – ref – –
  Inner regional 0.042 (0.002) <0.001 (0.014 to 0.080) 0.100 (0.003) <0.001 (0.025 to 0.174)
  Outer regional 0.149 (0.007) <0.001 (0124 to 0.158) 0.158 (0.001) <0.001 (0.103 to 0.253)
  Remote 0.158 (0.006) <0.001 (0.113 to 0.246) 0.189 (0.004) <0.001 (0.149 to 0.343)
  Very remote 0.278 (0.009) <0.001 (0.211 to 0.344) 0.205 (0.002) <0.001 (0.131 to 0.379)
Location (States)         
  Australian Capital Territory (ref) ref – – ref – –
  New South Wales 0.282 (0.008) <0.001 (0.187 to 0.376) 0.278 (0.008) <0.001 (0.184 to 0.372)
  Northern Territory 0.037 (0.009) 0.336 (−0.039 to 0.113) 0.024 (0.004) 0.560 (−0.055 to 
0.103)
  Queensland 0.234 (0.008) <0.001 (0.139 to 0.327) 0.223 (0.005) <0.001 (0.125 to 0.321)
  South Australia 0.171 (0.005) <0.001 (0.084 to 0.258) 0.154 (0.005) <0.001 (0.065 to 0.243)
  Tasmania 0.061 (0.004) 0.167 (−0.026 to 0.148) 0.076 (0.002) 0.070 (−0.007 to 
0.158)
  Victoria 0.268 (0.005) <0.001 (0.179 to 0.357) 0.263 (0.005) <0.001 (0.174 to 0.351)
  Western Australia 0.146 (0.009) <0.003 (0.048 to 0.244) 0.189 (0.004) <0.001 (0.104 to 0.275)
Index of economic resources         
  Q
1
 (least advantaged) 0.063 (0.002) 0.032 (0.019 to 0.146) 0.073 (0.004) 0.040 (0.032 to 0.159)
  Q
2
0.042 (0.004) 0.331 (−0.043 to 0.128) 0.046 (0.007) 0.320 (−0.045 to 
0.138)
  Q
3
0.039 (0.001) 0.343 (−0.042 to 0.120) 0.042 (0.004) 0.330 (−0.044 to 
0.128)
  Q
4
0.011 (0.003) 0.795 (−0.073 to 0.096) 0.010 (0.005) 0.830 (−0.079 to 
0.098)
  Q
5
 (most advantaged) ref – – ref – –
Constant 0.931 (0.004) <0.001 (0.885 to 0.978) 0.899 (0.008) <0.001 (0.864 to 0.935)
Family distribution Gaussian distribution Gaussian distribution
Link function Identity Identity
Deviance   25.13   14.85
Link- test (beta hat) 0.110 (0.018) <0.001 (0.075 to 0.145) 0.103 (0.008) <0.001 (0.087 to 0.119)
AIC 1.07 1.02
BIC 2.92 3.05
Note: Models 1 and 2 were constructed for 2011 and 2015, respectively; ref=reference group.
AIC, Akaike information criterion; BIC, Bayesian information criterion.
conducted in England,72 Australia73 and the USA74 also 
revealed that socioeconomically disadvantaged patients 
have a reduced likelihood of having radical prostatec-
tomy compared with patients with disadvantaged socio-
economic status who utilised more regularly hormone 
therapy, active surveillance, watchful waiting and partly 
radiation. There is an ongoing debate regarding the signif-
icant role of healthcare management as a contributing 
factor to inequalities in survival among prostate cancer 
patients.67
The results show that the overall incidence, cancer- 
related mortality and cancer burden (eg, YLL, YLD and 
DALYs) were significantly higher among the least advan-
taged group compared with the most advantaged. It was 
also found that the least advantaged quintile on average 
experienced 34% more cancer- related mortality than 
68
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their most advantaged counterparts. Similarly, patients 
in the least advantaged group experienced a significantly 
higher burden of cancer in terms of YLL (6.50% to 7.57%) 
compared with the richest (1.11%) from 2011 to 2015. 
Previous studies have also reported similar inequalities 
in YLL,75 76 whereas, a high proportion of patients in the 
most- deprived groups experienced very high years loss of 
life. Even though survival rates after cancer diagnosis have 
improved in recent years,7 disparities in cancer outcomes 
between the least- deprived and the most- deprived groups 
continue to persist. The magnitude of the cancer burden 
is negatively associated with socioeconomic status.77–80 For 
example, adverse health outcomes (eg, worse health status 
and shorter life expectancy) are disproportionately found 
in poorer people compared with those in higher quin-
tiles.77–80 Some reasons that have contributed to the high 
rate of cancer burden among the poorest groups includes 
smoking exposure,51 77 poverty and economic burden,61 81 
increased psychological pressure,3 lack of health educa-
tion and awareness82 and lower access to competent and 
effective public health interventions.82 There are several 
factors which lead to increased breast cancer incidence 
and cancer- related mortality. These can be classified into 
patients, tumour and treatment characteristics.83–85 These 
characteristics include patient age, ethnicity, tumour 
type, size, grade, stage, hormone receptor status, type of 
surgery and the use of adjuvant therapies.83–85 A recent 
review study demonstrated that treatment‐related factors 
and socioeconomic disadvantage are also responsible for 
high cancer burden in Australia.84
Moreover, low productivity, loss/reduction of house-
hold income and increased expenditure due to illness 
result in reduced earnings and higher expenditure that 
further disadvantage the poorest. Growing socioeco-
nomic inequalities of cancer outcomes need the atten-
tion of governments, health systems and decision- makers. 
These initiatives should aim for universal cancer care 
in all states. A sustained reduction of socioeconomic 
inequalities, which concerns poverty, gender, education 
and health, should promote universal equality in health 
and well- being and further enhance both socioeconomic 
and human development.
The present study has also identified that the fatal 
burden of cancer was high in 2011 among patients in very 
remote areas, but it was reduced by 2015. Similarly, the 
burden of cancer was high in New South Wales, Victoria 
and Queensland; however, the magnitude of fatal burden 
was unchanged during 2011 to 2015. Some previous 
studies have shown consistent findings, which have 
confirmed that the proportion of life lost for patients 
in geographical disadvantaged or low- resource settings 
had a higher cancer burden than their more advantaged 
counterparts.75 76 Socioeconomic inequalities in terms of 
poorer survival for geographically isolated patients was 
observed in cancer types in Australia including breast 
and colorectal cancer.86 Several issues might be asso-
ciated with a high burden of cancer among patients 
in regional and remote Australia, including a lack of 
appropriate skills among health professionals and a lack 
of adequate resources being available in remote and 
smaller cities.15 33 87 A recent study conducted in regional 
Australia identified that there was a paucity of medical 
professionals with expertise and appropriate cancer 
training in regional areas.68 The study also confirmed 
that a lack of communication and coordination persisted 
between different medical professionals (such as oncolo-
gists and GPs) and across geographical locations (major 
vs regional centres).
Difficulty in service accessibility and availability of 
appropriate cancer care services is faced by residents of 
rural, remote communities in Australia.87 However, only 
30% of the population lives outside the major cities.88 
The federal government has committed to improving the 
cancer infrastructure by building a network of new and 
enhanced regional cancer centres in regional Australia.89 
Furthermore, innovative cancer care models, including 
mobile clinics incorporating video conference and tele- 
oncology, have been introduced in order to address 
the challenges of distance. Advanced technology- based 
services such as tele- oncology have been implemented 
in Western Australia and North Queensland, allowing 
regional cancer patients to use the latest treatments 
including specialist consultations and chemotherapy 
treatments.90 91 These models have also been imple-
mented in the USA and Canada to ensure maximum 
access to services among people in limited resources 
settings, with high levels of satisfaction and acceptance 
of services.90–94
This study contributes to the existing literature by 
providing first- hand evidence on the trends of incidence, 
mortality and burden of cancer, using Australian nation-
ally representative population- based data. This study has 
used large national level data sets covering all states over 
the past 33 years. Due to paucity of survival data, this 
study has not captured in details inequalities regarding 
the cancer survivorship. However, there is a limited 
understanding of what is driving these changes of cancer 
outcomes reported here which may reflect random vari-
ation or changes in unknown risk factors, and therefore 
highlight the need for more research into the aetiology 
of cancer.
COnClusiOns
The overall burden of cancer is substantial in Australia 
across all socioeconomic strata and geographical regions. 
Compared with socioeconomically advantaged people, 
disadvantaged people had a substantially higher risk of 
cancer incidence and cancer- related mortality. Those 
living in remote areas also bear a higher burden than 
those in urban areas who are closer to prevention and 
treatment services. The findings of this study can inform 
efforts by healthcare policymakers and those involved in 
healthcare systems to improve cancer survival in Australia. 
This work also suggests that the provision of universal 
cancer care can reduce the burden by ensuring curable 
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and preventive cancer care services are accessible for all 
people regardless of socioeconomic status or location.
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2.2 Study 2 
Cancer burden: Long-term health status burden 
and consequences 
 
The first study of this thesis explored the understanding challenges of long-term 
national level cancer outcomes in Australia. Study 2 examined the long-term health 
status burden and consequences over an extended period.  
Article II: The impact of lifestyle risk factors, life satisfaction and chronic 
comorbid conditions on influencing in longitudinal health status burden among 
Australian cancer patients, 2013-2017 
 
The purpose of Study 2 was to examine longitudinal measures in health status burden 
among cancer patients and its associated predictors. The findings of the study 
showed that approximately 36% of cancer survivors had an initial high health status 
burden in 2013, while it had declined significantly (21%) by 2017. This was 
evidenced in significant improvements in body pain, social functioning, and mental 
health measures. Adequate levels of sleep, physical activity, social support, and 
higher economic status were significantly associated with improving health status. 
Factors that negatively influenced changes in health status burden included being 
unemployed, Indigenous, uninsured, living in a regional location, and having 
comorbid conditions. The Study 2 concludes that these findings shed light on which 
benefits attached to the health care system might be more valuable to cancer 
survivors. There is growing recognition of the importance of patient-focused 
outcomes in cancer care. The quality of a person’s life and the personal preferences 
and values of that person guide their health care, and thus should have a high priority 
in policy discussions. 
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2.2.1 Article II 
The impact of lifestyle risk factors, life satisfaction and chronic comorbid 
conditions on influencing in longitudinal health status burden among Australian 
cancer patients, 2013-2017 (under review: BMJ Open) 
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Abstract 
Objective: Cancer is one of the most public health concerns and the second leading 
cause of death worldwide. A cancer diagnosis signifies a negative effect on both 
short-term and long-term changes in their health status. The main objective of this 
study was to examine longitudinal measures in health status burden among cancer 
patients and its associated predictors.  
Settings: The study was conducted in Australia. 
Study design: A mixed longitudinal study design was used. 
Methods: The longitudinal effect was captured using generalized linear mixed 
model (GLMM) which estimated changes in health status burden influenced by 
socio-demographic, lifestyle, life conditions and location specific variables.  
Results: Approximately 36% of cancer survivors had an initial high health status 
burden in 2013, while it had declined significantly (21%) by 2017. The health status 
outcomes improved over the period (59.56 points to 65.06 points; p = 0.05). This 
was evidenced in significant improvements in body pain; social functioning; and 
mental health measures. Adequate levels of sleep, physical activity, social support, 
and higher economic status were significantly associated with improving health 
status. Factors that negatively influenced changes in health status burden included 
being unemployed, Indigenous, uninsured, living in a regional location, and having 
comorbid conditions.  
Conclusions: The study findings shed light on which benefits attached to the health 
care system might be more valuable to cancer survivors. There is growing 
recognition of the importance of patient-focused outcomes in cancer care. The 
quality of a person’s life and the personal preferences and values of that person guide 
their health care, and thus should have a high priority in policy discussions.  
Keywords 
Cancer survivors, Comorbid conditions, Longitudinal, Health status burden, 
Australia.  
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 Strengths and limitations of this study 
 This study examined longitudinal measures in health status burden among 
cancer patients and its associated predictors in the Australian context 
 This study included the prospective design of long term follow up, and the 
application of well-validated and reliable longitudinal wave measures of the 
impacts of cancer diagnosis on the health status burden. 
 
 This study considered the overall health status of cancer survivors, which 
might vary in terms of cancer stages and types of cancer.  
 
 The study findings were based on self-reported information that might have 
been impacted by respondents’ prejudice (e.g., silence and over-response), or 
due to problems in understanding and interpretation.  
Background 
Cancer is one of the most public health concerns and the second leading cause of 
death worldwide [1]; an estimated 9.6 million patients die from cancer each year. In 
Australia, it is also an alarming issue with the health system dealing with 483 new 
cases per 100,000 people in 2019, while on average 136 people will die from cancer 
each day [2]. Cancer accounts for 19% of the total burden of disease, followed by 
15% from cardiovascular diseases, and 12% from mental illness [3]. Increasing 
innovations in medical technology have played a significant role in earlier diagnoses 
and improved courses of treatment of several cancers have resulted in many people 
diagnosed with cancer having improved chances of surviving over the past few 
decades [4,5]. Globally, five-year survival rates have increased significantly from 
50% in 1990 to almost 70% in 2015 [2]. The survival rates vary across cancer type or 
sites in terms of the risk of developing and dying from cancer. Survivors face 
numerous physical, mental, social, spiritual and economic challenges as a result of 
their diagnosis, during their course of treatment, and for the remaining years of their 
lives. In addition, a cancer diagnosis signifies a negative effect on both short-term 
and long-term changes in their health status, including their health-related quality of 
life (HRQoL).  
Many of these problems could be ameliorated through public health initiatives, both 
through the prevention of secondary diseases or recurrence of cancer, and by 
improving the quality of life for each survivor. The quality of life for cancer 
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survivors is significant because of increasing and relatively high survival rates and 
extended life after diagnosis. The majority of cancer survivors living longer will be 
at a higher risk of long-term and late onset effects, as well as developing new cancers 
[5]. Moreover, cancer survivors suffer treatment-related side effects, leading to a 
substantial burden, impairing health status, reducing their independent physical 
capability, and decreasing productivity [6], which together leads to a decrease in a 
victim’s socioeconomic position [4]. Cancer survivors experience may challenge to 
their health status. 
Studying health status among cancer survivors is warranted. Globally, health status 
has been attracting considerable attention. Even with advanced treatment of side 
effects, cancer survivors undergo experiences that often reduce their capacity to 
conduct their usual activities, which in turn may affect their overall health status. 
Measuring health status has been integrated into the examination of treatment 
impacts on quality of life [7]. Understanding the quality of life outcomes of cancer 
survivors is important in examining their adverse post-treatment outcomes and can 
help to improve their health status [8]. The quality of life includes different 
dimensions of health status, such as self-reported functioning and well-being in the 
physical, psychological, and social domains. The concept of quality of life provides a 
comprehensive measure that includes mental, physical and social functioning 
capacity. In recent decades, quality of life assessments has become routine 
examinations used to evaluate health status in terms of treatment outcomes among 
cancer survivors [7–9]. Despite this, very little attention has been paid to measuring 
longitudinal quality of life in diagnosed cancer survivors during the oncology follow-
up period. 
 
A range of studies have previously quantified health status among cancer survivors 
in terms of treatment or surgical outcomes, and access to palliative care in different 
national settings [9–14]. The health status of cancer survivors’ issues is multifactorial 
and complex, and it is not always effortlessly addressed by medical professionals or 
during routine oncology follow-ups. The health status of cancer survivors can be 
adversely affected by pain [15], compromised nutritional status [16], and eating 
problems [17]. The ongoing evidence suggests that modifying or avoiding risk 
factors, such as alcohol consumption and an unhealthy diet with low fruit and 
vegetable intake, can significantly reduce the burden of cancer [1]. Moreover, 
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engaging in physical activities can lead to improved health status outcomes among 
cancer survivors [15].  
 
Similarly, cancer survivors who engage in less sedentary behaviour enjoy better 
quality of life, and this can also significantly contribute to reducing the risk of 
chronic comorbid conditions [18]. Furthermore, the comorbid condition of cancer 
survivors is an important parameter to predict a worse health status [19,20]. The 
patterns of cancer survivors’ life satisfaction factors (e.g., satisfaction with financial 
or social supports) are a crucial predictor of higher health status scores [10,21], but 
these satisfaction trajectories may vary over time. In terms of location, cancer 
survivors who live in remote areas like regional Australia experience a worse quality 
of life than those living in more urban settings [11,16]. The primary intention of 
these studies was to examine the impact of treatment or surgical outcomes on quality 
of life in terms of a cross-sectional, clinical or randomised control trial, considering a 
limited range of variables. The majority of studies pay little attention to examining 
the long-term impact of health status for cancer survivors’ over time. Therefore, it is 
significant for routine oncology follow-ups to explore how cancer survivors’ 
characteristics impact on health status outcomes, by examining the same individuals 
over an extended period.  
 
This study will measure the mixed longitudinal nature of health status outcomes. 
More specifically, the study proposes to develop a better understanding of the health 
burden in terms of quality of life, as well as its impact over longer periods. This 
study complements and contributes to this strand of ongoing cancer research to 
increase awareness and improve public health practice among sufferers and 
survivors, and to measure impact. Further, the findings could contribute to policy 
discussions around designing appropriate interventions or the provision of quality 
healthcare services and resources for ongoing surveillance of people living with, 
through and beyond cancer, and to determine what kinds of support survivors need.  
 
 
The point of departure of this study was to use patients’ self-reporting of their health 
status to examine the longitudinal nature of cancer patients’ health status and to 
determine the factors that predict their health status over the period. This will be 
achieved by using a special data set from the Household, Income and Labour 
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Dynamics in Australia (HILDA) survey. To achieve the research objective, the 
following two research questions (RQ) were posited:  
RQ-1: What is the longitudinal nature of health outcomes and the extent of health 
status burden among cancer patients in Australia? 
RQ-2: How does life style factors reflect on health status burden of cancer survivors 
in Australia?   
 
Material and methods 
Study design and perspective 
Data were extracted from the Household, Income and Labour Dynamics in Australia 
(HILDA) survey which is a nationally representative longitudinal study of Australian 
households. It commenced in 2001 and produces longitudinal data on the lives of 
Australian residents. A wide range of information on relationships, child care, 
employment, income, health and wellbeing is covered. Data were collected from 
selected household members aged 15 or over through face-to-face interviews, using 
quantitative structural instruments and then re-interviews with the same people in 
subsequent years. The study participants were derived from HILDA wave-13 in 2013 
(n = 517) and wave-17 in 2017 (n = 576). However, the present study design was 
considered a mixed longitudinal perspective for two reasons: a limited number of 
cancer patients participated in the HILDA survey; the mortality rate was also high among 
cancer patients, and the temporal changes or treatment effects among the study participants 
were captured. A mixed-longitudinal study design in which several cohorts are 
followed for a shorter period are compared by their precision, potential for bias due 
to age, time and cohort effects, and feasibility. In addition, a mixed longitudinal 
study has two advantages over longitudinal studies: isolation of time and age effects 
and shorter completion time. 
 
The mixed longitudinal study perspective was underpinned by a stress-coping theory 
in order to determine if it could predict HRQoL of cancer survivors over an extended 
period. The analytical framework of the stress-coping theory was designed by 
Lazarus and colleagues [22,23] to investigate which antecedent factors may be 
aligned with better quality of life outcomes. They investigated individuals who faced 
the burden of life-threatening cancer and examined the magnitude of the cancer 
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burden associated with its initial appraisal as well as their ability to manage the 
secondary occurrence appraisal. In terms of secondary appraisal, individuals 
reconsidered their health status based on the magnitude of the burden (as either more 
or less). The theory of stress-coping is that the burden extended over an extended 
period adversely affects health status, including health status outcomes [23]. To 
examine the longitudinal effects of the model, it is hypothesised that several 
antecedent variables (e.g., individual characteristics, social factors, and disease-
related factors), measured at the symptom-level might predict outcome factors 
(appraisal of disease with comorbidities, course of treatment, caregiving, life 
condition, uncertainty). Moreover, the combination of factors (e.g., antecedent and 
outcomes) was assumed to predict patients’ health status outcomes. 
Measuring health status burden of cancer patients   
The quality of life scores was measured using the medical outcomes study short-form 
(SF-36) [24]. The SF-36 is one of the most common and widely used tools when it 
comes to self-completion measures of quality of life, which is widely used to assess 
the burden of disease in the context of different country settings [25]. The SF-36 was 
designed to examine an individual’s health status across eight domains including 
physical functioning, role-physical, body pain, general health, vitality, social 
functioning, role-emotional, and mental health. It has psychometric properties to 
enable profiling of physical functional health and well-being and to quantify disease 
burden across eight domains [26]. Considering these dimensions, the total score on 
each SF-36 subscale ranges between 0 and 100, labelling ‘worst imaginable health’ 
and ‘best imaginable health state’, respectively. It is signified that the higher scores 
represent better health outcomes. Health status burden was measured based on total 
quality of life scores and levels were: high burden if SF-36 score was less than 50 
points; moderate burden if SF-36 score was greater than or equal to 50 but less than 
90; and no burden if SF-36 score was greater than or equal to 90 [27].  
Variable selection 
Several demographic, socioeconomic and health and lifestyle-related variables were 
used as predictors of health status outcomes. The domains of these study variables 
were selected based on stress-coping theory and the literature. The socio-
demographic related variables included were: gender, age, educational background, 
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employment status and marital status. Ethnic background was defined as Aboriginal 
or non-Aboriginal. Lifestyle factors included hours of sleep per night and physical 
activities status. Life conditions-related variables, such as satisfaction with household 
members, employment, financial situation and social supports, were also considered 
as potential predictors. The level of satisfaction-related variables ranged from 0 
(totally dissatisfied) to 10 (totally satisfied). Private insurance coverage of 
participants was defined as dichotomous (‘insured’ if present or ‘uninsured’ 
otherwise). Treatment status was defined as ‘with medication’ or ‘without 
medication’. The comorbid condition was dichotomous as ‘yes’ if the participant had 
arthritis or osteoporosis, chronic bronchitis or emphysema, diabetes, heart or 
coronary disease, depression or anxiety, high blood pressure or hypertension, 
obesity, or any other circulatory condition or other mental illness, or ‘no’ otherwise. 
This study covered each comorbid condition in the analyses, rather than using a 
comorbidity index [28] because such indices were designed to predict survival 
outcomes and include diagnoses associated with morbidity (e.g., arthritis). 
Furthermore, severity information, which is important for measuring a comorbidity 
index, was not captured in the survey data.  
Location was defined according to the accessibility to services and the Remoteness 
Index of Australia [29]. Location was classified into five groups: major cities, inner 
regional, outer regional, and remote or very remote. The index of relative socio-
economic disadvantage (IRSD) was considered to measure socioeconomic status 
(SES). The IRSD was constructed using factors such as the percentage of occupants 
in each statistical local area (SLA) in terms of income and their educational level, and 
whether they were in unskilled occupations, or unemployed [30]. This was a 
geographical area-based estimate of socioeconomic status whereby communities 
were categorised from economically disadvantaged to wealthy. The cut-off values for 
each of the quintiles were as follows: Q1 (IRSD ≤ 927.0), Q2 (927.0 > IRSD ≤ 965.8), 
Q3 (965.8 > IRSD ≤ 1001.8), Q4 (1001.8 > IRSD ≤ 1056.0), or Q5 (IRSD > 1056.0) 
[30]. Each quintile represents an increasing advantage that corresponds to 
geographical settings, covering the 20% of the population in the lowest socio-
economic position (Q1, most disadvantaged), while the fifth quintile (Q5) refers to the 
20% of the population occupying the highest socioeconomic position. 
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Estimation strategies  
The descriptive analyses quantify the distribution of participants reporting health 
status scores over the study period. A paired t-test was performed to compare health 
status scores among cancer survivors, since the mean score of health status outcome 
was continuous and quantitative in nature. Data were gathered from the participants 
across two successive points in time; these repeated data were correlated over the 
period. Generalized linear mixed model (GLMM) was performed to find the potential 
predictors that influenced in health status burden of cancer patients. The GLMM 
model produces more efficient and unbiased regression estimates when examining 
quantitative nature continuous outcome variable in longitudinal study design. The 
GLMM model extends the generalized linear mixed model to accommodate 
correlated data. Longitudinal study design has the purpose of explaining the marginal 
expectations of the outcome as a function of the potential predictors. The GLMM 
model provided a framework for the analyses of quantitative outcomes (e.g., 
continuous outcomes), but relaxes several assumptions of traditional regression 
models. It has however been assumed that the outcome variable (health status scores) 
are linearly connected to the predictors. In addition, the model was tested for 
sensitivity with the robust standard error to ultimately identify a parsimonious model. 
In this study, two-tailed probability values of <0.05 were considered as the 
statistically significant level. Data management and all statistical analyses were 
undertaken using Stata/SE 13.0 (StataCorp, College Station, TX, USA).  
Patient and public involvement: 
Patient and public were not involved in the design or planning of this study. 
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Results 
Background characteristics of study participants 
The distribution of demographic characteristics, the sample consisted of 54% males 
with an average age of 63 (± 17) years in 2013, while this was 56% in 2017. Most 
were aged over 46 years (84%) at diagnosis and 86% in the period of 2017. 
Approximately half of the participants had completed tertiary or technical education, 
and 58% of patients were married. Furthermore, 33% of cancer patients reported 
being employed in 2013, but the proportion of employed wherein 36% in 2017. Two-
thirds of patients exhibited an adequate sleep duration (≥ 6 hours/night) while 50% of 
patients undertook moderate or high-level physical activities each week. Among the 
sample, 60% of cancer survivors had health insurance coverage. Regarding the life 
satisfaction score, the average satisfaction scores (standard deviation) were 8.10 
points (±1.87), 3.32 points (± 3.89), 6.55 points (± 2.48) and 7.76 points (± 1.98), 
respectively, for household member, employment, financial situation and social 
supports. In terms of comorbid conditions at diagnosis: arthritis or osteoporosis 
(42%), high blood pressure/hypertension (37%), obesity (25%), depression or 
anxiety (19%), asthma (16%), heart/coronary disease (16%), diabetes (14%), or 
chronic bronchitis or emphysema (7%) in 2013. Approximately 74% of cancer 
survivors had utilised cancer-related medication at diagnosis which had increased to 
70% in 2017. Nearly 65% of patients lived in major cities in 2013, followed by 
regional locations (30%). 
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Table 1. Background characteristics of cancer survivors 
Characteristics  
Cancer survivors in 2013 
 (n = 517) 
Cancer patients in wave-17  
(n = 576) 
Percentage (%) 95% CI Percentage (%) 95% CI 
Sex 
      Male 53.90 (49.64 , 58.24) 56.08 (51.98  , 60.09) 
  Female 46.00 (41.76 , 50.36) 43.92 (39.91  , 48.02) 
Age  
     <25 years 3.20 (02.05 , 05.23) 02.95 (01.83  , 04.70) 
 25-45 years 12.38 (09.80 , 15.52)  10.76 (08.48  , 13.58) 
 46-65 years 36.94 (32.88 , 41.21) 36.46 (32.61  , 40.48) 
 >65 years 47.39 (43.10 , 51.72) 49.83 (45.74  , 53.91) 
Educational attainment 
      Year 11 or below 36.56 (32.50 , 40.81) 34.55 (30.76  , 38.54) 
  Year 12 07.16 (05.22 , 09.73) 07.99 (06.03  , 10.51) 
  Trade/certificate/diploma  41.97 (37.77 , 46.29) 40.28 (36.33  , 44.35) 
  Tertiary  14.31 (11.54 , 17.62) 17.19 (14.31  , 20.50) 
Employment status 
      Employed 33.27 (29.33 , 37.46) 35.94 (32.11  , 39.95) 
  Unemployed 66.73 (62.54 , 70.67) 64.06 (60.05  , 67.89) 
Marital status 
      Single 12.19 (09.63 , 15.31) 12.67 (10.19  , 15.66) 
  Married 58.61 (54.29 , 62.79) 57.12 (53.03  , 61.15) 
  Others (separated, divorced or widowed) 29.21 (25.43 , 33.29) 30.21 (26.58  , 30.09) 
Ethnic status  
     Aboriginal 98.07 (96.44 , 98.96) 98.09 (95.58  , 98.94) 
 Non aboriginal 01.93 (01.04 , 03.56) 01.91 (01.05  , 03.42) 
Hours of sleep per week 
      <6 hours 23.60 (20.12 , 27.46) 25.35 (21.95  , 29.07) 
  ≥6 hours 76.40 (72.54 , 79.88) 74.65 (70.93  , 78.05) 
Physical activity status 
      Low  43.33 (39.10 , 47.65) 47.22 (43.16  , 51.32) 
  Moderate 32.69 (28.77 , 36.87) 30.73 (27.08  , 34.63) 
  High 23.98 (20.49 , 27.87) 22.05 (18.84  , 25.63) 
Health insurance coverage  (= insured) 55.51 (51.18 , 59.76) 56.60 (52.50  , 60.60) 
Life conditions, mean scores (SD) 
      Satisfaction with household members 8.10 (01.87) (07.94 , 08.26) 8.08 (1.92) (07.92  , 08.24) 
  Satisfaction overall employment 3.32 (03.89) (02.99 , 03.66) 3.09 (3.87) (02.78  , 03.41) 
  Satisfaction financial situation 6.55 (02.48) (06.34 , 06.77) 6.75 (2.38) (06.55  , 06.94) 
  Satisfaction with social supports 7.76 (01.98) (07.59 , 07.93) 7.76 (1.79) (07.62  , 07.91) 
Diagnosed with co-morbidities 
      Arthritis or osteoporosis (= yes) 41.97 (37.77 , 46.29) 38.02 (34.13  , 42.07) 
  Asthma (= yes) 15.86 (12.95 , 19.28) 14.24 (11.61  , 17.34) 
  Chronic bronchitis or emphysema (= yes) 07.16 (05.22 , 09.73) 06.08 (04.39  , 08.35) 
  Diabetes (= yes) 14.12 (11.37 , 17.41) 13.89 (11.29  , 16.97) 
  Heart /Coronary disease (= yes) 15.67 (12.77 , 19.07) 16.67 (13.83  , 19.95) 
  Depression or anxiety (=yes) 19.34 (16.15 , 22.99) 23.09 (19.82  , 26.72) 
  Other mental illness( = yes) 02.32 (01.32 , 04.05) 02.96 (1.84  , 04.70) 
  High blood pressure/hypertension (= yes) 36.75 (32.69 , 41.01) 37.15 (33.29  , 41.19) 
  Obesity (= yes) 24.95 (21.39 , 28.88) 26.56 (23.11  , 30.33) 
  Any other circulatory condition (= yes) 10.06 (07.74 , 12.98) 07.64 (05.73  , 10.19) 
Treatment status for diagnosed cancer 
      With medication 73.96 (70.21 , 77.39) 70.21 (70.21  , 77.39) 
  Without medication 26.04 (22.61 , 29.79) 22.61 (22.61  , 29.79) 
Location 
     Major cities  64.80 (60.56 , 68.81) 59.90 (55.82  , 63.84) 
 Inner regional 22.63 (19.22 , 26.45) 28.30 (24.76  , 32.13) 
 Outer regional 11.41 (08.94 , 14.46) 09.38 (07.24  , 12.05) 
 Remote or very remote 01.16 (0.520 , 02.57) 02.43 (01.44  , 04.07) 
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Table 1. (Continued) 
Characteristics 
Cancer survivors in 2013 
(n = 517) 
Cancer patients in wave-17 
(n = 576) 
Percentage (%) 95% CI Percentage (%) 95% CI 
Socioeconomic status 
      Q1 (lowest 20%) (ref) 22.24 (18.85 , 26.05) 18.06 (15.12  , 21.42) 
  Q2  23.02 (19.58 , 26.86) 22.92 (19.66  , 26.54) 
  Q3  14.89 (12.07 , 18.24) 17.71 (14.79  , 21.05) 
  Q4  20.50 (17.23 , 24.21) 20.14 (17.05  , 23.62) 
  Q5 (highest 20%) 19.34 (16.15 , 22.99) 21.18 (18.03  , 24.72) 
 
Longitudinal nature of health status burden among cancer patients    
Table 2 shows the distribution of health status scores across cancer survivor 
characteristics and the changes over the period. There was a significant improvement 
in health status scores in males (59.85 points to 66.57 points; p<0.001); older 
patients (54.82 points to 62.76 points; p<0.001); the unemployed (54.68 points to 
62.69 points; p<0.001); those of non-Aboriginal heritage (59.61 points to 65.30 
points; p<0.001); those with adequate sleeping hours (61.35 points to 75.89 points; 
p<0.001); the uninsured (51.64 points to 60.66 points; p<0.01); those with an 
adequate level of physical activity (69.94 points to 75.17 points; p<0.001); patients 
in the medication group (53.48 points to 62.43 points; p<0.01); and for those who 
lived in major cities (59.88 points to 66.36 points; p<0.01).  
Table 2. Distribution of health status scores among cancer patients 
 
Characteristics 
Cancer patients in 
wave-13 (2013) 
(Mean  ±  SD) 
Cancer patients in 
wave-17 (2017) 
(Mean  ±  SD) 
Mean difference over 
time (95% CI)1 
Sex 
 
  
   Male 59.85  ±  24.90 66.57  ±  16.34 6.72*** (1.24 , 12.20) 
  Female 58.21  ±  24.99 62.70  ±  17.33 4.49 (-2.34 , 11.32) 
Age  
 
  
  <25 years 60.82  ±  26.97 62.95  ±  17.78 2.13 (-24.82 , 29.08) 
 25-45 years 59.53  ±  26.60 69.05  ±  17.50 9.52 (-11.08 , 30.12) 
 46-65 years 64.27  ±  23.76 68.99  ±  17.78 4.72 (-2.50 , 11.94) 
 >65 years 54.82  ±  24.60 62.76  ±  15.95 7.94*** (2.43 , 13.45) 
Educational attainment 
 
  
   Year 11 or below 51.58  ±  24.62 62.17  ±  16.31 10.59*** (3.90 , 17.28) 
  Year 12 64.15  ±  24.03 66.70  ±  19.21 2.55 (-14.07 , 19.17) 
  Trade/certificate/diploma  62.65  ±  24.25 68.08  ±  16.30 5.43 (-1.37 , 12.23) 
  Tertiary  65.35  ±  23.94 64.72  ±  17.83 -0.63 (-11.18 , 9.92) 
Employment status 
 
  
   Employed 67.95  ±  22.99 71.54  ±  14.17 3.59 (-3.89 , 11.07) 
  Unemployed 54.68  ±  24.72 62.69  ±  17.10 8.01*** (3.02 , 13.00) 
Marital status 
 
  
   Single 51.69  ±  26.63 62.74  ±  15.08 11.05 (-2.39 , 24.49) 
  Married 62.64  ±  23.92 67.10  ±  16.87 4.46 (-0.80 , 9.72) 
  Others  55.07  ±  25.07 61.37  ±  16.90 6.30 (-1.98 , 14.58) 
Ethnic status (= non aboriginal) 59.61  ±  24.74 65.30  ±  16.72 5.69*** (1.43 , 9.95) 
Hours of sleep per week 
 
  
   <6 hours 51.80  ±  24.55 62.28  ±  16.94 10.48** (1.62 , 19.34) 
  ≥6 hours 61.35  ±  24.65 65.89  ±  16.72 4.54* (2.27 , 9.35) 
(Continued) 
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Table 2. (Continued) 
Characteristics 
Cancer patients in 
wave-13 (2013) 
(Mean  ±  SD) 
Cancer patients in 
wave-17 (2017) 
(Mean  ±  SD) 
Mean difference 
over time (95% 
CI)1 
Physical activity status 
 
  
   Low  49.78  ±  24.66 59.56  ±  15.72 9.78*** (3.66 , 15.90)
  Moderate 63.48  ±  22.14 66.55  ±  16.93 3.07 (-3.86 , 10.00) 
  High 69.94  ±  23.09 75.17  ±  13.88 5.23 (-3.21 , 13.67) 
Smoking exposure  
 
  
   No 60.05  ±  25.01 65.86  ±  16.72 5.81** (1.28 , 10.34) 
  Yes 52.57  ±  23.55 58.50  ±  16.36 5.93 (-6.48 , 18.34) 
Health insurance coverage 
 
  
  Insured 65.07  ±  23.31 67.16  ±  17.32 2.09 (-2.90 , 7.08) 
 Uninsured 51.64  ±  24.93 60.66  ±  14.81 9.02** (1.67 , 16.37) 
Diagnosed with co-morbidities 
 
  
   Arthritis or osteoporosis (= yes) 51.50  ±  22.05 61.04  ±  15.43 9.54*** (3.57 , 15.51) 
  Asthma (= yes) 49.03  ±  23.43 54.16  ±  15.77 5.13 (-5.60 , 15.86) 
  Chronic bronchitis or emphysema (= yes) 38.80  ±  21.03 57.34  ±  11.43 18.54* (3.23 , 40.31) 
  Diabetes (= yes) 48.64  ±  23.23 59.45  ±  13.94 10.81*** (1.64 , 19.98) 
  Heart /Coronary disease (= yes) 47.84  ±  22.42 59.73  ±  16.73 11.89*** (2.71 , 21.07) 
  Depression or anxiety (= yes) 42.48  ±  21.69 50.36  ±  12.37 7.88 (-1.83 , 17.59) 
  Other mental illness (= yes) 25.31  ±  08.16 45.26  ±  7.15 19.95*** (8.78 , 31.12) 
  High blood pressure/hypertension (= yes) 55.87  ±  22.68 62.12  ±  15.18 6.25** (0.48 , 12.02) 
  Obesity (= yes) 60.06  ±  21.76 59.30  ±  15.67 -0.76 (-7.86 , 6.34) 
  Any other circulatory condition (= yes) 43.02  ±  18.28 56.31  ±  19.64 13.29** (2.12 , 24.46) 
Treatment status for diagnosed cancer 
 
  
   With medication 53.48  ±  23.70 62.43  ±  16.18 8.95*** (4.45 , 13.45) 
  Without medication 72.69  ±  22.56 78.14  ±  13.48 5.45 (-3.73 , 14.63) 
Location 
 
  
  Major cities  59.88  ±  25.21 66.36  ±  17.29 6.48** (1.14 , 11.82) 
 Inner regional 60.42  ±  23.72 63.21  ±  14.98 2.79 (-5.60 , 11.18) 
 Outer regional 52.15  ±  25.11 62.19  ±  20.09 10.04 (-5.36 , 25.44) 
 Remote or very remote 57.50  ±  26.05 58.20  ±  03.72 0.70 (-30.14 , 31.54) 
Socioeconomic status 
 
  
   Q1 (lowest 20%) (ref) 49.46  ±  23.98 58.53  ±  17.08 9.07* (-0.15 , 18.29) 
  Q2  57.71  ±  24.52 64.62  ±  17.55 6.91 (-2.24 , 16.06) 
  Q3  59.89  ±  25.26 66.62  ±  16.81 6.73 (-4.01 , 17.47) 
  Q4  59.88  ±  24.91 62.98  ±  14.40 3.10 (-6.80 , 13.00) 
  Q5 (highest 20%) 70.38  ±  21.78 71.58  ±  15.88 1.20 (-6.74 , 9.14) 
  1Two sample t-test performed, ***, ** and * denotes significant at 0.1%, 1% and 5% risk level respectively and 
Qi = ith wealth quintile (i =1, 2. . . 5; higher i represents a quintile with higher wealth), SD = standard 
deviation, CI = confidence interval. 
 
Although overall cancer patient’s health status outcomes improved during the period 
across health states, a significant improvement was observed in terms of body pain 
(54.93 points to 60.26 points; p<0.05); social functioning (67.11 points to 73.46 
points; p = 0.027); and mental health (67.41 points to 72.23 points; p = 0.028). 
Furthermore, a monotonic decline in health burden was most pronounced for the SF-
36 scales. There was a significant reduction of ‘high health burden’ among cancer 
survivors (36% to 21%; p<0.01) (Figure 1). A significant reduction was also 
observed in physical functioning (34% to 26%; p<0.05); role-physical (50% to 9%; 
p<0.001); social functioning (27% to 17%; p = 0.04); role-emotional (36% to 9%; p 
<0.001); and mental health (21% to 9%; p = 0.002). 
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Factors influencing health status scores among cancer survivors 
Several predictors had a significant and independent impact on health status (Table 
3). A block of socio-demographic, ethnicity, and lifestyle variables were included in 
model-1. Unemployed (β = -6.28 points; p<0.001) and Indigenous (β = -14.81 
points; p<0.001) cancer survivors had significantly worse health status outcomes. 
However, cancer survivors who were married (β = 4.66 points; p<0.001); were 
highly educated (β = 10.29 points; p<0.001); had adequate sleep (β = 5.41 points; 
p<0.001); and who maintained a moderate (β = 9.33 points; p<0.001) or adequate (β 
= 15.65 points; p<0.001) level of physical activity had higher health status. An 
additional set of control predictors to account for a range of different life conditions 
were introduced in model-2. Cancer patients’ satisfaction related to their financial 
situation (β = 1.98 points; p<0.001); and level of social support (β = 1.10 points; 
p<0.001) were also decisively associated with higher health status scores. 
Conversely, cancer survivors without health insurance coverage (β = -4.31 points; 
p<0.001); and those who were on prescription medication (β = -9.55 points; 
p<0.001) had significantly worse health status scores compared to their counterparts. 
Comorbid conditions were examined in model-3. The majority of the reported 
comorbid condition survivors had a significantly lower quality of life compared to 
those without exposure to conditions including arthritis or osteoporosis (β =-3.84 
points; p<0.001); chronic bronchitis or emphysema (β =-9.94 points; p<0.001); heart 
or coronary disease (β = -4.26 points; p<0.01); depression or anxiety (β = -8.21 
points; p<0.001); or another mental illness (β = -4.26 points; p<0.01). Finally, 
location and socioeconomic position-related variables were introduced in model-4. 
Patients who lived in regional locations (β = -7.17 points; p<0.001) had a 
significantly worse health status, while patients belonging to the richest households 
(β = 1.49 points; p<0.01) had a better health status compared with their lowest 
quintile counterparts.  
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Table 3. Factors influencing in health status outcomes of cancer patients 
Characteristics  
Model 1 Model 2 Model 3 Model 4 
β (SE) β (SE) β (SE) β (SE) 
Female 1.82 (1.47) 1.29 (1.4) 2.11 (1.32) 2.09* (1.31) 
Age  -0.03 (0.06) -0.11* (0.06) -0.08* (0.06) -0.1 (0.06) 
Educational attainment 
      Year 11 or below (ref) - - - -
  Year 12 **6.91 (2.99) 6.21** (2.78) 5.47 (2.54) 5.30** (2.45) 
  Trade/certificate/diploma  ***6.92 (1.72) 6.39*** (1.66) 6.29*** (1.54) 6.11*** (1.52) 
  Tertiary  ***10.29 (2.12) 8.20*** (2) 6.81*** (1.98) 5.96*** (1.99) 
Unemployed (ref = employed) -6.28*** (1.73) -3.90** (1.88) -1.81* (1.75) -1.53 (1.74) 
Marital status     
  Single (ref) - - - - 
  Married 4.66* (2.33) 1.13 (2.32) 1.25 (2.30) 1.70 (2.33) 
  Others (separated/divorced/widowed) 1.08 (2.51) -0.13 (2.42) 1.05 (2.35) 1.20 (2.37) 
Ethnic status ( ref = Indigenous) -14.81*** (4.14) -11.09** (4.38) -8.19* (4.63) -7.54* (4.78) 
Hours of sleep per week 
      <6 hours (ref) - - - -
  ≥6 hours 5.41*** (1.55) 3.59** (1.48) 1.54** (1.40) 1.83** (1.41) 
Physical activity status 
      Low (ref) - - - -
  Moderate 9.33*** (1.53) 8.03*** (1.49) 7.10*** (1.40) 7.30*** (1.40) 
  High 15.65*** (1.68) 13.36*** (1.67) 11.32*** (1.60) 11.63*** (1.59) 
Life conditions, mean scores (SD) 
      Satisfaction with household members 
 
0.46 (0.41) 0.37 (0.41) 0.43 (0.41)
  Satisfaction overall employment 
 
0.35* (0.21) 0.10 (0.19) 0.09 (0.19) 
  Satisfaction financial situation 
 
1.98*** (0.32) 1.27*** (0.31) 1.29*** (0.31) 
  Satisfaction with social supports 
 
1.10*** (0.38) 0.92** (0.36) 1.04*** (0.36) 
Uninsured (ref = insured) 
  
-2.87* (1.39) 2.39** (1.39) 
Prescription medication (ref = no) 
  
-6.30*** (1.68) -6.00*** (1.68) 
Diagnosed with comorbidities (ref = no) 
      Arthritis or osteoporosis (= yes) 
  
-3.84*** (1.30) -3.62*** (1.31)
  Asthma (= yes) 
  
-1.50 (1.71) -0.58 (1.70) 
  Chronic bronchitis or emphysema (= yes) 
  
-9.94*** (2.47) -9.88*** (2.49) 
  Diabetes (= yes) 
  
-4.61*** (1.80) -4.83*** (1.79) 
  Heart /Coronary disease (= yes) 
  
-4.26** (1.70) -4.18** (1.70) 
  Depression or anxiety (=yes) 
  
-8.21*** (1.63) -8.30*** (1.64) 
  Other mental illness( = yes) 
  
-16.15*** (2.62) -15.40*** (2.56) 
  High blood pressure/hypertension (= yes) 
  
-1.10 (1.42) 0.87 (1.42) 
  Obesity (= yes) 
  
-1.91* (1.31) 1.63 (1.31) 
  Any other circulatory condition (= yes) 
  
-0.69 (1.91) 0.19 (1.97) 
Location 
      Major cities (ref) 
   
-    
  Inner regional 
   
-2.57* (1.48) 
  Outer regional 
   
-7.17*** (2.32) 
  Remote or very remote 
   
1.79 (3.53) 
Socioeconomic status 
      Q1 (lowest 20%) (ref) 
   
-    
  Q2  
   
-0.97** (2.04) 
  Q3  
   
-1.36 (2.03) 
  Q4  
   
1.26** (2.07) 
  Q5 (highest 20%)    1.49** (1.89) 
 ***, ** and * denotes significant at 0.1%, 1% and 5% risk level respectively and Qi = ith wealth quintile (i =1, 2. . . 5; higher i 
represents a quintile with higher wealth), β = regression coefficient, SE = standard error, SD = standard deviation, ref= 
reference group   
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Table 4. Standardised betas of longitudinal generalized linear mixed models evaluating the association of predictors with HRQoL of cancer patients  
Characteristics  
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 Model 8 
Physical 
functioning (PF) 
Role-physical (RP) 
Body pain 
(BP) 
General health (GH) Vitality (VT) 
Social 
functioning (SF) 
Role-emotional 
(RE) 
Mental health 
 (MH) 
β (SE) β (SE) β (SE) β (SE) β (SE) β (SE) β (SE) β (SE) 
Female 0.15 (1.56) 1.22 (2.20) 1.05 (1.55) 2.91* (1.56) 1.41 (1.60) 3.58** (2.06) 7.29*** (2.54) 3.99** (1.72) 
Age  -0.22* (0.07) -0.28*** (0.09) -0.02 (0.07) 0 (0.07) -0.05 (0.08) -0.12 (0.10) -0.22* (0.12) 0.03 (0.09) 
Educational attainment 
          Year 11 or below (ref) - - - - - - - -
  Year 12 8.59*** (2.92) 6.85* (4.11) 3.47 (3.09) 2.92 (3.05) 2.65 (3.12) 4.99 (3.91) 13.22*** (4.77) 4.47 (3.49) 
  Trade/certificate/diploma  7.50*** (1.84) 6.37*** (2.51) 4.75*** (1.76) 3.49** (1.77) 6.33*** (1.87) 8.61*** (2.42) 15.13*** (3.07) 6.92*** (2.10) 
  Tertiary  9.05*** (2.47) 6.10* (3.45) 3.23 (2.34) 2.65* (2.39) 8.72*** (2.33) 8.53** (3.10) 15.04*** (3.94) 8.35*** (2.49) 
Unemployed (ref = employed) -5.70** (2.04) -0.75 (2.94) -1.94 (1.97) -1.03 (2.12) 1.65 (2.14) 0.04 (2.69) -3.81 (3.26) -1.13 (2.30) 
Marital status 
          Single (ref) - - - - - - - -
  Married 1.95 (2.63) 1.46 (3.69) -2.39 (2.69) -1.9 (2.72) 2.98 (2.76) 3.11 (3.65) 6.77 (4.37) 3.47 (3.11) 
  Others (separated/divorced/widowed) -0.14 (2.71) 2.69 (3.72) -1.13 (2.76) -0.22 (2.77) 1.97 (2.82) 1.65 (3.70) 4.19 (4.44) 0.93 (3.21) 
Household sizes 
          <3 members (ref) - - - - - - - -
  3 to 4 members 0.38 (2.17) -0.31 (3.14) -0.51 (2.20) -2.74 (2.16) -2.23 (2.28) -3.59 (2.91) -7.23* (3.59) -2.23 (2.49) 
  ≥ 5 members 4.35 (3.63) 9.19* (4.51) 3.40 (3.37) 4.24 (3.37) 0.83 (3.32) 1.36 (4.43) 5.14 (5.07) 0.55 (3.69) 
Ethnic status (= Indigenous) -3.52 (5.11) -6.87 (8.52) -12.02** (5.44) -6.04 (5.58) -13.03** (5.08) -16.51** (6.45) -16.11* (9.66) -15.09** (6.95) 
Hours of sleep per week 
          <6 hours (ref) - - - - - - - -
  ≥6 hours 1.48* (1.72) 2.84* (2.45) 2.03* (1.66) 2.88** (1.61) 3.38** (1.74) 2.57* (2.26) 1.17* (2.92) 1.55* (1.92) 
Physical activity status 
          Low (ref) - - - - - - - -
  Moderate 11.84*** (1.63) 10.61*** (2.47) 6.85*** (1.68) 4.42*** (1.59) 5.59*** (1.73) 10.85*** (2.28) 10.16*** (2.92) 3.10* (1.92) 
  High 15.28*** (1.89) 17.02*** (2.75) 10.31*** (1.84) 11.01*** (1.76) 10.52*** (1.95) 16.54*** (2.51) 14.30*** (3.19) 4.99*** (2.07) 
Life conditions, mean scores (SD) 
          Satisfaction with household members 0.33 (0.55) 1.12 (0.70) -0.46 (0.49) 0.83 (0.52) 0.90** (0.50) 1.08 (0.66) 0.49 (0.81) 0.92 (0.58)
  Satisfaction overall employment 0.39* (0.22) 0.15 (0.34) 0.05 (0.21) -0.09 (0.23) 0.05 (0.24) 0.23 (0.31) 0.03 (0.38) -0.43 (0.27) 
  Satisfaction financial situation 0.74* (0.38) 1.26** (0.51) 1.71*** (0.36) 0.96*** (0.37) 0.95*** (0.40) 1.46*** (0.51) 2.21*** (0.63) 1.72*** (0.44) 
  Satisfaction with social supports 0.76* (0.45) 0.47 (0.63) 1.48*** (0.46) 0.86** (0.44) 0.89** (0.46) 1.21*** (0.59) 1.37** (0.79) 1.03* (0.54) 
Uninsured (ref = insured) -1.65 (1.70) -3.72* (2.35) -3.36* (1.65) -2.84* (1.68) -1.83 (1.72) -1.74 (2.20) -4.00 (2.80) -2.21* (1.92) 
Prescription medication (ref = no) -5.7*** (1.92) -10.10*** (2.94) -5.81*** (1.88) -8.83*** (1.96) -6.39*** (2.04) -6.92*** (2.52) -5.33* (3.12) -3.96* (2.06) 
Diagnosed with comorbidities (ref = no) 
          Arthritis or osteoporosis (= yes) -6.33*** (1.57) -9.79*** (2.34) -8.44*** (1.61) -1.69 (1.55) -0.09* (1.59) 0.35 (2.07) 0.45 (2.74) 1.10 (1.77)
  Asthma (= yes) -2.99 (2.18) 1.20 (2.93) -1.23 (1.96) -1.67 (1.87) -0.77 (2.07) 0.89 (2.78) 0.65 (3.51) 0.06 (2.45) 
  Chronic bronchitis or emphysema (= yes) -10.82*** (2.85) -12.29*** (3.59) -5.89* (2.92) -11.68*** (2.89) -8.72*** (3.24) -11.18*** (4.32) -15.79*** (5.14) -8.05* (4.00) 
  Diabetes (= yes) -4.20*** (2.30) -3.74 (2.91) -2.38 (2.12) -5.51** (2.07) -4.58*** (2.33) -5.13* (2.99) -8.84*** (3.93) -5.50** (2.57) 
  Heart /Coronary disease (= yes) -5.62*** (2.03) -4.6 (2.88) -2.17 (2.15) -5.83*** (2.00) -6.06*** (2.26) -8.72*** (2.95) -2.97 (3.71) -5.15** (2.54) 
  Depression or anxiety (=yes) -2.77 (1.97) -6.77*** (2.72) -3.40* (1.93) -6.34*** (1.99) -6.96*** (1.94) -8.83*** (2.62) -19.13*** (3.53) -11.98*** (2.23) 
  Other mental illness( = yes) -15.69*** (4.21) -19.01*** (4.51) -15.52*** (3.17) -9.97*** (4.39) -17.39*** (4.24) -24.92*** (5.27) -28.72*** (6.06) -16.78*** (5.43) 
  High blood pressure/hypertension (= yes) -0.38 (1.74) -4.12* (2.42) -2.5 (1.71) -1.13 (1.72) -1.50 (1.80) 2.90 (2.30) -5.22** (2.87) -0.62 (1.99) 
  Obesity (= yes) -0.29 (1.67) 2.39 (2.49) -0.96 (1.69) 1.21 (1.57) -5.47*** (1.50) -7.49** (2.03) -5.78*** (2.69) -10.20*** (1.60) 
  Any other circulatory condition (= yes) -2.47 (2.76) 3.42 (3.32) 3.04 (2.62) -2.39 (2.40) 1.68 (2.29) 1.37 (3.20) -2.87 (4.79) 2.72 (2.87) 
(Continued) 
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Table 4. (Continued) 
Characteristics  
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 Model 8 
Physical 
functioning 
(PF) 
Role-physical  
(RP) 
Body pain 
(BP) 
General health  
(GH) 
Vitality  
(VT) 
Social functioning 
(SF) 
Role-emotional 
(RE) 
Mental health 
 (MH) 
β (SE) β (SE) β (SE) β (SE) β (SE) β (SE) β (SE) β (SE) 
Location 
          Major cities (ref) - - - - - - - -
  Inner regional -0.48 (1.80) -8.89*** (2.48) -1.12 (1.79) -0.76 (1.82) -1.10 (1.80) -3.62 (2.32) -5.81** (2.96) -0.57 (1.98) 
  Outer regional -5.48* (2.79) -10.09*** (3.57) -7.70*** (2.44) -4.57* (2.62) -4.42** (2.89) -7.60*** (3.79) -16.09*** (4.85) -4.00 (3.35) 
  Remote or very remote -2.87 (4.64) 2.60 (6.29) 6.83* (3.37) 0.77 (4.69) -1.97 (4.41) 0.31 (6.02) -6.01 (9.25) -3.26 (5.18) 
Socioeconomic status 
          Q1 (lowest 20%) (ref) - - - - - - - -
  Q2  0.06** (2.36) 1.52 (3.05) -0.76 (2.18) 1.43 (2.32) 2.28 (2.30) 1.48 (3.03) 1.23 (3.96) 0.27 (2.65) 
  Q3  0.39 (2.52) -4.39 (3.43) -1.83 (2.45) 2.28 (2.50) 1.28 (2.54) 1.93 (3.29) 3.92 (4.31) 0.35 (2.82) 
  Q4  -2.46 (2.38) -2.86 (3.34) -1.85 (2.46) -0.66 (2.54) -0.38 (2.49) 0.85 (3.24) -2.14 (4.28) -0.50 (2.86) 
  Q5 (highest 20%) 2.25* (2.54) -0.6 (3.44) -0.27 (2.57) 2.56 (2.56) 0.14 (2.50) 4.41 (3.36) 0.50 (4.17) -1.01 (2.76) 
 Note: ***, ** and * denotes significant at 0.1%, 1% and 5% risk level respectively and Qi = ith wealth quintile (i =1, 2. . . 5; higher i represents a quintile with higher wealth), β = regression coefficient, SE = standard 
error, SD = standard deviation, ref= reference group.   
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In addition, this study also investigated health scores across the SF-36 subscales 
including physical functioning, role-physical, body pain, general health, vitality, 
social functioning, role-emotional, and mental health. The model was also used to 
find the important parameters for predicting the quality of life of cancer survivors in 
a separate model for subscales (Table 4). These results closely followed the overall 
health status scores and showed the statistical significance of almost all the 
determined parameters outlined above.  
Discussion 
This study used cancer survivors’ self-reported health status scores to examine the 
longitudinal course of patients in Australia and determine influencing factors that 
predicted their health status. Overall, the cancer survivors experienced improved 
health status outcomes over the four years following their diagnosis. Significantly 
this applied in particular to health states such as body pain, social functioning and 
mental health. While most cancer survivors recovered well over time, a considerable 
subgroup endured a long-term health burden. It is therefore argued that early 
interventions, including palliative care, which can improve the overall quality of life 
of people with cancer are of utmost significance. In this context, social cognitive 
theory-based interventions may be most salient [31], and a pivotal role should thus 
be afforded to cognitive, vicarious, self-reflective and self-regulatory factors and 
their impact on human adaptation and change. Advanced treatment targets 
comprising outcome expectations, self-efficacy, and self-regulation were 
significantly associated with better health status [14,32].   
Approximately three-quarters of cancer survivors experienced at least one 
comorbidity condition with about 45% of cancer survivors having two or three 
comorbidities and this latter group had the largest negative association with health 
status. Other studies have confirmed that a significant number of cancer survivors are 
exposed more than one comorbidity condition and that this significantly and 
negatively influences their quality of life score [19,20]. However, cancer survivors’ 
unhealthy lifestyles including tobacco use, poor diet and lack of access to 
preventative care significantly contributes to a higher risk of chronic illness including 
respiratory diseases, heart disease, stroke, diabetes, and obesity. The number of 
comorbid conditions, along with their severity, also impedes early cancer detection, 
course of treatment, prognosis, and survival outcomes [33]. The measured burden of 
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comorbid conditions of people with cancer significantly and negatively impacts on 
quality of life outcomes in different settings, including Australia [12,19,20]. 
Regional cancer survivors reported worse health status outcomes compared with 
patients who lived in major cities. Considerable evidence showed that geographically 
disadvantaged cancer survivors experienced significantly worse health status 
compared with other Australians [34–36]. 
These findings were in contrast to other studies [9,11], in which it was found that 
cancer survivors who survived with cancer in regional areas appeared to have an 
overall better quality of life. This situation may depend on access to healthcare 
facilities and the structure of healthcare service delivery. In Australia, cancer care 
services across the states are centralised in nature which disadvantages non-urban 
patients (e.g., regional or remote) who need to travel frequently for oncology follow-
up treatments (e.g., chemotherapy and radiotherapy) at secondary or tertiary level 
health facilities. In this context, regional cancer patients face an additional challenge 
to receive cancer care due to their locations and the associated costs of transport as 
well as being reliant on caregiver support to access care [34,37]. Difficulty in 
accessibility and availability of appropriate healthcare services are challenges for all 
residents in regional and remote Australia with approximately 30% of the population 
living outside the major cities in Australia [38]. The national government is devoted 
to improving the cancer infrastructure by developing a structured network of new 
and improved cancer centres in regional Australia [39]. There is also a growing 
interest in the advanced technology-based model of service delivery in oncology. 
Technology-based models (e.g., tele-oncology) have been conducted in Western 
Australia and North Queensland, helping regional cancer patients to access 
healthcare services (e.g., specialist consultation, and therapeutic treatments) [40, 41]. 
Thus, the benefits of specialist support for an ongoing course of cancer treatment 
with high-level satisfaction and acceptance of services can lead to improved health 
status for cancer survivors living in regional areas [40, 41].     
This study also found that engagement in moderate or adequate physical activities 
was related to a better quality of life which is consistent with previous study findings 
in that cancer survivors who had higher levels of physical activity had better health 
status [42]. Some studies have proven that physical exercise-related therapy can 
reduce fatigue and ensure better quality of life outcomes for cancer survivors [15,42]. 
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Cancer patients or cancer survivors might improve their physical strength through 
proper exercise, which in turn increases acceptance of physical fatigue and metabolic 
efficiency which can change the characteristics of skeletal muscle, increase the 
number of oxidative fibers, or cause a decline in the number of glycolytic fibers [43]. 
Oxidative fibers can eradicate lactate from blood which reduces fatigue levels. Thus, 
increased muscle efficiency explains how patients with increased levels of physical 
activity can carry out normal daily activities with less fatigue [15]. 
Finally, the patterns of cancer survivors’ life satisfaction-related factors decisively 
predicted higher health status scores over the period. Life satisfaction was 
conceptualised as the outcome of an individual’s judgment about the extent of their 
current quality of life according to their self-imposed life behaviours. Previous 
studies have consistently concluded that life satisfaction factors predominantly 
contribute to quality of life outcomes [10,21]. The quality of life outcomes of 
patients in terms of life satisfaction trajectories may vary, i.e. both decline and 
increase over time, but they seem to return mostly to their full health state [10]. In 
this context, financial satisfaction is crucial to the outcome of cancer treatments 
which is usually very expensive, and often involves large out of pocket payments and 
reduce cancer patients’ socioeconomic position. Life satisfaction may respond to 
changes (e.g., cancer diagnosis), but it is usually a temporary phenomenon [44]. This 
expression of an individuals’ resilience following a cancer diagnosis helps explain 
the return to a more normal sense of life satisfaction after their cancer experience. 
The present study did have some limitations. Study participants were derived from 
the HILDA survey covering the health, economic, employment, income and health 
characteristics of household members aged 15 years and older. Children who 
suffered from cancer were not included in this study. This study considered the 
overall health status of cancer survivors, which might vary in terms of cancer stages 
and types of cancer. The authors were not able to measure the cancer-specific health 
status of cancer patients due to the paucity of available information. The study 
findings were based on self-reported information that might have been impacted by 
respondents’ prejudice (e.g., silence and over-response), or due to problems in 
understanding and interpretation. However, the key strengths of this study include 
the prospective design of long term follow up, and the application of well-validated 
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and reliable longitudinal wave measures of the impacts of cancer diagnosis on the 
quality of life.  
Conclusions 
Overall, the self-reported health status of cancer survivors improved over the period. 
The findings of this study could help policymakers to design new health 
interventions to address some of the contributing factors to the poor health status for 
cancer patients in Australia. This might include promoting adequate access to quality 
cancer care and exercise during treatment. These initiatives might directly or 
indirectly influence better health status of cancer survivors. The present results add to 
the ongoing body of evidence about the heterogeneous nature of individual 
adjustments after cancer diagnosis and further highlight the importance of 
considering inter-individual differences in research with this population group, as 
well as in planning service delivery. Life satisfaction appears in this population 
group to be temporally stable, and this may reflect individuals’ psychological 
resilience during their cancer experience. There is a growing recognition of the 
importance of patient-focused outcomes in cancer care [44], whereby the quality of a 
person’s life and the personal preferences and values of that person guide their health 
care. The inclusion of quality of life in future research, as a distinct adjustment 
outcome based on the individual’s point of reference, is therefore warranted. 
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2.3 Study 3 
Cancer burden: Long-term chronic comorbid 
conditions and consequences 
 
The second study of this thesis examined longitudinal measures in health status 
burden among cancer patients and its associated predictors. Study 3 investigated the 
long-term chronic comorbid conditions in terms of disease pattern along with 
potential predictors among cancer patients and consequences over an extended 
period.  
Article III: The burden of chronic diseases among Australian cancer patients: 
Evidence from a longitudinal exploration, 2007-2017 
The objective of Study 3 was to investigate the distribution of burden of chronic 
comorbid conditions and associated predictors among cancer patients in Australia 
over the period of 2007-2017. This study found that sixty-one percent of cancer 
patients experienced at least one chronic disease over the period, and 21% of patients 
experienced three or more chronic diseases. This study determined that advancing 
age, inadequate levels of physical activity, patients who suffered from extreme health 
burden or moderate health burden, and patients living in the poorest households were 
significant predictors associated with a higher risk of chronic comorbid conditions. 
This study concludes that a large number of cancer patients experience an extreme 
burden of chronic comorbid conditions and the different dimensions of these in 
cancer survivors have the potential to affect the trajectory of their cancer burden. It is 
also significant for health care providers, including physical therapists and 
oncologists, who must manage the unique problems that challenge this population 
and who should advocate for prevention and evidence-based interventions.  
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Abstract
Introduction
Cancer is a major public health concern in terms of morbidity and mortality worldwide. Sev-
eral types of cancer patients suffer from chronic comorbid conditions that are a major clinical
challenge for treatment and cancer management. The main objective of this study was to
investigate the distribution of the burden of chronic comorbid conditions and associated pre-
dictors among cancer patients in Australia over the period of 2007–2017.
Methods
The study employed a prospective longitudinal design using data from the Household,
Income and Labour Dynamics in Australia survey. The number of chronic comorbid condi-
tions was measured for each respondent. The longitudinal effect was captured using a
fixed-effect negative binomial regression model, which predicted the potential factors that
played a significant role in the occurrence of chronic comorbid conditions.
Results
Sixty-one percent of cancer patients experienced at least one chronic disease over
the period, and 21% of patients experienced three or more chronic diseases. Age
(>65 years old) (incidence rate ratio, IRR = 1.15; 95% confidence interval, CI: 1.05, 1.40),
inadequate levels of physical activity (IRR = 1.25; 95% CI: 1.09, 1.59), patients who suf-
fered from extreme health burden (IRR = 2.30; 95% CI: 1.73, 3.05) or moderate health
burden (IRR = 1.90; 95% CI: 1.45, 2.48), and patients living in the poorest households
(IRR = 1.21; 95% CI: 1.11, 1.29) were significant predictors associated with a higher risk
of chronic comorbid conditions.
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Conclusions
A large number of cancer patients experience an extreme burden of chronic comorbid condi-
tions and the different dimensions of these in cancer survivors have the potential to affect
the trajectory of their cancer burden. It is also significant for health care providers, including
physical therapists and oncologists, who must manage the unique problems that challenge
this population and who should advocate for prevention and evidence-based interventions.
Introduction
Cancer is one of the most pressing public health problems worldwide [1]; an estimated 9.6 mil-
lion patients die from cancer each year. In Australia, it is also an alarming issue with the health
system dealing with 483 new cases per 100,000 people in 2019, while on average 136 people die
from cancer each day [2]. Cancer contributes 18% of the total burden of disease in terms of
disability-adjusted life years, followed by 14% from cardiovascular diseases, 13% frommuscu-
loskeletal conditions, and 12% frommental and substance use disorders in Australia [3]. Fur-
ther, there are approximately one million survivors in Australia who have been diagnosed with
cancer in the past [4]. The five-year survival from all cancers combined improved from 48% to
69% between 1990 and 2011–2015 [2].
However, the majority of cancer patients suffer from chronic diseases or conditions,
commonly referred to as comorbidity. The risk of having comorbidity increases during
treatment as well as oncology follow-up periods [3,5,6], which adversely influences treat-
ment choices and outcomes. Chronic comorbid conditions of cancer patients contribute to
a major clinical challenge in terms of cancer diagnosis, ill health, the course of treatment,
long-term disability and disease management [7]. In 2014–15, more than 11 million Austra-
lians (50%) reported having at least one chronic disease, wherein approximately 1 in 4 (23%)
Australians had two or more chronic conditions [8]. This rate was more pronounced for
people aged 65 and over (87%) compared with people aged 0–44 (35%), females (52%) com-
pared with males (48%), people in disadvantaged socioeconomic areas (55%) compared with
those in the most advantaged socioeconomic areas (47%), and people living in regional
and remote areas (54%) compared with those in the major cities (48%) [8]. Ultimately, the
severity of comorbidity leads to an increased risk of hospitalisation, reduced health status,
increased mortality, and increased financial burden on the healthcare system [9–11]. It may
also adversely impact an individual’s access to advanced cancer treatments (e.g., chemother-
apy and radiotherapy) and the effectiveness of that treatment [12]. This is a substantial
prognostic factor for the long-term survival of cancer patients. There is a growing body of
research on the significant impact of chronic comorbid conditions among patients with can-
cer. However, there are limited empirical studies on comorbidities available in the Australian
setting [7,13–15].
Comorbidity has a well documented detrimental effect on cancer survival [9] and it
describes the existence of a long-term health condition or disorder in the presence of primary
disease or illness [16]. In the case of cancer, chronic comorbidity refers to the existence of one
or more comorbid conditions in a person simultaneously. While the existence of these comor-
bid health conditions may be extraneous, particularly chronic diseases, there is an association
between them. Further, many chronic diseases share common risk factors. Cancer patients
with comorbid conditions also experience a higher physiological burden of disease [7]. The
presence of specific severe comorbidities or psychiatric disorders is associated with delayed
The burden of chronic diseases among Australian cancer patients
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cancer diagnosis [11]. Further, patients with chronic diseases with regular medical consulta-
tions and follow-up had their cancer detected at an earlier stage [12].
The chance of improving health status and completing a course of cancer treatment in the
presence of comorbidities is significantly lower among cancer patients [4,13,15,17,18] and is
associated with a higher rate of mortality depending on the severity of disease and associated
comorbidity [11]. For instance, the mortality rate is substantially higher among cancer patients
with comorbidities (47%) compared with cancer patients without comorbidities (34%) [19].
Given the clinical significance of comorbidity and its high prevalence in cancer survivors, it is
essential to have a measure for quantifying likely effects on cancer outcomes [20]. Understand-
ing more about comorbidities among cancer patients can generate possible evidence as well as
provide direction for prevention, management, and treatment of chronic diseases.
A number of studies confirm that comorbid chronic conditions were more pronounced
among cancer patients [4,11,13–15,21,22]. The most prevalent risk factors were age (over 65
years) [23,24], unhealthy behaviors (e.g., alcohol consumption and smoking tobacco) [25,26],
obesity, limited engagement with physical activity [27] and inadequate diet [25] and they are
significantly related to a higher risk of developing cancer along with multiple chronic diseases
[5,7,25]. Further, comorbid conditions of cancer patients are significantly associated with
worse health status during treatment and oncology follow-up periods [28,29] as well as low or
intermediate socioeconomic status [30], and poor nutritional status [31]. The ongoing evidence
shows that modifying or avoiding risk factors can significantly reduce the burden of chronic
comorbid conditions among cancer patients [1]. For example, cancer survivors who engage in
less sedentary behavior enjoy a better quality of life [32], and this can also significantly contrib-
ute to reducing the risk of experiencing chronic comorbid conditions [33].
The primary intention of these studies was to examine the distribution, trend, pattern, and
disparity in comorbidity status among cancer patients when considering a limited range of
variables. The majority of these studies pay little attention to examining the long-term impact
of chronic comorbid conditions for cancer survivors’ over times. Therefore, routine oncology
follow-ups must explore how cancer survivors’ characteristics impact on the number of
chronic comorbid conditions they experience.
This study will examine the longitudinal nature of chronic comorbid conditions of cancer
patients. More specifically, the study proposes to develop a better understanding of the lon-
gitudinal distribution of chronic comorbidity status among cancer patients as well as its
impact over time. This study complements and contributes to this strand of ongoing cancer
research to increase awareness and improve public health practice among sufferers and sur-
vivors, and to measure impact. The findings could contribute to designing appropriate inter-
ventions and/or the provision of quality healthcare services and resources for ongoing
surveillance of people living with, through and beyond cancer, and help determine what
kinds of support survivors need. This study, therefore, aims to investigate the distribution,
potential predictors and associated burden of chronic comorbid conditions among cancer
patients by using a longitudinal data set from the Household, Income and Labour Dynamics
in Australia (HILDA) survey.
Materials and methods
Study design
The study design is a longitudinal exploration using a household-based panel over an extended
period of 2007 to 2017. Individuals who face the burden of life-threatening cancer were inter-
viewed with a focus on the magnitude of the cancer burden associated with their chronic
comorbid conditions. The magnitude of the cancer burden includes their course of treatment
The burden of chronic diseases among Australian cancer patients
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over an extended oncology follow-up period which can affect their health status burden and
includes chronic comorbid conditions, disability, and adverse events.
Conceptual framework
The distribution of comorbidity varies by patient-level factors (Fig 1). Like cancer itself, it
increases with age. Functional status, a measure of patients’ ability to perform everyday activi-
ties, is related to both the presence and the consequences of chronic comorbid conditions.
Health status burden is associated with increased vulnerability to stressors that result from
decreased health scores as well as physiological strength [34]. Further, health status burden is
strongly associated with increased age and the severity of the disease. In the context of comor-
bidity experiences, patients assess their health status depending on the severity of disease (as
either better or worse) [35]. Despite strong associations between them, comorbidity, functional
status, and health status burden are separate entities, and each has an independent effect on
outcomes [34]. To investigate the longitudinal effects, it is assumed that several predictors
(e.g., individual background characteristics, social factors, and disease-related symptomatic
factors), measured at the symptom-level might predict outcome factors (e.g., appraisal of dis-
ease severity levels, utilisation of advanced treatment, life satisfaction, and uncertainty). More-
over, the combination of predictors was expected to predict patients’ health outcomes (e.g.,
chronic comorbid conditions, long-term health problems or disability, and adverse events).
Data source
Data came from the Household, Income and Labour Dynamics in Australia (HILDA) survey
[36]. TheHILDA survey commenced in 2001 and is a nationally representative household-
based panel study that produces data on the lives of Australian residents aged 15 or over. As
per theHILDA protocol, written or verbal consent was collected from all potential participants
before conducting the survey. Data were collected through face-to-face interviews using quanti-
tative survey instruments, followed by re-interviews with the same people in subsequent years.
The details of the methods of data collection, including the sampling technique, have been
explained elsewhere [36]. The present study participants were diagnosed with cancer patients,
Fig 1. Conceptual framework of the study.
https://doi.org/10.1371/journal.pone.0228744.g001
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and data were restricted to four waves (e.g., wave-7, wave-9, wave-13 and wave-17) based on
the availability of data related to cancer. However, wave-3 was excluded from the analysis due
to the limited data related to comorbidity status. Other survey waves were excluded from the
analyses due to the paucity of cancer-related information. A total of 2,066 diagnosed cancer
patients were potential study participants from the four waves: wave-7 in 2007 (n2 = 557),
wave-9 in 2009 (n3 = 416), wave-13 in 2013 (n4 = 517) and wave-17 in 2017 (n5 = 576).
Study variables
Outcome variable. The chronic comorbid conditions were classified into disease groupings
and cover the most common types of long-term health conditions experienced by cancer patients
in the Australian community. A previous review study identified that at least 21 approaches have
been executed to measure comorbidity status [37]. There is no gold-standard method for mea-
suring comorbidity among cancer populations [37]. The selection of the method depends on the
study research question, data availability, and population studied. A number of methods related
to measuring comorbidity status have been used in the context of cancer-related studies includ-
ing exploration of the impact of single conditions (such as diabetes or congestive heart failure)
[38–40], single condition counts [41–43], weighted indices [43–47], and organ-based systems
[48–50]. Although all these approaches aim to evaluate the same underlying construct, they vary
in terms of the study purpose for which the measures were performed. These approaches vary in
the context of study perspective and design. The simplest approach to measuring comorbidity
status is to investigate the distribution of individual comorbid conditions and to treat them inde-
pendently and/or to combine them by summing the total number of conditions [51]. In this
study, a single condition count approach was performed to measure comorbidity status. Cancer
patients reporting chronic condition(s) were considered an outcome variable in the analysis.
Chronic comorbid conditions included being diagnosed with serious chronic illness, including
arthritis or osteoporosis, heart disease, diabetes, hypertension, mental illness, or circulatory con-
ditions. The count of chronic health conditions was measured for each respondent based on the
number of disease exposures and who had been prescribed medication for their illness. If the
respondents had multiple chronic conditions, it was counted as multiple responses.
Explanatory variables. This study considered several demographic, socio-economic and
health and lifestyle-related variables based on the conceptual framework, as putative predictors
of chronic comorbid conditions. Socio-demographic factors, such as sex, age, educational
achievement, employment status, and marital status were considered as potential factors in the
analysis. Lifestyle factors such as alcohol consumption, smoking exposure, and physical activity
were also included. The level of physical activity was categorized into three groups as low, mod-
erate, or high [27,52,53]. Further, life condition-related factors such as satisfaction with
employment, financial situation, and social supports were also selected as potential predictors.
Ethnic status was defined as Aboriginal or non-Aboriginal. The quality of life scores was mea-
sured using the medical outcomes study short-form (SF-36) [54]. The SF-36 is one of the most
common generic measures of health-related quality of life, which is widely used to assess the
burden of disease in the context of different country settings [55]. It uses psychometric proper-
ties to enable profiling of physical functional health and well-being and to quantify disease
burden across eight domains, including physical functioning, role-physical, body pain, general
health, vitality, social functioning, role-emotional, and mental health. Considering these
dimensions, the total score on each SF-36 subscale ranges between 0 and 100, labelling ‘worst
imaginable health’ and ‘best imaginable health state’, respectively. It is signified that the higher
scores represent better health status. A recent review study confirmed that several studies used
a total score of SF-36 items to derive quality of life scores across the eight domains of SF-36
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[56]. The levels of health status burden were proposed based on the magnitude of quality of life
scores as follows: (1) high burden if the short form-36 (SF-36) scores< 50.00, (2) moderate
burden if 50.00�SF-36 scores< 90.00, and (3) no burden if SF-36 scores� 90.00. The level of
health status burden captured the severity of disease for cancer patients. Work disability was
measured based on the severity of disability score ranged from 0 to 10, with 10 indicating ‘able
to do any work’ and 0 indicating ‘not at all’. The severity of disability level was defined as fol-
lows: (i) ‘no disability’ if disability score was equal to zero, (ii) ‘moderate disability’ for disability
scores of 1 to 6, and (iii) ‘severe disability’ for disability scores of 7 to 10. Geographical locations
were defined according to the accessibility to services and the Remoteness Index of Australia
[57], and they were categorized into five groups: major cities, inner regional, outer regional and
remote or very remote. The index of relative socioeconomic disadvantage (IRSD) was used to
measure socioeconomic status (SES). The index was defined into five groups with these thresh-
old values: Q1 (IRSD� 927.0), Q2 (927.0> IRSD� 965.8), Q3 (965.8> IRSD� 1001.8),
Q4 (1001.8> IRSD� 1056.0), or Q5 (IRSD> 1056.0) [58]. This is a geographical area-based
estimate of socioeconomic status using income, education level and occupation where commu-
nities are categorised from economically disadvantaged to wealthy.
Statistical analysis
This study utilised descriptive analyses to compare patients with cancer and chronic medical
conditions across the characteristics. The trend of chronic comorbid conditions among cancer
patients was performed using the Cochran-Armitage trend test [59]. In the analytical explora-
tion, the adjusted fixed-effect negative binomial regression model was used to identify the
potential factors that had a significant role in the exposure to chronic comorbid conditions. In
the regression model, the dependent variable (number of chronic comorbid conditions) was
characterised as a count measure. An unadjusted analysis was performed using only separated
explanatory variables for the following reasons: (1) primary screening of the selection of quali-
fied predictors, which were added in the adjusted model, (2) although the chi-square tests (or
one-way analysis where appropriate) are only used to find the association between outcome
and explanatory variables. However, the majority of the predictor variables were categorical
nature with two or more labels in this study. Therefore, an un-adjusted analysis was performed
to find the association between outcome and the labels of explanatory variables. The predictor
variables were included in the adjusted model only if any label of the predictor was significant
at 5% or less risk level in the unadjusted model, which in turn was used to adjust for the effects
of other potential confounders. However, insignificant predictors were not included in the
adjusted model. The model was tested for sensitivity by the forward selection procedure (e.g.,
including and excluding specific variables) with robust standard errors. For the independent
variables, the category found to be least at risk of having chronic comorbid conditions in the
analysis was considered as the reference for constructing incidence risk ratios (IRR). Statistical
significance was considered at the 5% risk level. All data analyses were undertaken using the
statistical software Stata/SE 13 (StataCorp, College Station, TX, USA).
Ethical considerations
The Household, Income and Labour Dynamics in Australia (HILDA) data are used under
strict licensing. Data can be potentially obtained and shared subject to a peer-reviewed applica-
tion. Ethical approval for theHILDA study was obtained from the Faculty of Business and
Economics Human Ethics Advisory Committee at the University of Melbourne (#1647030).
Approval for the use ofHILDA data was provided by the Department of Social Services. Ethical
approval was not required from an institutional review board because the patient information
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was de-identified. Appropriate approval was obtained for this study from the Department of
Social Services to access the de-identified longitudinal dataset.
Results
Background characteristics of the study population
A total of 2,066 cancer patients were potential participants (Tables 1 and 2). Approximately
54% of patients were male, with 58% of patients being married. A higher proportion (46%)
of the patients were senior or old senior-aged (more than 65 years), followed by middle-aged
(37%). Approximately 47% had completed middle or high school level education, with 316
cancer patients (15%) having tertiary education. Sixty three percent of 63% of patients were
unemployed, while 45% of patients had inadequate physical activity, with only 23% of patients
having high-level physical activities per week. Two-third of 75% of patients consumed alcohol
frequently. The majority of participants (89%) reported a moderate or extreme health burden,
whereas 42% of patients experienced moderate or severe disability levels. In addition, 72%
received prescribed medication, and 61% lived in major cities.
Distribution and changes of chronic comorbid conditions with cancer
patients over time
The prevalence of comorbid conditions was reported by cancer patients as follows: arthritis
or osteoporosis (45%), high blood pressure or hypertension (39%), obesity (23%), depression
or anxiety (22%), heart disease (14%), and asthma (13%). These were significantly increased
in the prevalence of depression or anxiety (p<0.01), mental illness (p = 0.052) and obesity
(p = 0.003) over the period (Fig 2). However, a downward trend in the prevalence of comorbid
conditions was observed for arthritis/osteoporosis (p = 0.012) over time.
Overall, approximately 42% of patients suffered from one to two chronic comorbid condi-
tions, while 21% of patients experienced at least three or more comorbid conditions (Table 1).
The prevalence of comorbid conditions was prominently distributed by age. The majority of
comorbidities were highly pronounced in patients due to a lack of physical activity. For exam-
ple, 56% of patients were more likely to report three or more comorbid conditions. This preva-
lence was disproportionately low (14%) in those who engaged in a high level of physical activity.
Further, patients who suffered from at least one comorbid condition were significantly aligned
with the magnitude of high or moderate health status burden (e.g., 62% for severe burden and
36% for moderate burden). Similarly, an upward trend of the upper extremity of disability levels
was observed with an increased number of comorbid exposures among the poorest cancer sur-
vivors during the period (Fig 3). Regarding socioeconomic position, the magnitude of comorbid
conditions was more pronounced in the most disadvantaged socio-economic group. For exam-
ple, 28% of patients who lived in the poorest households were significantly exposed to three or
more comorbid conditions compared with the richest households (13%). Also, the severity of
disability score was also highest among patients in the poorest households along with an
increasing number of comorbid conditions (Fig 3).
Factors influencing chronic comorbid exposure of cancer patients
Table 3 exhibits the results of the fixed effect negative binomial regression analyses. In the
adjusted model, older patients, the magnitude of health status burden associated with cancer,
utilisation of healthcare, and patients living in the poorest households were significant predic-
tors associated with a higher risk of comorbid conditions. An aged patient (>65 years old) has
1.15 times higher risk of having comorbid conditions (incidence rate ratio, IRR = 1.15; 95%
The burden of chronic diseases among Australian cancer patients
PLOSONE | https://doi.org/10.1371/journal.pone.0228744 February 12, 2020 7 / 20
109
notator - www.PDFAnnotator.com
Table 1. Summary statistics by the number of chronic condition among cancer patients for wave 7 and wave 9.
Variables Number of observations, n (%) Wave-7 Wave-9
Number of chronic comorbid conditions, n
(%)
Number of chronic comorbid conditions, n
(%)
0 1–2 3 or more 0 1–2 3 or more
Sex
Male 1,123 (54.36) 234 (54.80) 77 (59.23) na 45 (51.14) 110 (48.46) 55 (54.46)
Female 943 (45.64) 193 (45.20) 53 (40.77) na 43 (48.86) 117 (51.54) 46 (45.54)
Age
<25 years 53 (2.57) 10 (2.34) 3 (2.31) na 1 (1.14) 4 (1.76) 1 (0.99)
25–45 years 283 (13.70) 77 (18.03) 17 (13.08) na 23 (26.14) 32 (14.10) 8 (7.92)
46–65 years 771 (37.32) 146 (34.19) 69 (53.08) na 39 (44.32) 86 (37.89) 30 (29.7)
>65 years 959 (46.42) 194 (45.43) 41 (31.54) na 25 (28.41) 105 (46.26) 62 (61.39)
Educational attainment
Year 11 or below 774 (37.46) 169 (39.58) 48 (36.92) na 26 (29.55) 97 (42.73) 46 (45.54)
Year 12 168 (8.13) 37 (8.67) 14 (10.77) na 10 (11.36) 15 (6.61) 9 (8.91)
Trade/certificate/diploma 808 (39.11) 149 (34.89) 54 (41.54) na 35 (39.77) 81 (35.68) 40 (39.6)
Tertiary 316 (15.30) 72 (16.86) 14 (10.77) na 17 (19.32) 34 (14.98) 6 (5.94)
Unemployed 1,306 (63.21) 250 (58.55) 66 (50.77) na 40 (45.45) 150 (66.08) 86 (85.15)
Marital status
Single 258 (12.49) 52 (12.18) 20 (15.38) na 16 (18.18) 27 (11.89) 7 (6.93)
Married 1,196 (57.89) 256 (59.95) 80 (61.54) na 46 (52.27) 130 (57.27) 52 (51.49)
Others 612 (29.62) 119 (27.87) 30 (23.08) na 26 (29.55) 70 (30.84) 42 (41.58)
Alcohol consumption (= yes) 1,500 (72.60) 341 (79.86) 102 (78.46) na 64 (72.73) 158 (69.60) 66 (65.35)
Smoking exposure (= yes) 276 (13.36) 64 (14.99) 22 (16.92) na 11 (12.50) 32 (14.10) 13 (12.87)
Physical activity status
Low 876 (42.40) 153 (55.11) 88 (55.11) 36 (55.11) 98 (55.11) 52 (55.11)
Moderate 701 (33.93) 134 (29.55) 30 (29.55) 28 (29.55) 74 (29.55) 33 (29.55)
High 489 (23.67) 140 (15.34) 12 (15.34) 24 (15.34) 55 (15.34) 16 (15.34)
Health status burden
No burden 208 (10.07) 57 (13.35) 13 (10.00) na 24 (27.27) 19 (8.37) 1 (0.99)
Moderate burden 1,205 (58.33) 268 (62.76) 82 (63.08) na 48 (54.55) 135 (59.47) 41 (40.59)
Severe burden 653 (31.61) 102 (23.89) 35 (26.92) na 16 (18.18) 73 (32.16) 59 (58.42)
Disability status
No disability 1,172 (56.73) 258 (60.42) 76 (58.46) na 76 (86.36) 124 (54.63) 32 (31.68)
Moderate disability 509 (24.64) 92 (21.55) 26 (20.00) na 7 (7.95) 63 (27.75) 39 (38.61)
Severe disability 385 (18.64) 77 (18.03) 28 (21.54) na 5 (5.68) 40 (17.62) 30 (29.70)
Healthcare utilisation (= yes) 1,093 (72.43) 219 (65.45) 63 (46.95) na 22 (25.00) 181 (79.74) 98 (97.03)
Life satisfaction with-
Employment,mean (sd) 3.39 (3.96) 3.51 (4.03) 3.86 (3.94) na 5.3 (3.98) 3.55 (3.98) 2.36 (3.88)
Financial situation,mean (sd) 6.73 (2.37) 7.05 (2.27) 6.65 (2.43) na 6.98 (2.14) 6.63 (2.45) 6.04 (2.59)
Social supports,mean (sd) 7.83 (1.82) 8.09 (1.54) 7.97 (1.54) na 7.91 (1.73) 7.64 (2.03) 7.78 (1.98)
Remoteness
Major Cities 1,264 (61.18) 270 (63.23) 75 (57.69) na 48 (54.55) 128 (56.39) 63 (62.38)
Inner Regional 519 (25.12) 98 (22.95) 34 (26.15) na 24 (27.27) 59 (25.99) 24 (23.76)
Outer Regional 247 (11.96) 50 (11.71) 21 (16.15) na 13 (14.77) 38 (16.74) 12 (11.88)
Remote or very remote 36 (1.74) 9 (2.11) na na 3 (3.41) 2 (0.88) 2 (1.98)
Socioeconomic status
Q1 (lowest 20%) (ref) 407 (19.70) 81 (18.97) 23 (17.69) na 11 (12.50) 46 (20.26) 27 (26.73)
(Continued)
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confidence interval, CI: 1.08, 1.45) compared with a young patient (<25 years). Patients who
performed lower levels of physical activity were 1.25 times more likely to have a chronic
comorbid condition (IRR = 1.25; 95% CI: 1.09, 1.59) compared with patients who engaged in
high-level physical activity. Further, patients who faced an extreme health burden were 2.30
times significantly higher risk of having comorbid conditions than those with no health bur-
den. The risks of having a comorbid condition were more pronounced among patients who
suffered from extreme health burden (IRR = 2.30 times) or moderate burden level (IRR = 1.90
times) compared with patients who reported excellent health status. Similarly, a higher risk of
having a comorbid exposure was significantly observed in cancer patients who lived in the
poorest households (IRR = 1.21; 95% CI: 1.11, 1.29) compared with their richest counterparts.
Discussion
The study results show that approximately 63% of cancer patients suffered from at least one
chronic disease. The most prevalent comorbid conditions were arthritis or osteoporosis, high
blood pressure or hypertension, obesity, depression or anxiety, heart disease, and asthma.
However, these were significantly increased in the presence of diabetes, depression or anxiety,
mental illness, heart disease and obesity over time. In the adjusted model, older patients, inad-
equate level of physical activities, the magnitude of health burden associated with cancer, utili-
sation of healthcare, and patients living in the poorest households were significant predictors
associated with a higher risk of comorbid conditions.
Further, patients who faced an extreme health burden had a three times higher risk of hav-
ing comorbid conditions than who reported excellent health status. Some studies have con-
firmed that the poor health status of cancer patients resulted in a greater burden of functional
disability (e.g., specific task difficulties) [60,61] along with a higher burden of chronic diseases
[15,30,62]. However, the prevalence of long-term health problems, including chronic illness,
short or long-term disability, was also more concentrated in combination with a cancer diag-
nosis [63–68]. Advanced cancer treatments can damage healthy cells or organs [69], for exam-
ple, radiation and chemotherapy may impose short and long-term chronic health problems
and impact on the spinal cord, nerves, and brain, which then may significantly contribute to
long-term adverse health outcomes like death, physical and mental disabilities.
The results indicate that aged cancer patients (older than 65 years) were at a 1.15 times
higher risk of having chronic comorbid conditions compared with younger patients. This find-
ing is consistent with previous studies, which revealed that elderly cancer patients reported sig-
nificantly more exposure to chronic comorbid conditions [23,70,71], required more assistance
with daily living activities [72], and had deficits in performing work-related activities in terms
Table 1. (Continued)
Variables Number of observations, n (%) Wave-7 Wave-9
Number of chronic comorbid conditions, n
(%)
Number of chronic comorbid conditions, n
(%)
0 1–2 3 or more 0 1–2 3 or more
Q2 470 (22.75) 87 (20.37) 27 (20.77) na 16 (18.18) 60 (26.43) 29 (28.71)
Q3 369 (17.86) 79 (18.50) 33 (25.38) na 25 (28.41) 39 (17.18) 14 (13.86)
Q4 428 (20.72) 98 (22.95) 28 (21.54) na 20 (22.73) 39 (17.18) 21 (20.79)
Q5 (highest 20%) 392 (18.97) 82 (19.20) 19 (14.62) na 16 (18.18) 43 (18.94) 10 (9.90)
Overall 2,066 (100) 427 (76.66) 130 (23.34) na 88 (21.15) 227 (54.57) 101 (24.28)
Na = not available
https://doi.org/10.1371/journal.pone.0228744.t001
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Table 2. Summary statistics by the number of chronic condition among cancer patients for wave 13 and wave 17.
Variables Wave-13 Wave-17 Overall
Number of chronic comorbid conditions,
n (%)
Number of chronic comorbid conditions,
n (%)
Number of chronic comorbid conditions,
n(%
0 1–2 3 or more 0 1–2 3 or more 0 1–2 3 or more
Sex
Male 70 (58.82) 122 (50.41) 87 (55.77) 73 (57.94) 160 (58.39) 90 (51.14) 422 (55.53) 469 (53.72) 232 (53.58)
Female 49 (41.18) 120 (49.59) 69 (44.23) 53 (42.06) 114 (41.61) 86 (48.86) 338 (44.47) 404 (46.28) 201 (46.42)
Age
<25 years 6 (5.04) 9 (3.72) 2 (1.28) 6 (4.76) 5 (1.82) 6 (3.41) 23 (3.03) 21 (2.41) 9 (2.08)
25–45 years 25 (21.01) 30 (12.4) 9 (5.77) 26 (20.63) 28 (10.22) 8 (4.55) 151 (19.87) 107 (12.26) 25 (5.77)
46–65 years 51 (42.86) 93 (38.43) 47 (30.13) 56 (44.44) 98 (35.77) 56 (31.82) 292 (38.42) 346 (39.63) 133 (30.72)
>65 years 37 (31.09) 110 (45.45) 98 (62.82) 38 (30.16) 143 (52.19) 106 (60.23) 294 (38.68) 399 (45.7) 266 (61.43)
Educational attainment
Year 11 or below 31 (26.05) 88 (36.36) 70 (44.87) 30 (23.81) 91 (33.21) 78 (44.32) 256 (33.68) 324 (37.11) 194 (44.8)
Year 12 9 (7.56) 20 (8.26) 8 (5.13) 12 (9.52) 21 (7.66) 13 (7.39) 68 (8.95) 70 (8.02) 30 (6.93)
Trade/certificate/diploma 51 (42.86) 107 (44.21) 59 (37.82) 47 (37.3) 117 (42.7) 68 (38.64) 282 (37.11) 359 (41.12) 167 (38.57)
Tertiary 28 (23.53) 27 (11.16) 19 (12.18) 37 (29.37) 45 (16.42) 17 (9.66) 154 (20.26) 120 (13.75) 42 (9.7)
Unemployed 58 (48.74) 159 (65.70) 128 (82.05) 54 (42.86) 177 (64.60) 138 (78.41) 402 (52.89) 552 (63.23) 352 (81.29)
Marital status
Single 21 (17.65) 30 (12.4) 12 (7.69) 24 (19.05) 30 (10.95) 19 (10.8) 113 (14.87) 107 (12.26) 38 (8.78)
Married 72 (60.5) 141 (58.26) 90 (57.69) 69 (54.76) 164 (59.85) 96 (54.55) 443 (58.29) 515 (58.99) 238 (54.97)
Others 26 (21.85) 71 (29.34) 54 (34.62) 33 (26.19) 80 (29.2) 61 (34.66) 204 (26.84) 251 (28.75) 157 (36.26)
Alcohol consumption (= yes) 91 (76.47) 178 (73.55) 100 (64.10) 84 (66.67) 205 (74.82) 111 (63.07) 580 (76.32) 643 (73.65) 277 (63.97)
Smoking exposure (= yes) 11 (9.24) 32 (13.22) 23 (14.74) 14 (11.11) 32 (11.68) 22 (12.50) 100 (13.16) 118 (13.52) 58 (13.39)
Physical activity status
Low 35 (29.41) 95 (39.26) 94 (60.26) 50 (39.68) 125 (45.62) 97 (55.11) 274 (36.05) 406 (46.51) 243 (56.12)
Moderate 44 (36.97) 81 (33.47) 44 (28.21) 36 (28.57) 89 (32.48) 52 (29.55) 242 (31.84) 274 (31.39) 129 (29.79)
High 40 (33.61) 66 (27.27) 18 (11.54) 40 (31.75) 60 (21.9) 27 (15.34) 244 (32.11) 193 (22.11) 61 (14.09)
Health status burden
No burden 30 (25.21) 15 (6.2) 0 (0) 22 (17.46) 22 (8.03) 5 (2.84) 132 (17.37) 69 (7.9) 6 (1.39)
Moderate burden 64 (53.78) 172 (71.07) 75 (48.08) 76 (60.32) 175 (63.87) 69 (39.2) 422 (55.53) 513 (58.76) 156 (36.03)
Severe burden 25 (21.01) 55 (22.73) 81 (51.92) 28 (22.22) 77 (28.1) 102 (57.95) 206 (27.11) 291 (33.33) 271 (62.59)
Disability status
No disability 96 (80.67) 146 (60.33) 41 (26.28) 104 (82.54) 153 (55.84) 66 (37.50) 534 (70.26) 499 (57.16) 139 (32.10)
Moderate disability 9 (7.56) 59 (24.38) 56 (35.9) 10 (7.94) 84 (30.66) 64 (36.36) 118 (15.53) 232 (26.58) 159 (36.72)
Severe disability 14 (11.76) 37 (15.29) 59 (37.82) 12 (9.52) 37 (13.5) 46 (26.14) 108 (14.21) 142 (16.27) 135 (31.18)
Healthcare utilisation (= yes) 39 (32.77) 175 (72.31) 152 (97.44) 47 (37.30) 209 (76.28) 170 (96.59) 108 (9.88) 565 (51.69) 420 (38.43)
Life satisfaction with-
Employment,mean (sd) 4.82 (3.89) 3.47 (3.9) 1.96 (3.43) 4.48 (3.97) 3.39 (3.97) 1.64 (3.12) 4.08 (4.04) 3.52 (3.95) 1.92 (3.43)
Financial situation,mean (sd) 7.39 (1.98) 6.5 (2.53) 5.99 (2.57) 7.33 (2.01) 6.76 (2.31) 6.32 (2.65) 7.14 (2.17) 6.64 (2.43) 6.13 (2.6)
Social supports,mean (sd) 7.94 (1.68) 7.67 (2.17) 7.74 (1.95) 7.82 (1.74) 7.92 (1.71) 7.44 (2.1) 8 (1.62) 7.78 (1.91) 7.63 (2.02)
Remoteness
Major Cities 79 (66.39) 151 (62.4) 105 (67.31) 91 (72.22) 151 (55.11) 103 (58.52) 488 (64.21) 505 (57.85) 271 (62.59)
Inner Regional 27 (22.69) 55 (22.73) 35 (22.44) 26 (20.63) 87 (31.75) 50 (28.41) 175 (23.03) 235 (26.92) 109 (25.17)
Outer Regional 11 (9.24) 32 (13.22) 16 (10.26) 6 (4.76) 28 (10.22) 20 (11.36) 80 (10.53) 119 (13.63) 48 (11.09)
Remote or very remote 2 (1.68) 4 (1.65) 0 (0) 3 (2.38) 8 (2.92) 3 (1.7) 17 (2.24) 14 (1.6) 5 (1.15)
Socioeconomic status
Q1 (lowest 20%) (ref) 17 (14.29) 50 (20.66) 48 (30.77) 18 (14.29) 41 (14.96) 45 (25.57) 127 (16.71) 160 (18.33) 120 (27.71)
(Continued)
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of their physical ability [60,73]. Several reasons might influence this reduction in their physical
strength. For example, a course of advanced cancer treatment is associated with considerable
physical and psychological side effects in elderly cancer patients (e.g., weight change, muscle
loss, fatigue, and physical weakness) [74], and exposure to multiple comorbidities [64,65,75]
will presumably contribute to worse health status. Although, cancer patients in older age
groups are less likely to be offered cancer treatments (e.g., chemotherapy, radiotherapy and
axillary lymph node dissection) that may then contribute to a greater burden of health [74].
This result indicates that rehabilitation-related interventions (e.g., physical therapies) are
essential to prevent or alleviate chronic comorbid conditions and an emerging cancer research
area, particularly focused on the elderly [76].
The present study found that cancer patients who performed lower levels of physical activi-
ties were strongly associated with an extreme level of chronic comorbidities compared with
patients engaged in high-level physical activity. This finding is in line with other studies
[52,77,78], whereby it was found that limited physical activity levels were significantly associ-
ated with a higher risk of having chronic comorbid conditions in cancer patients. The magni-
tude of limited physical activity level may decrease the risk for several cancers by some
mechanisms, including decreasing sex hormones, metabolic hormones and inflammation, and
improving immune function [77]. In terms of cancer risk, high levels of physical activities
(compared with low levels) played a significant role in the prevention of several cancers (e.g.,
42% for gastrointestinal cancer, 23% for renal cancer, and 20% for myeloid leukemia) [79].
Table 2. (Continued)
Variables Wave-13 Wave-17 Overall
Number of chronic comorbid conditions,
n (%)
Number of chronic comorbid conditions,
n (%)
Number of chronic comorbid conditions,
n(%
0 1–2 3 or more 0 1–2 3 or more 0 1–2 3 or more
Q2 22 (18.49) 59 (24.38) 38 (24.36) 22 (17.46) 62 (22.63) 48 (27.27) 147 (19.34) 208 (23.83) 115 (26.56)
Q3 21 (17.65) 29 (11.98) 27 (17.31) 21 (16.67) 51 (18.61) 30 (17.05) 146 (19.21) 152 (17.41) 71 (16.40)
Q4 32 (26.89) 51 (21.07) 23 (14.74) 27 (21.43) 64 (23.36) 25 (14.20) 177 (23.29) 182 (20.85) 69 (15.94)
Q5 (highest 20%) 27 (22.69) 53 (21.9) 20 (12.82) 38 (30.16) 56 (20.44) 28 (15.91) 163 (21.45) 171 (19.59) 58 (13.39)
Overall 119 (23.02) 242 (46.81) 156 (30.17) 126 (21.88) 274 (47.57) 176 (30.56) 760 (36.79) 873 (42.26) 433 (20.96)
Na = not available
https://doi.org/10.1371/journal.pone.0228744.t002
Fig 2. The trend of disease pattern among patients with cancer.
https://doi.org/10.1371/journal.pone.0228744.g002
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This includes averting genetic damage, improving the immune system, reducing chronic infec-
tions, and controlling cancer cells [79]. In addition, some past studies confirmed that physical
activity plays an effective role in controlling the side effects of cancer treatment and disease
progression, reducing psychological conditions [77,80] and reducing the risk of developing
future cancers [81]. Several hypotheses and mechanisms have been suggested regarding the
anti-cancer effects of physical activities. The American Cancer Society guidelines for cancer
survivors [82] recommend daily physical activities, including a continuation of normal daily
life activities immediately after diagnosis, which help to significantly reduce physical stamina
and muscle strength erosion as well as anxiety levels, thereby resulting in the prevention of
long-term adverse health outcomes (e.g., extreme comorbidity burden and disability) [83]. In
this context, future research could examine the influence that physical activity has on the effec-
tiveness of chronic comorbid conditions among cancer patients.
The risks of having extreme chronic comorbidity conditions amongst cancer patients who
lived in the poorest households were more pronounced compared with their richer counter-
parts. Recent studies confirm this result with the disadvantaged socioeconomic status of cancer
survivors being negatively associated with long-term adverse health outcomes (e.g., multiple
chronic illnesses, physical disability) [83–93]. Some studies also provided evidence that the mag-
nitude of the cancer burden is adversely associated with socioeconomic status [16, 32–35].
Further, adverse cancer outcomes (e.g., worse health status and long-term chronic illness) were
disproportionately found in poorer people as opposed to those of higher socioeconomic status
[13, 16, 32, 34]. Some reasons that have contributed to the high rates of long term health impacts
among the poorest groups include higher tobacco consumption [16,28], economic burden
[36,37], increased mental illness [94], lack of health education and awareness [95], and less
access to competent and effective health care services [95]. Low productivity, loss/reduction of
household income, and increased healthcare expenditure are more pronounced amongst the
poorest cancer patients. Growing socioeconomic disparities of cancer outcomes need the
Fig 3. Unequal distribution of the presence of chronic comorbidities with the severity of disability among cancer patients across socioeconomic
status.
https://doi.org/10.1371/journal.pone.0228744.g003
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Table 3. Factors influencing chronic comorbid conditions of cancer patients using a fixed-effect negative binomial regression model.
Variables Unadjusted model1 Adjusted model2
IRR (SE) 95% CI IRR (SE) 95% CI
Female (ref = male) 1.04 (0.05) (0.94, 1.14) - -
Age group
< 25 years (= ref) 1.00 - 1.00 -
25–45 years 0.72 (0.13) (0.51, 1.03) 0.85 (0.14) (0.61, 1.18)
46–65 years 1.15 (0.19) (0.83, 1.58) 1.07 (0.16) (0.79, 1.45)
>65 years 1.49��� (0.24) (1.09, 2.04) 1.15�� (0.17) (1.08, 1.45)
Educational attainment
Year 11 or below 1.48��� (0.12) (1.26, 1.74) 1.16�� (0.09) (1.01, 1.35)
Year 12 1.11 (0.13) (0.88, 1.40) 1.13 (0.12) (0.91, 1.40)
Trade/certificate/diploma 1.38��� (0.12) (1.17, 1.63) 1.21��� (0.09) (1.05, 1.40)
Tertiary (= ref) 1.00 - 1.00 -
Unemployed (ref = employed) 1.80��� (0.10) (1.62, 2.00) 1.08 (0.07) (0.95, 1.23)
Marital status
Single (= ref) 1.00 - 1.00 -
Married 1.21�� (0.10) (1.02, 1.42) 1.02 (0.08) (0.87, 1.20)
Others 1.41��� (0.12) (1.19, 1.68) 1.06 (0.09) (0.90, 1.25)
Physical activity status
Low 1.60��� (0.12) (1.39, 1.85) 1.25�� (0.07) (1.09, 1.59)
Moderate 1.30��� (0.10) (1.12, 1.52) 1.06 (0.07) (0.92, 1.21)
High (= ref) 1.00 - 1.00 -
Alcohol consumption (ref = yes) 1.26��� (0.06) (1.14, 1.39) 0.91 (0.05) (0.82, 1.00)
Smoking exposure (ref = no) 1.02 (0.07) (0.88, 1.18) - -
Healthcare utilisation (ref = no) 0.27 (0.02) (0.24, 0.31) 0.38��� (0.03) (0.33, 0.45)
Health status burden
No burden (= ref) 1.00 - 1.00 -
Moderate burden 2.44��� (0.27) (1.96, 3.03) 1.90��� (0.26) (1.45, 2.48)
Severe burden 4.18��� (0.47) (3.36, 5.21) 2.30��� (0.33) (1.73, 3.05)
Disability status
No disability (= ref) 1.00 - 1.00 -
Moderate disability 1.82��� (0.10) (1.64, 2.02) 1.22��� (0.07) (1.10, 1.36)
Severe disability 1.99��� (0.12) (1.76, 2.24) 1.25��� (0.08) (1.11, 1.41)
Life satisfaction with-
Employment 0.94��� (0.01) (0.92, 0.95) 0.98��� (0.01) (0.97, 0.99)
Financial situation 0.97�� (0.01) (0.95, 0.99) 0.96��� (0.01) (0.94, 0.98)
Social supports 0.96��� (0.01) (0.93, 0.98) 1.03�� (0.01) (1.01, 1.05)
Remoteness
Major cities (= ref) 1.00 - - -
Inner regional 1.02 (0.06) (0.91, 1.14) - -
Outer regional 1.04 (0.08) (0.90, 1.21) - -
Remote or very remote 0.77 (0.14) (0.54, 1.11) - -
Socioeconomic status
Q1 (lowest 20%) 1.51
��� (0.12) (1.29, 1.77) 1.21��� (0.08) (1.11, 1.29)
Q2 1.35
��� (0.11) (1.15, 1.57) 1.09 (0.08) (0.95, 1.26)
Q3 1.19
�� (0.10) (1.01, 1.41) 1.15 (0.09) (0.99, 1.34)
Q4 1.08 (0.09) (0.92, 1.27) 0.99 (0.08) (0.85, 1.15)
(Continued)
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attention of governments, health systems, and decision-makers. For example, Cancer Council
Australia has an optimal care pathway project, which has already addressed several cancer sites
in disadvantaged areas. Such initiatives might help to reduce socio-economic disparities, which
are related to poverty, gender, education, and health, and they should promote universal access
to health care which can further enhance both socio-economic and human development.
This study has some limitations. Study participants were accessed from theHILDA survey,
which covers health, economic, employment, income and health characteristics of household
members aged 15 years and older. Children who suffered from cancer were excluded from this
study. The study findings established a relationship between cancer diagnosis and chronic
comorbidity conditions among cancer survivors, which might vary in terms of cancer stages
and types of cancer. The authors were not able to estimate the cancer type analysis due to the
paucity of relevant data. Further, the study findings were based on self-reported responses that
might have been impacted by respondents’ prejudice (e.g., silence and over-response), and by
problems in understanding and interpreting the survey questions.
Despite these limitations, this study has some strengths including the use of a prospective
longitudinal design of long term follow-ups and the application of well-validated and reliable
longitudinal wave measures of the impacts of a cancer diagnosis on the burden of chronic
comorbid conditions of individuals over the 2007–2017 period. The study population captured
different dimensions including ethnically, geographically, and socio-economically diverse
groups. Furthermore, this study included several potential confounding factors such as health
status burden, the severity of the disability level as well as life satisfaction (e.g., employment,
financial situation and, social supports) that were not present in previous studies. For this study,
data were gathered from four-wave of theHILDA survey for cancer survivors. The length of the
survey period may have introduced uncontrolled bias, as changes in health status are not instan-
taneous and might emerge only after time, which was not captured in this study. Due to the
paucity of funding, the authors were unable to consider cancer patients who registered for can-
cer surveillance as well as received health care from other health facilities (e.g., private clinics,
community clinics and, secondary or tertiary hospitals). Future study is required using a similar
study design, perspective, and analytical methods in terms of cancer-specific exploration.
Conclusions
This study has shown an extreme burden of chronic comorbid conditions among cancer
patients in Australia. Older patients, inadequate level of physical activities, the magnitude of
health burden, and patients living in the poorest households were significant predictors associ-
ated with a higher risk of having chronic comorbidity conditions. The findings have further
Table 3. (Continued)
Variables Unadjusted model1 Adjusted model2
IRR (SE) 95% CI IRR (SE) 95% CI
Q5 (highest 20%) (= ref) 1.00 - 1.00 -
Note:
�p<0.05,
��p<0.01,
���p<0.001,
IRR = incidence rate ratio, SE = standard error, CI = confidence interval,
1Single explanatory variable was included in un-adjusted model,
2Explanatory variables were included in the adjusted model only if any label of the variable was significant at 5% or less risk level in the unadjusted model
https://doi.org/10.1371/journal.pone.0228744.t003
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implications for improving public health policy and reducing population-level unhealthy life-
styles, which should be recommended. The study results could be used to better outline the
management of a sequelae course of treatment for those who should undergo more intensive
physical rehabilitation aimed at reducing the risk of adverse health outcomes. Given the clini-
cal significance of comorbidity in cancer survivors, this study may play a significant role in
providing comprehensive evidence for health care providers, including physical therapists and
oncologists, who should be aware of the unique problems that challenge this population and
who should advocate for prevention and evidence-based interventions. Finally, a greater
awareness of the importance of managing a patients overall health status within the context of
comorbidity is warranted together with emphasised research on comorbidity to generate an
appropriate scientific basis on which to build evidence-based care guidelines for these chronic
comorbid conditions patients.
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2.4 Study 4 
Cancer burden: Impact of long-term productivity 
related work disability and consequences 
 
The third study of this thesis investigated the long-term chronic comorbid conditions 
in terms of disease pattern along with potential predictors among cancer patients and 
consequences over an extended period. Study 4 captured the long-term impact of 
productivity-related work disability among cancer patients and consequences over an 
extended period.  
Article IV: The changing relationship between health burden and work 
disability of Australian cancer survivors, 2003-2017: Evidence from a 
longitudinal survey  
Study 4 aimed to examine the impact of health burden on the magnitude of work 
disability of cancer survivors in Australia over an extended period of 2003-2017. 
This study found that the prevalence of long-term disability among cancer survivors 
was 50%, while 18% of patients had experienced extreme work disability. The 
magnitude of disability levels has increased significantly with the level of health 
burden. Cancer survivors who faced a severe health burden were significantly higher 
risk of having work disability compared with patients who had no health burden. 
Other potential predictors, such as older patients, those engaged in lower levels of 
physical activities, those who drink alcohol, and poor socioeconomic status were all 
significantly associated with extreme work disability. This study concluded that a 
substantial proportion of cancer survivors experienced work disability that was more 
pronounced with the magnitude of health burden.  
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Background: The purpose of this study was to examine the relationship between the cancer health burden and
themagnitude of work disability on cancer survivors in Australia from 2003 to 2017.
Methods: A longitudinal prospective study design was undertaken among cancer patients using data from the
Household, Income and Labour Dynamics in Australia survey. The longitudinal effect was captured using a fixed
effect multinomial logistic regression model, which predicted changes in the relationship between cancer burden
and work disability level controlling for socio-demographic, lifestyle and life conditions predictors.
Results: The prevalence of long-term disability among cancer survivors was 50%, with 18% of patients experiencing
extreme work disability. The magnitude of disability levels increased significantly with the level of health burden.
Cancer survivors who faced a severe health burden were at 5.32 times significantly higher risk of having work
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95% CI: 1.16, 2.23) were all significantly associated with extreme work disability.
Conclusion: A substantial proportion of cancer survivors experienced work disability which was more pronounced
with the magnitude of the cancer health burden. The different dimensions of disability might be prevented by
introducing cancer survivor-specific evidence-based interventions, and incorporating comprehensive social support.
Recommendations to improve public health policy aimed at reducing population-level unhealthy lifestyle
behaviours include: using these findings to better outline the management of a sequelae course of treatment for
cancer survivors; and identifying those who should undergo more intensive physical rehabilitation aimed at
reducing their work disability level.
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Background
Worldwide, work participation of cancer survivors has
seen a surge of attention in the last two of decades [1].
A cancer diagnosis can be a devastating and, often,life-
threatening experience [2], which frequently results in
short- or long-term disability [3–6] due to both health
and economic burdens [7]. Cancer imposes a substantial
burden in terms of reducing the autonomy of individuals
to perform their general daily activities [1, 8]. Further-
more, a cancer diagnosis negatively affects employment
status in terms of job opportunities, work participation
and work ability due to the illness [1, 8]. The adverse
side-effects of treatment results in physical and psycho-
logical limitations that can be a barrier to work partici-
pation [9]. However, the burden of physical disability
levels varies by cancer stages and types [10]. Cancer sur-
vivors run a significantly high risk of unemployment and
early retirement, and they have less opportunity to be
re-employed [1]. A cohort study showed that 20% of
cancer survivors reported disabilities due to cancer over
a 5 year follow-up period [11]. An estimated 30% of can-
cer survivors reported work disabilities post-treatment
[12]. However, a prospective cohort study confirmed
that the employment opportunities of cancer survivors
were adversely impacted by their recovery and health
status [13]. Return to work participation may assist can-
cer survivors to recover faster, improve their quality of
life, help return them to their former ‘normal’ life,
increase their self-confidence, and may support them to
overcome the negative side-effects of treatment [14, 15].
Furthermore, improvement of work participation of can-
cer survivors contributes to societal benefit, by reducing
absenteeism, and reducing disability benefit payments
and productivity losses [16]. Notably, cancer survivors’
earnings are 10% lower compared to non-cancer survi-
vors [17]. Therefore, there is a greater need to provide
supportive services (e.g., related to rehabilitation) to both
help cancer survivors adapt to disability, and prevent
work disability in this patient population.
In Australia, the incidence of cancer in individuals re-
sults in different disability levels for cancer survivors [2].
The long-term effects of cancer treatment are a signifi-
cant cause of greater absenteeism, higher unemployment
and early retirement [18], and overall reduced participa-
tion in work [2–6]. Approximately 40% of Australian
cancer patients are of working age [19], with 46% being
unable to return to employment after a cancer diagnosis
[20], and 67% changing their employment status follow-
ing diagnosed [21]. This results in a reduction of $1.7
billion to Australian gross domestic product (GDP)
annually [20]. The impact of work disability constitute a
substantial burden for people who have not had an
occupation due to cancer, as well as to their families and
employers. Furthermore, cancer-related treatment
results in patients experiencing economic burden due to
high out-of-pocket expenses (e.g., medicines and
advanced treatments, including diagnostics), lost prod-
uctivity, loss/reduction of household income, and other
induced expenditure [22]. The majority of cancer
patients depend on family, relatives and friends for phys-
ical and economic support during their course of treat-
ment and in the last stages of the disease [23, 24].
Ultimately, cancer survivors are faced with a double bur-
den in terms of their health and economic situation.
Existing studies have focused on cancer survivors’
characteristics and work participation, including in the
United States [1, 10, 12, 16, 25–27], Canada [3, 13],
South Korea [8], the Netherlands [5, 6, 9], and Belgium
[4, 28]. A number of factors adversely influencing work
participation of patients with cancer has been
determined in different settings. These parameters are
associated with patients’ socio-demographic characteris-
tics (e.g., age, educational status and economic position)
[5, 6, 9, 27], disease-related factors (e.g., tumor site,
advanced tumor stage), advanced course of treatment
(e.g., chemotherapy) [3, 6, 7, 27], and work-related fac-
tors (e.g., physical work demands) [1, 9]. The presence
of comorbid conditions in cancer patients creates a
higher likelihood of work-related disability [3]. That is,
cancer survivors with poor health status were signifi-
cantly correlated with a higher level of work disability
[27]. A study conducted in the Netherlands found that
cancer survivors who had experienced hormone therapy,
metastatic disease, had limited physical strength, and
limited workability, were strongly and adversely associ-
ated with a higher risk of work disability [5, 6]. The poor
perceptions of cancer survivors, in terms of their health
and work ability [6], their unhealthy behaviours (e.g.,
alcohol consumption), and their clinical stage [29] were
also significant predictors in determining independent
effects of their work disability levels.
In Australia, studies have been conducted among cancer
patients exploring the psychological effects of current
treatment or level of disability [30], association with work-
related stress and cancer [31], and lost productivity due to
cancer [20]. However, very limited evidence exists of the
health burden in relation to work disability of cancer sur-
vivors in Australia. That is, potential factors associated
with work disability of cancer survivors are poorly ex-
plored. This may be partially accounted for by various
study designs, analytical rigour and follow-up periods. For
instance, many international studies have used a limited
number of predictors. The majority of the previous studies
have been cross-sectional in nature, in terms of clinical
and treatment perspectives. Thus, a comprehensive study
is important to examine the impact of the health burden
in relation to the magnitude of work disability as a long-
term sequela of patients with cancer. There has been a
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recent surge of attention in the field of cancer survivor-
ship, leading to efforts to identify and manage treatment-
related sequelae, enhance quality of life, and improve the
overall functioning of people who are receiving long-term
follow-up care after cancer treatment.
Using longitudinal data from nationally representative
Australian samples, these findings will help to improve
the understanding of potential employment opportun-
ities after a cancer diagnosis. In addition, these findings
may be considered from different perspectives in cancer
policy discussions: the cancer survivor (e.g., health sta-
tus, work disability level, return to employment); the
caregiver and the family (e.g., the health burden, reduc-
tion of socio-economic position, risk of poverty); the
employer and co-workers (e.g., employment conditions,
workload); the health care provider (e.g., supportive care
needs, effective programs and interventions); and the
community or society (e.g., economic and policy
changes).
The present study aims to examine the health burden
impact on the magnitude of work disability of cancer
survivors after controlling several factors (e.g., socioeco-
nomic, lifestyle, healthcare utilisation, and geographical
location) over an extended period of 2003–2017. To
achieve the research aim, the following three research
questions (RQ) were posed:
RQ-1: What is the magnitude of work disability levels
among cancer patients in Australia?
RQ-2: What is the longitudinal association between
health burden and the magnitude of work disability
among cancer patients in Australia over 2003–2017?
RQ-3: What are the potential predictors associated
with the magnitude of work disability for cancer patients
in Australia over this extended period?
Methods
Setting and data source
The study was conducted in the context of Australia.
The Household, Income and Labour Dynamics in
Australia (HILDA) study is a nationally representative
household-based panel study. Data were collected
from Australia residents aged 15 or over through
face-to-face interviews and questionnaires, followed by
re-interviews with the people in subsequent years.
The details of the methods of data collection, includ-
ing the sampling technique, have been reported else-
where [32]. The overall goal of HILDA study is to
collect data on the lives of Australian residents in
terms of wealth, retirement, fertility, health, education,
skills and abilities. Households and individuals are
interviewed every year, allowing researchers to see
how participants’lives change over time. Household
longitudinal data, known as panel data, provides a
more complete picture than cross-sectional data as it
documents the life course each person takes. In many
cases, panel data allows causal inferences that are
more credible than those elicitedfrom other types of
data. In particular, statistical methods known as
‘fixed-effects’ regression models can be employed to
examine the effects of various factors on life out-
comes such as long-term health conditions, earnings,
unemployment, income and life satisfaction. These
models can control for the effects of stable character-
istics of individuals that are typically not observed,
such as innate ability, motivation and optimism, that
confound estimates of causal effects in cross-sectional
settings.
Study participants
The study was a sub-study with participants selected
based on inclusion criteria of the HILDAsurvey [32],
namely: 1) population aged 15 years or more (as per
HILDA study participants), ii) diagnosed cancer patients,
iii) longitudinal household members, and iv) willing to
participate in HILDA study. The study participants were
patients with cancer and data were derived from HILDA
waves 3, 7, 9, 13 and 17, all of which had a health focus
and asked specific questions related to cancer. Other
survey waves were excluded from this study due to the
paucity of cancer related information. A total of 2571
patients with diagnosed cancer were potential study par-
ticipants (Fig. 1) from the five waves (505 patients from
wave-3 in 2003, 557 patients from wave-7 in 2007, 416
patients from wave-9 in 2009, 517 patients from wave-
13 in 2013 and 576 patients from wave-17 in 2017).
Study design
The present study design was a mixed-longitudinal
quantitative design in patients with cancer. Individ-
uals who experienced a cancer diagnosis were exam-
ined with a focus on the magnitude of the cancer
burden associated with their long-term-disability. To
examine the mixed-longitudinal effects, this study
hypothesised that several factors related to individ-
uals’ socio-demographic characteristics, social factors,
and disease-related symptomatic factors might influ-
ence outcome factors like disability. The combin-
ation of factors was expected to predict the patients’
long-term disability or adverse occurrence.
Study variables
Outcome variable
Disability status and severity of disability were consid-
ered outcome measures. Work disability was measured
by asking participants if they had any long-term health
condition, impairment or disability that limited the kind
or amount of work they could do. The magnitude of dis-
ability level was measured based on patients’ responses
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as “Could you pick a number between 0 and 10 to indi-
cate how much your condition [s] limit [s] the amount
of work you can do?” The severity of disability score was
ranged from 0 to 10, with 10 indicating ‘able to do any
work’ and 0 indicating ‘not at all’. The severity of disabil-
ity level was defined as follows: (i) ‘no disability’ if dis-
ability score was equal to zero, (ii) ‘moderate disability’
for disability scores of 1 to 6, and (iii) ‘severe disability’
for disability scores of 7 to 10. The levels of disability
were considered dependent variables in the analytical
model.
Explanatory variables
This study considered several demographic, socio-
economic and health and lifestyle-related variables as
predictors of long-term disability. The demographic
variables included participant’s gender (male or fe-
male); age (< 25 years, 25–45 years, 46–65 years, or >
65 years), educational background (up to year 11,
year 12, trade/certificate/diploma, or tertiary educa-
tion), employment status (employed or unemployed),
marital status (single, married, other including sepa-
rated, divorced or widowed), and household size (< 3
members, 3 to 4 members, 5 or more members).
Ethnic status was defined as Aboriginal or non-
Aboriginal. Lifestyle factors include physical activity
status (low, moderate, or high). Life condition-
related variables such as satisfaction with household
members, overall employment situation, financial
situation and social supports were also considered as
potential predictors. The level of satisfaction-related
variables ranged from 0 (totally dissatisfied) to 10
(totally satisfied). Private insurance coverage of pa-
tients was dichotomous (insured or uninsured).
Medication status was defined as ‘with medication’
or ‘without medication’.
To measure the impact upon quality of life the short
form (SF)-36 was used. Health burden levels were
defined as follows: (1) high burden if SF-36 score was
less than 50, (2) moderate burden if SF-36 score was
greater than or equal to 50 but less than 90, (3) no bur-
den if SF-36 score was greater than or equal to 90 [33].
Remote locations were defined according to the accessi-
bility to services and the Remoteness Index of Australia
[34], and they were classified into five groups: major cit-
ies, inner regional, outer regional and remote or very
remote. The index of relative socio-economic disadvan-
tage (IRSD) was used to measure socio-economic status
(SES). T This is a geographical area-based estimate of
socio-economic status using a combination of income,
education level and occupation where communities are
ranked and categorised from economically disadvantaged
to wealthy.he cut-off values for each of the quintiles are
as follows: Q1 (IRSD ≤927.0), Q2 (927.0 > IRSD ≤965.8),
Q3 (965.8 > IRSD ≤1001.8), Q4 (1001.8 > IRSD ≤1056.0),
or Q5 (IRSD > 1056.0) [35].
Fig. 1 Distribution of study participants
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Statistical analysis
The overall cohort, and the subgroup that dropped out
over the course of study, were characterized using fre-
quency, means and proportions to summarise the partic-
ipants’ characteristics in terms of demographics,
unhealthy behaviours, life satisfaction, healthcare utilisa-
tion, remoteness and socioeconomic status. The associ-
ation between the level of disability or disability status
and the variables of greatest interest was analysed using
the chi-square test or one way analysis of variance
(ANOVA) where appropriate. During the analytical
exploration, the present study also considered the miss-
ing data mechanisms as suggested by Rubin et al. (1976)
and Little and Rubin (2002) [36, 37]. They classified the
missing data process into three mechanisms: missing
completely at random (MCAR), missing at random
(MAR), and non-ignorable missing (NIM). In the study
of work disability among cancer patients over time,
missing data are closed to MCAR if the probability of
attrition does not depend on the presence or severity of
work disability (i.e., no disability, moderate disability or
severe disability). A fixed-effects multinomial logistic
regression model was used for analysis under the
assumption of MCAR.
Both unadjusted and adjusted fixed-effect multinomial
logistic regression models were used to identify the
potential factors that had a significant role in the severity
of disability level. In the regression model, the
dependent variable (the severity of disability) was char-
acterised by a categorical variable with three different
levels (no disability, moderate disability or severe disabil-
ity). The model was tested for sensitivity by the forward
selection procedure (e.g., including and excluding spe-
cific variables) with the robust standard error. The pre-
dictor variables were included in the adjusted model
only if any label of the predictor was significant at ≤5%
risk level in the unadjusted regression model, which in
turn was used to adjust for the effects of other potential
confounders. Insignificant predictors were not included
in the adjusted model. For independent variables, the
category found to be least at risk of having an extreme
or moderate disability level in the analysis was consid-
ered as the reference for constructing relative risk ratio
(RRR), using fixed-effect multinomial logistic regression.
During the data analysis, the study also looked at inter-
action effects in the analytical exploration, the inter-
action effects of the magnitude of long-term work
disability in relation to RQ-3 by examining: age, employ-
ment status, life satisfactions, unhealthy behaviors and
socio-economic status. We did not include the inter-
action effects in the results section and tables because
the effects were insignificant in unadjusted model at a
borderline risk level (P = 0.125). All data analyses were
undertaken using the statistical software Stata/SE 13
(StataCorp, College Station, TX, USA). The statistical
significance was considered at a 5% risk level.
Results
Description of study participants
Data from 2571 cancer patients were included in the
analysis (Table 1). The percentage of male participants
(54%) was higher than the female (46%). Approximately
45% of patients were senior, aged (> 65 years), followed
by middle-aged (38%) (46 to 65 years). Approximately
47% had a middle or high school level education, with
15% of cancer patients having tertiary educationl qualifi-
cations. Approximately 45% of patients had limited
exposure to physical activity, and only 23% of patients
experienced high-level physical activities each week.
Two-thirds of participants drank alcohol frequently. The
majority of participants (90%) reported a moderate or
high health burden in terms of their quality of life. In
addition, 56% were insured, 72% received prescribed
medication, and 60% lived in major cities.
Distribution of disability status among cancer patients
(for RQ 1)
Table 2 shows participants’ characteristics, overall and
by disability status, across the selected variables. Half of
the male patients experienced a long-term disability.
The prevalence of disability increased significantly (P <
0.001) as patients aged (e.g., 17% for below 25 years, 27%
for 25–45 years, 42% for 46–65 years, 66% for more than
65 years old). Approximately 58% of patients who had
completed a middle or high school education level lived
with a disability, followed by 48% of tertiary educated
patients. The prevalence of disability was pronounced
amongst the unemployed (65%), those who were poorly
engaged in physical activities (61%) and those who were
uninsured (59%). Furthermore, the proportion of disabil-
ity was significantly aligned with the magnitude of can-
cer burden (e.g., 71% for severe burden, 45% for
moderate burden and 23% for no burden). Regarding
socio-economic status, the magnitude of work disability
was found to be highest in the lowest socio-economic
quintile. For example, patients who lived in the poorest
households (23%) were significantly exposed to long-
term disability (P < 0.001) compared with those in the
richest households (16%). However, an upward trend in
work disability levels was observed among the poorest
cancer survivors during 2003–2017 (Fig. 2).
Association between severity of disability and patient’s
characteristics (for RQ 2)
The age distribution of patients contributed significantly
(P < 0.001) to the magnitude of long-term disability
(Table 2). Educational background was significantly
associated with disability level (P < 0.001). Several patient
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Table 1 Characteristics of cancer patients by disability status
Variables n (%) / n
(mean)
Disability distribution among cancer survivors P-value
Any disability, n (%) No disability, n (%)
Sex
Male 1398 (54.38) 711 (50.86) 687 (49.14) 0.353
Female 1173 (45.62) 575 (49.02) 598 (50.98)
Age
< 25 years 63 (2.45) 11 (17.46) 52 (82.54) < 0.001
25–45 years 383 (14.90) 103 (26.89) 280 (73.11)
46–65 years 975 (37.92) 409 (41.95) 566 (58.05)
> 65 years 1150 (44.73) 763 (66.35) 387 (33.65)
Educational attainment
Year 12 or below 989 (38.47) 573 (57.94) 416 (42.06) < 0.001
Year 12 220 (8.56) 97 (44.09) 123 (55.91)
Trade/certificate/diploma 977 (38.00) 468 (47.90) 509 (52.10)
Tertiary 385 (14.97) 148 (38.44) 237 (61.56)
Employment status
Employed 974 (37.88) 247 (25.36) 727 (74.64) < 0.001
Unemployed 1597 (62.12) 1039 (65.06) 558 (34.94)
Physical activity status
Low 496 (45.38) 301 (60.69) 195 (39.31) < 0.001
Moderate 346 (31.66) 176 (50.87) 170 (49.13)
High 251 (22.96) 99 (39.44) 152 (60.56)
Alcohol consumption (= yes) 1903 (74.02) 887 (46.61) 1016 (53.39) < 0.001
Smoking exposure (= yes) 370 (14.39) 179 (48.38) 191 (51.62) 0.095
Health burden
No burden 257 (10.00) 59 (22.96) 198 (77.04) < 0.001
Moderate burden 1566 (60.91) 698 (44.57) 868 (55.43)
Severe burden 748 (29.09) 529 (70.72) 219 (29.28)
Private insurance coverage
Yes 613 (56.08) 292 (47.63) 321 (52.37) < 0.001
No 480 (43.92) 284 (59.17) 196 (40.83)
Healthcare utilisation
Yes 1093 (72.43) 682 (62.40) 411 (37.60) < 0.001
No 416 (27.57) 115 (27.64) 301 (72.36)
Life satisfaction with (mean scores)
Household members 2571 (8.20) 8.23 (1.85) 8.17 (1.83) 0.786
Employment 2571 (3.37) 2.29 (3.62) 4.45 (3.98) < 0.001
Financial situation 2571 (6.72) 6.54 (2.49) 6.89 (2.29) 0.005
Social supports 2571 (7.91) 7.79 (1.89) 8.03 (1.73) < 0.001
Remoteness
Major cities 1552 (60.37) 774 (49.87) 778 (50.13) < 0.001
Inner regional 660 (25.67) 336 (50.91) 324 (49.09)
Outer regional 314 (12.21) 158 (50.32) 156 (49.68)
Remote or very remote 45 (1.75) 18 (40.00) 27 (60.00)
Socioeconomic status
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characteristics including employment status (P < 0.001),
insurance coverage (P = 0.005), utilisation of prescribed
medication (P < 0.001), life satisfaction related-factors
(P < 0.05), alcohol consumption (P < 0.001), geographical
location (P < 0.001) and socio-economic status (P <
0.001) were significant predictors of disability level. Fur-
thermore, the level of physical activity (P < 0.001) and
the health burden related to cancer (P < 0.001) were
dominant variables for the severity of the disability.
Factors influencing disability among patients with cancer
(for RQ 3)
Table 3 shows the results of the fixed effect multinomial
logistic regression analysis. In the final model, age, edu-
cational achievement, physical activities, health burden
associated with cancer, utilisation of prescribed medica-
tion, patients living in a regional location, and those in
the poorest households were significant predictors of a
higher risk of long-term disability. An aged patient (> 65
years old) was at 1.82 times higher risk of having an
extreme disability (RRR = 1.82; 95% CI: 1.57, 5.87) com-
pared with a younger patient (< 25 years), while being
1.40 times more likely to have a moderate level of dis-
ability (RRR = 1.40; 95% CI: 1.09, 4.00). Patients who
were unemployed had a significantly higher risk of being
affected by severe disability (RRR = 2.01; 95% CI: 1.15,
3.50) or a moderate level of disability (RRR = 1.55; 95%
CI: 1.01, 2.39) compared with their employed counter-
parts. Similarly, patients who performed a lower level of
physical activities were 1.91 times more likely to have an
extreme disability (RRR = 1.91; 95% CI: 1.07, 3.40) com-
pared with patients engage in high-level physical activ-
ities. Patients who had an extreme health burden
associated with cancer were at approximately five times
significantly higher risk of experiencing a severe or mod-
erate disability level compared with patients who
reported excellent health status. Unhealthy behavioural
factors like alcohol consumption (RRR = 1.29; 95% CI:
1.15, 1.49) were associated with work disability com-
pared with patients who had not consumed alcohol. The
risks of having an extreme disability (RRR = 1.28 times)
or moderate disability level (RRR = 1.36 times) of cancer
patients who lived in the poorest households were more
pronounced compared with their richer counterparts.
Discussion
Cancer is significantly correlated with workdays lost and
high levels of work-related disability [29, 38–40]. The
main objectives of this study were to investigate the
magnitude of work disability due to a cancer diagnosis
and measure the longitudinal association between health
burden and disability, and the potential predictors of
work disability of cancer patients. The study results
show that 50% of cancer patients experienced a long-
term disability, whereas approximately 18% of patients
had reached an extreme level of work disability. Further-
more, the prevalence of disability was pronounced in
relation to the level of the cancer burden (e.g., 71% for
severe burden, 45% for moderate burden, and 23% for
no burden), aged patients (66%), and unemployed
patients (65%), those engaged in limited physical activ-
ities (61%), the uninsured (59%), and the poorest socio-
economic group (23%). Potential predictors, which
included factors such as age, those who exercise less or
not at all, those who have an extreme health burden,
and engage in unhealthy behaviours (e.g., alcohol con-
sumption), were significantly associated with a higher
risk of having an extreme disability.
The results showed that a higher risk of a severe or
moderate disability level was pronounced among cancer
patients who faced an extreme health burden, compared
with patients who reported an excellent health status. A
previous study found that poor health status of cancer
patients resulted in greater functional disability (e.g.,
specific task difficulties) [41, 42]. However, the preva-
lence of long-term disability was more pronounced in
combination with a cancer diagnosis [5, 6, 12, 27, 29].
Advanced cancer treatments can damage healthy cells or
organs [43]. For example, radiation and chemotherapy
may impose short and long-term health problems and
impact on the spinal cord, nerves and brain, which then
may significantly contribute to long-term adverse out-
comes like work-related disability. In the context of
Australia, a significant proportion (46%) of cancer
Table 1 Characteristics of cancer patients by disability status (Continued)
Variables n (%) / n
(mean)
Disability distribution among cancer survivors P-value
Any disability, n (%) No disability, n (%)
Q1 (lowest 20%) (ref) 516 (20.07) 293 (22.78) 223 (17.35) < 0.001
Q2 595 (23.14) 322 (25.04) 273 (21.25)
Q3 463 (18.01) 225 (17.50) 238 (18.52)
Q4 534 (20.77) 238 (18.51) 296 (23.04)
Q5 (highest 20%) 463 (18.01) 208 (16.17) 255 (19.84)
Overall 2571 (100.00) 1286 (50.02) 1285 (49.98)
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Table 2 Association of severity of disability and characteristics of cancer patients
Variables Severity of disability
No disability Moderate disability Severe disability P-value
n % (95% CI) n % (95% CI) n % (95% CI)
Sex
Male 816 58.37 (55.76, 60.93) 335 23.96 (21.80, 26.27) 247 17.67 (15.76, 19.76) 0.728
Female 672 57.29 (54.43, 60.10) 297 25.32 (22.91, 27.89) 204 17.39 (15.33, 19.67)
Age
< 25 years 46 73.02 (60.69, 82.58) 9 14.29 (7.56, 25.35) 8 12.70 (6.44, 23.51) < 0.001
25–45 years 285 74.41 (69.80, 78.54) 61 16.00 (12.59, 19.95) 37 9.66 (7.08, 13.06)
46–65 years 606 62.15 (59.06, 65.15) 214 21.95 (19.46, 24.66) 155 15.90 (13.73, 18.33)
> 65 years 551 47.91 (45.03, 50.81) 348 30.26 (27.67, 32.98) 251 21.83 (19.53, 24.31)
Educational attainment
Year 12 or below 489 49.44 (46.33, 52.56) 284 28.72 (25.98, 31.62) 216 21.84 (19.37, 24.53) < 0.001
Year 12 147 66.82 (60.31, 72.74) 36 16.36 (12.03, 21.87) 37 16.82 (12.42, 22.37)
Trade/certificate/diploma 588 60.18 (57.08, 63.21) 234 23.95 (21.38, 26.73) 155 15.86 (13.70, 18.29)
Tertiary 264 68.57 (63.75, 73.02) 78 20.26 (16.53, 24.58) 43 11.17 (8.38, 14.73)
Employment status
Employed 740 75.98 (73.19, 78.56) 158 16.22 (14.04, 18.67) 76 7.80 (6.27, 9.66) < 0.001
Unemployed 748 46.84 (44.40, 49.29) 474 29.68 (27.49, 31.97) 375 23.48 (21.47, 25.63)
Physical activity status
Low 233 46.98 (42.61, 51.39) 126 25.40 (21.76, 29.43) 137 27.62 (23.86, 31.73) < 0.001
Moderate 197 56.94 (51.65, 62.07) 101 29.19 (24.63, 34.21) 48 13.87 (10.61, 17.94)
High 176 70.12 (64.15, 75.47) 55 21.91 (17.21, 27.47) 20 7.97 (5.19, 12.04)
Alcohol consumption (= yes) 1175 61.74 (59.54, 63.90) 448 23.54 (21.69, 25.50) 280 14.71 (13.19, 16.38) < 0.001
Smoking exposure (= yes) 224 60.54 (55.46, 65.41) 82 22.16 (18.21, 26.69) 64 17.30 (13.77, 21.50) 0.455
Health burden
No burden 248 96.50 (93.40, 98.17) 7 2.72 (1.30, 5.61) 2 0.78 (0.19, 3.07) < 0.001
Moderate burden 1018 65.01 (62.61, 67.33) 403 25.73 (23.63, 27.96) 145 9.26 (7.92, 10.80)
Severe burden 222 29.68 (26.51, 33.06) 222 29.68 (26.51, 33.06) 304 40.64 (37.17, 44.21)
Private insurance coverage (= yes) 362 59.05 (55.10, 62.89) 155 25.29 (22.00, 28.89) 96 15.66 (12.99, 18.76) 0.005
Healthcare utilisation (= yes) 495 45.29 (42.35, 48.26) 340 31.00 (28.43, 33.92) 258 23.60 (21.18, 26.22) < 0.001
Life satisfaction with (mean scores)
Household members 1488 8.18 (8.09, 8.27) 632 8.24 (8.10, 8.38) 451 8.20 (8.01, 8.39) 0.034
Employment 1488 4.30 (4.10, 4.51) 632 2.48 (2.20, 2.77) 451 1.53 (1.25, 1.82) < 0.001
Financial situation 1488 6.94 (6.83, 7.06) 632 6.59 (6.40, 6.78) 451 6.15 (5.91, 6.39) < 0.001
Social supports 1488 8.01 (7.93, 8.09) 632 7.92 (7.78, 8.06) 451 7.61 (7.42, 7.80) < 0.001
Remoteness
Major cities 945 60.89 (58.43, 63.29) 347 22.36 (20.35, 24.50) 260 16.75 (14.97, 18.7) < 0.001
Inner regional 344 52.12 (48.30, 55.92) 194 29.39 (26.04, 32.99) 122 18.00 (15.70, 21.64)
Outer regional 169 53.82 (48.27, 59.28) 80 25.00 (20.95, 30.60) 65 20.70 (16.57, 25.55)
Remote or very remote 30 66.67 (51.65, 78.92) 11 24.44 (13.99, 39.16) 4 8.89 (3.34, 21.61)
Socioeconomic status
Q1 (lowest 20%) (ref) 258 50.00 (45.69, 54.31) 133 25.78 (22.18, 29.73) 125 24.22 (20.72, 28.12) < 0.001
Q2 312 52.44 (48.41, 56.43) 163 27.39 (23.96, 31.13) 120 20.17 (17.13, 23.59)
Q3 280 60.48 (55.94, 64.84) 120 25.92 (22.12, 30.11) 63 13.61 (10.77, 17.05)
Mahumud et al. BMC Public Health          (2020) 20:548 Page 8 of 14
131
patients are unable to return to employment after their
diagnosis [20].
Furthermore, work disability leads to a substantial eco-
nomic burden on society, individuals and their families,
resulting in a reduction of $1.7 billion annually to GDP
in Australia [20] and an approximately 5% GDP reduc-
tion in the Organisation for Economic Co-operation and
Development (OECD) countries [44]. Therefore, cancer
survivors may require psycho-social healthcare services
and other therapeutic modalities, such as physical and
occupational therapy, to assist in their return to a pro-
ductive work life. Cancer patients with physically
demanding jobs may require assistance during treat-
ment, and possibly physical rehabilitation following
treatment, in order to minimize morbidity. However,
developing new and improved treatments with fewer
side effects is another potentially important strategy to
reduce cancer-related disability.
The results indicate that elderly cancer patients (older
than 65 years) were at a significantly higher risk of having
an extreme disability compared with younger patients (<
25 years). This finding is consistent with a previous study,
which revealed that elderly cancer patients reported signifi-
cantly more functional disabilities [45], required more
assistance with daily living activities [46], and had deficits in
performing work-related activities in terms of their physical
ability [41, 47]. Thus, several factors might influence the
reduction in their physical functioning. For example, a
course of advanced cancer treatment is associated with
considerable physical and psychological side effects in eld-
erly cancer patients (e.g., weight change, muscle loss, fatigue
and physical weakness) [48], and having multiple comor-
bidities [3, 27, 29] will presumably contribute to reduced
daily activities. Moreover, an elderly cancer patient may
have a limited acceptance of advanced treatment and health
outcomes that may then contribute to a greater burden of
health [48]. This result indicates that rehabilitation-related
interventions (e.g., occupational and physical therapies) are
essential to prevent ongoing work disability of cancer
patients [49], and is an emerging cancer research area, par-
ticularly focused on the elderly [50].
The study results found that low level or no physical
activities in cancer patients was strongly associated with
an extreme level of work-related disability compared
Table 2 Association of severity of disability and characteristics of cancer patients (Continued)
Variables Severity of disability
No disability Moderate disability Severe disability P-value
Q4 329 61.61 (57.41, 65.65) 119 22.28 (18.95, 26.02) 86 16.10 (13.22, 19.48)
Q5 (highest 20%) 309 66.74 (62.31, 70.89) 97 20.95 (17.48, 24.90) 57 12.31 (9.61, 15.63)
Overall 1488 57.88 (55.96, 59.77) 632 24.58 (22.95, 26.29) 451 17.54 (16.12, 19.06)
P-value was derived using chi-square test or one way analysis of variance (ANOVA) where appropriate
Fig. 2 Unequal distribution of health burden and upper extremity work disability across socioeconomic status
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Table 3 Factors influencing severity of disability of cancer patients
Variables Moderate disability vs No disability Severe disability vs No disability
Un-adjusted model Adjusted model Un-adjusted model Adjusted model
RRR (95% CI) RRR (95% CI) RRR (95% CI) RRR (95% CI)
Health burden
No burden (= ref) 1.00 1.00 1.00 1.00
Moderate burden 7.88*** (4.26, 10.04) 4.03*** (3.56, 9.99) 5.66*** (4.35, 7.79) 5.92** (1.38, 25.40)
Severe burden 7.27*** (6.28, 18.4) 5.43*** (3.34, 7.81) 6.80*** (4.78, 9.09) 5.32*** (2.75, 11.60)
Female (ref = male) 1.08 (0.89, 1.30) 1.00 (0.81, 1.24)
Age
< 25 years (= ref) 1.00 1.00 1.00 1.00
25–45 years 1.09 (0.51, 2.35) 1.12 (0.37, 3.37) 0.75 (0.33, 1.70) 0.85 (0.24, 2.97)
46–65 years 1.80 (0.87, 3.75) 1.31 (0.47, 3.66) 1.47 (0.68, 3.18) 1.39 (0.45, 4.34)
> 65 years 3.23*** (1.56, 6.68) 1.40** (1.09, 4.00) 2.62*** (1.22, 5.63) 1.82*** (1.57, 5.87)
Educational achievement
Year 11 or below (= ref) 1.00 1.00 1.00 1.00
Year 12 0.42*** (0.28, 0.62) 1.36 (0.82, 2.24) 0.57*** (0.38, 0.85) 0.77 (0.43, 1.39)
Trade/certificate/diploma 0.69*** (0.56, 0.85) 1.10 (0.51, 2.36) 0.60*** (0.47, 0.76) 1.54 (0.68, 3.47)
Tertiary or university 0.51*** (0.38, 0.68) 1.00 (0.62, 1.61) 0.37*** (0.26, 0.53) 0.77 (0.43, 1.36)
Unemployed (ref = employed) 2.97*** (3.65, 0.62) 1.55** (1.01, 2.39) 4.88*** (6.37, 0.85) 2.01*** (1.15, 3.50)
Marital status
Single (= ref) 1.00 1.00 1.00 1.00
Married 1.68*** (1.22, 2.32) 1.41 (0.79, 2.54) 1.33 (0.94, 1.88) 0.69 (0.37, 1.31)
Others 2.25*** (1.60, 3.16) 1.44 (0.79, 2.62) 1.86*** (1.29, 2.68) 0.89 (0.47, 1.69)
Physical activity status
Low 1.73*** (1.19, 2.51) 0.98 (0.64, 1.50) 5.17*** (3.11, 8.60) 1.91** (1.07, 3.40)
Moderate 1.64*** (1.11, 2.41) 1.30 (0.85, 2.00) 2.14*** (1.22, 3.75) 1.43 (0.77, 2.65)
High (= ref) 1.00 1.00 1.00 1.00
Alcohol consumption (ref = no) 1.54*** (1.25, 1.91) 0.94 (0.65, 1.35) 2.29*** (1.83, 2.88) 1.29*** (1.15, 1.49)
Smoking exposure (ref = no) 1.19 (0.91, 1.56) 1.07 (0.79, 1.45)
Private insurance coverage (ref = yes) 1.22 (0.91, 1.62) 0.88 (0.62, 1.24) 1.68*** (1.22, 2.32) 1.02 (0.68, 1.53)
Healthcare utilisation (ref = yes) 4.62*** (3.34, 6.39) 0.29*** (0.19, 0.44) 8.13*** (5.15, 12.83) 0.34*** (0.20, 0.60)
Life satisfaction with
Household members 1.02 (0.97, 1.07) 1.00 (0.90, 1.10) 1.01 (0.95, 1.07) 1.01 (0.90, 1.13)
Employment 0.89*** (0.87, 0.91) 0.99 (0.95, 1.04) 0.81*** (0.79, 0.84) 0.96 (0.91, 1.02)
Financial situation 0.94*** (0.90, 0.98) 0.95 (0.88, 1.03) 0.88*** (0.84, 0.91) 0.94 (0.86, 1.02)
Social supports 0.97 (0.92, 1.02) 1.00 (0.90, 1.10) 0.89*** (0.84, 0.94) 0.98 (0.88, 1.10)
Remoteness
Major cities (= ref) 1.00 1.00 1.00 1.00
Inner regional 1.54*** (1.24, 1.90) 1.75*** (1.21, 2.52) 1.29* (1.01, 1.65) 1.60** (1.04, 2.48)
Outer regional 1.29 (0.96, 1.73) 0.95 (0.55, 1.63) 1.40* (1.02, 1.92) 1.27 (0.70, 2.31)
Remote or very remote 1.00 (0.50, 2.01) 0.80 (0.26, 2.43) 0.48 (0.17, 1.39) 0.22 (0.03, 1.81)
Socioeconomic status
Q1 (lowest 20%) 1.64*** (1.21, 2.24) 1.36** (1.09, 2.33) 2.63*** (1.84, 3.74) 1.28*** (1.16, 2.23)
Q2 1.66*** (1.24, 2.24) 1.44 (0.87, 2.39) 2.09*** (1.47, 2.97) 1.25 (0.68, 2.32)
Q3 1.37* (1.00, 1.87) 1.49 (0.87, 2.54) 1.22 (0.82, 1.81) 1.09 (0.56, 2.14)
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with patients engaged in high-level physical activity. This
finding is consistent with other research [38, 51–54],
whereby authors found that limited physical activity
levels were significantly associated with a higher risk of
work disability among cancer patients. Further, a num-
ber of previous studies have proven that physical activity
plays an effective role in ensuring improved health status
[55], reducing the risk of developing future cancers [54],
and also expressively contributing to lower mortality risk
[56], which ultimately produces significant health bene-
fits and reduces medical expenditures and treatment
outcome disparities [55]. In terms of cancer risk, high
levels of physical activities (compared with low levels)
played a significant role in prevention of several cancers
(e.g., 42% for gastrointestinal cancer, 23% for renal can-
cer, and 20% for myeloid leukemia) [57]. This included
averting genetic damage, improving the immune system,
reducing chronic infections, and controlling cancer cells
[57]. Several hypotheses and mechanisms have been sug-
gested regarding the anti-cancer effects of physical activ-
ities. The American Cancer Society guidelines for cancer
survivors [58] recommend daily physical activities, in-
cluding a continuation of normal daily life activities im-
mediately after diagnosis, which help to significantly
reduce physical stamina and muscle strength erosion as
well as anxiety levels, thereby resulting in the prevention
of long-term adverse health outcomes (e.g., work-related
disability) [59].
This study results found an increased risk of work dis-
ability among cancer patients who consumed alcohol
compared with patients who did not. In this study, alco-
hol consumption had a robust effect on patient out-
comes. Formal drinkers represented two-thirds (≈ 75%)
of the cohort and had a 46% greater risk of disability.
The last Global Burden of Disease study, conducted in
2016, found a similar result, namely that alcohol con-
sumption was a dominating determinant for higher risk
of having a disability [60]. The World Health Organisa-
tion (WHO) has suggested that harmful alcohol con-
sumption causes a high burden of disease, including
cancer [61], which is often underappreciated [60]. This
finding has further implications for the reform of public
health policy, and decreasing population-level alcohol
consumption should be recommended.
The risks of having an extreme disability level amongst
cancer patients who lived in the poorest households
were more pronounced compared with their richer
counterparts. Recent studies have confirmed this result
with disadvantaged socio-economic status of cancer sur-
vivors being negatively associated with long-term health
effects or work-related disability [62, 63]. Some studies
have also provided evidence that the magnitude of the
cancer burden is negatively associated with socio-
economic status [16, 31–34]. Furthermore, adverse
health outcomes (e.g., worse health status, long and
short-term disability and shorter life expectancy) were
disproportionately found in poorer people as opposed to
those with higher socio-economic status [13, 16, 31, 33,
64–71]. Contribtuing factors to the high rates of long
term health impacts among the poorest groups includes
higher tobacco rates [16, 27], economic burden [35, 36],
increased mental illness [72], lack of health education
and awareness [73], and less access to competent and
effective health care services [73].
Low productivity, loss/reduction of household income,
and increased healthcare expenditure are pronounced
amongst the poorest cancer patients. Growing socio-
economic inequalities of cancer outcomes need the
attention of governments, health systems and decision
makers. For example, Cancer Australia has an optimal
care pathway project, which has already addressed sev-
eral cancer types. Such initiatives might help to reduce
socio-economic inequalities, which are related to pov-
erty, gender, education, and health, and should promote
universal access to health care which can further
enhance both socio-economic and human development.
The ability to continue in the labour force, and allow-
ing an individual the choice to do so, signifies a key
aspect of the health status often threatened by disease.
Long-term disability threatens the economic well-being
of survivors and their families. Additionally, the health
status of cancer patients who are restricted in their cap-
acity to work may be affected by the loss of identity, life
satisfaction, and social relationships that work often pro-
vides. Cancer survivorship, work disability and employ-
ment may be considered from different perspectives: the
cancer survivor (e.g., health status, work disability level
and return to employment), the caregiver and the family
Table 3 Factors influencing severity of disability of cancer patients (Continued)
Variables Moderate disability vs No disability Severe disability vs No disability
Un-adjusted model Adjusted model Un-adjusted model Adjusted model
RRR (95% CI) RRR (95% CI) RRR (95% CI) RRR (95% CI)
Q4 1.15 (0.85, 1.57) 1.21 (0.72, 2.01) 1.42 (0.98, 2.05) 1.36 (0.73, 2.52)
Q5 (highest 20%) (= ref) 1.00 1.00 1.00 1.00
RRR Relative risk ratio, CI Confidence interval, ref. Reference group
Mahumud et al. BMC Public Health          (2020) 20:548 Page 11 of 14
134
(e.g., the health burden, reduction of socioeconomic pos-
ition and risk for poverty), the employer and co-workers
(e.g., employment conditions and workload), the health
care provider (e.g., supportive care needs, effective pro-
grams and interventions), and the community or society
(e.g., economic and policy changes).
This study includes some caveats. Study participants
were accessed from the HILDA survey, which covers
health, economic, employment, income and health char-
acteristics of household members aged 15 years and
older. Children who suffered from cancer were excluded
from this study. Examining the long-term work disability
is widely perceived to have substantial potential as an
endpoint in health outcomes research; however, results
are partially dependent upon study methods and out-
come variables of interest. The participants of the
present study were derived from the protocol “HILDA
study” [32], wherein long-terms health conditions of
cancer patients might change for independent study
designs as well as application of survey instruments.
This study findings established a relationship between
overall cancer burden and work-related disability among
cancer survivors, which might vary in terms of cancer
stages and types of cancer. The authors were not able to
estimate the cancer-specific health burden nor the work
disability of cancer survivors due to the paucity of rele-
vant data. Further, the study findings were based on self-
reported responses that might have been impacted by re-
spondents’ prejudice (e.g., silence and over-response),
and by problems in understanding and interpreting the
survey questions.
Despite these limitations, this study has noteworthy
strengths including the use of a prospective design of
long term follow-ups, and the application of well-
validated and reliable longitudinal wave measures of the
impacts of cancer diagnosis on the health burden and
work disability of individuals over the 2003–2017 period.
The study population was ethnically, geographically, and
socio-economically diverse. Furthermore, this study
included several potential confounding analytical factors
that were not present in previous studies. For this study,
data were gathered from five-waves of the HILDA survey
of cancer survivors. The length of the survey period may
have introduced uncontrolled bias, as changes in health
status are not instantaneous and might emerge only after
time, which was not captured in this study. Due to fund-
ing restrictions, the authors were unable to consider
cancer patients who registered for cancer surveillance as
well as received health care from health facilities (e.g.,
private clinics, community clinics, secondary or tertiary
hospitals). Due to the paucity of cancer-related data in
HILDA study, the authors were unable to perform
cancer-specific analysis and period of treatment analysis.
Future research is required using a similar study design,
perspective and analytical methods in terms of cancer-
specific exploration.
Conclusions
This study has identified a high rate of work-related dis-
ability that leads to a substantial decrease in a cancer
survivor’s socio-economic position. Several demographic,
social, lifestyle and health burden variables were associ-
ated with the magnitude of disability. The findings have
further implications for improving public health policy,
and reducing population-level unhealthy lifestyle behav-
iours which should be recommended. The study results
could be used to better outline the management of a
sequelae course of treatment for those who should
undergo more intensive physical rehabilitation aimed at
reducing work disability levels. This may apply to cancer
survivors who choose or need to work after cancer diag-
nosis and treatment especially those still active in the
work force. This is important in light of the increasing
prevalence of cancer and fortunately, the growing num-
bers of patients surviving cancer in Australia, and the
likelihood of the development of impairments and activ-
ity limitations after cancer treatment. It is also signifi-
cant for health care providers, including physical and
occupational therapists and oncologists, who should be
aware of the unique problems that challenge this popu-
lation and who should advocate for prevention and
evidence-based interventions. Therefore, it is recom-
mended that effective and efficient cancer survivor-
specific evidence-based interventions be developed to
reduce the impacts of work disability by incorporating
comprehensive social supports which ultimately, have
the potential to affect the trajectory of the cancer burden
in a positive way.
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2.5 Study 5 
Prevention strategy of cancer: Economics of 
cancer vaccination in Australia 
 
The Study 4 of this thesis captured the long-term impact of productivity-related work 
disability among cancer patients and consequences over an extended period. Study 5 
was to assess the prevention strategy of cancer vaccination regarding the economics 
context using economics evaluation (cost-effectiveness analysis). Study 5 included 
two articles such as Article V examined evidence of the cost-effectiveness evaluation 
of the 9-valent HPV vaccine within a global context. Further, Article VI assessed the 
cost-effectiveness of adding a nonavalent new Gardasil-9® (9vHPV) vaccine to the 
national immunisation schedule in Australia across three different delivery strategies 
from the health system and societal perspectives.  
 
Article V: Cost-effectiveness evaluations of the 9-valent human papillomavirus 
(HPV) vaccine: Evidence from a systematic review. 
This review examined evidence of the cost-effectiveness evaluation of the 9-valent 
HPV vaccine within a global context. Searches were performed until 31 July 2019 
using two databases: PubMed and Scopus. A combined checklist (i.e., WHO, 
Drummond and Consolidated Health Economic Evaluation Reporting 
Standards, CHEERS) was used to examine the quality of eligible studies. A total of 
12 studies were eligible for review and nearly all were conducted in developed 
countries. Despite some heterogeneity in approaches to measuring cost-effectiveness, 
ten studies concluded that 9vHPV vaccination was cost-effective while two studies 
were not. The addition of adolescent boys into immunisation program was cost 
effective when vaccine price and coverage was comparatively low. When 
vaccination coverage for female was more than 75%, gender neutral HPV 
vaccination was less cost-effective than when targeting only girls aged 9–18 years. 
Multi cohort immunization approach was cost-effective in the age range of 9–14 
years but the upper age limit at which vaccination was no longer cost-effective 
requires to be further evaluated. Most dominating parameters determined were 
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duration of vaccine protection, time horizon, vaccine price, coverage, healthcare 
costs, efficacy and discounting rates. These findings are anticipated to support 
policymakers in extending HPV immunization programs on either switching to the 9-
valent vaccine or inclusion of adolescent boys’ vaccination or extending the age of 
vaccination. Further, this review also supports extending vaccination to low-resource 
settings where vaccine prices are competitive, donor funding is offered, cervical 
cancer burden is high and screening options are limited. 
Article VI: The cost-effectiveness of controlling cervical cancer using a new 9-
valent human papillomavirus vaccine among school-aged girls in Australia 
The objective of Study 5 was to assess the cost-effectiveness of adding a nonavalent 
new Gardasil-9® (9vHPV) vaccine to the national immunisation schedule in Australia 
across three different delivery strategies from the health system and societal 
perspectives. This study was an extensive cost-effectiveness analysis of 9vHPV 
vaccination in Australia from both the health system and societal perspectives. The 
introduction of the 9vHPV immunisation was assessed to be very cost-effective from 
both perspectives. It incorporated three delivery strategies (school-based, health 
facility-based, and outreach-based). However, this high-value vaccination would 
need substantial upfront investments. Considering a two-dose schedule, the 9vHPV 
vaccination demonstrated ‘good value for money’, if the vaccination could 
accomplish a high vaccination coverage and provide protection. The findings of this 
evaluation contribute to decision-making about the incorporation of the 9vHPV 
vaccine into a universal cervical cancer vaccination program in Australia. With 
continued assessment of the potential vaccine properties as well as vaccine delivery 
and scale-up strategies, the two-dose 9vHPV vaccine would provide significant 
health and economic benefits for preadolescents and society. Finally, the success of 
9vHPV vaccination will be contingent on several predominating factors, including 
value for money, feasibility, acceptability, and affordability. 
 
 
 
 
RESEARCH ARTICLE
Cost-effectiveness evaluations of the 9-Valent
human papillomavirus (HPV) vaccine:
Evidence from a systematic review
Rashidul Alam MahumudID1,2,3,4,5*, Khorshed Alam1,2, Syed Afroz Keramat1,2,6, Gail
M. Ormsby7, Jeff Dunn1,8,9, Jeff Gow1,2,10
1 Health Economics and Policy Research, Centre for Health Research, University of Southern Queensland,
Toowoomba, Queensland, Australia, 2 School of Commerce, University of Southern Queensland,
Toowoomba, Queensland, Australia, 3 Health Systems and Population Studies Division, Health Economics
and Financing Research, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b),
Dhaka, Bangladesh, 4 School of Social Sciences, Western Sydney University, Penrith, Australia,
5 Translational Health Research Institute, Western Sydney University, Penrith, Australia, 6 Economics
Discipline, School of Social Science, University of Khulna, Khulna, Bangladesh, 7 School of Health and
Wellbeing, University of Southern Queensland, Toowoomba, Queensland, Australia, 8 Cancer Research
Centre, Cancer Council Queensland, Fortitude Valley, Queensland, Australia, 9 Prostate Cancer Foundation
of Australia, St Leonards, NSW, Australia, 10 School of Accounting, Economics and Finance, University of
KwaZulu-Natal, Durban, South Africa
* rashidul.icddrb@gmail.com, rashed.mahumud@usq.edu.au
Abstract
Introduction
TheWorld Health Organization (WHO) recommends that human papillomavirus (HPV) vac-
cination programs are established to be cost-effective before implementation. WHO recom-
mends HPV vaccination for girls aged 9–13 years to tackle the high burden of cervical
cancer. This review examined the existing evidence on the cost-effectiveness of the 9-valent
HPV vaccine within a global context.
Methods
The literature search covering a period of January 2000 to 31 July 2019 was conducted in
PubMed and Scopus bibliographic databases. A combined checklist (i.e., WHO, Drummond
and CHEERS) was used to examine the quality of eligible studies. A total of 12 studies were
eligible for this review and most of them were conducted in developed countries.
Results
Despite some heterogeneity in approaches to measure cost-effectiveness, ten studies con-
cluded that 9vHPV vaccination was cost-effective and two did not. The addition of adoles-
cent boys into immunisation programs was cost effective when vaccine price and coverage
was comparatively low. When vaccination coverage for females was more than 75%, gen-
der neutral HPV vaccination was less cost-effective than vaccination targeting only girls
aged 9–18 years. Multi cohort immunization approach was found cost-effective in the age
range of 9–14 years. However, the upper age limit at which vaccination was found not cost-
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effective requires further evaluation. This review identified duration of vaccine protection,
time horizon, vaccine price, coverage, healthcare costs, efficacy and discounting rates as
the most dominating parameters in determining cost-effectiveness.
Conclusions
These findings have implications in extending HPV immunization programs whether switch-
ing to the 9-valent vaccine or the inclusion of adolescent boys’ vaccination or extending the
age of vaccination. Further, this review also supports extending vaccination programs to
low-resource settings where vaccine prices are competitive, donor funding is available, bur-
den of cervical cancer is high and screening options are limited.
Introduction
Cervical cancer (CC) is the third most common cancer and the leading cause of cancer-related
deaths in women worldwide [1]. Approximately 570,000 new cases of CC were diagnosed in
2018, composing 6.6% of all cancers in women [1]. The burden of CC is an alarming issue
across the globe, especially in low-and middle-income countries (LMICs). Approximately 85%
of CC cases and 90% of deaths from CC occur in LMICs [1]. Persistent infections with human
papillomavirus (HPV) are a key cause of CC and is an established carcinogen of CC [2].HPV is
predominantly transmitted to women of reproductive age through sexual contact [3]. Most
HPV infections are transient and can be cleared up within a short period, usually a few months
after their acquisition. However, untreatedHPV infections can continue and evolve into can-
cer in some cases. There are more than 100 types ofHPV infections, and high-risk types
develop into CC [4]. Thirteen high-risk HPV genotypes are known to be predominantly
responsible for malignant and premalignant lesions of the anogenital area [5], and these are
the leading causes of most aggressive CC [6]. Further,HPV is also responsible for the majority
of anogenital cervical cancers, including anal cancers (88%), vulvar cancers (43%), invasive
vaginal carcinomas (70%), and all penile cancers (50%) globally [4].
The burden of CC (i.e., high incidence and mortality rates) globally is preventable through
the implementation of a primary prevention strategy such as vaccination [1]. There are vac-
cines that can protect common cancer-causing types ofHPV and reduce the risk of CC signifi-
cantly. Three types of HPV vaccines, namely bivalent (Cervarix), quadrivalent (Gardasil) and
9-valent vaccine (Gardasil-9), are currently available in the market. Unfortunately, as of March
2017, only 71 countries (37% of all countries) have includedHPV vaccines in their national
immunization programs for girls, and 11 countries (6%) included for both sexes [2]. The first
global recommendation onHPV vaccination was proposed by the World Health Organiza-
tion’s Strategic Advisory Group of Experts on Immunization in October 2008 [7], whereHPV
vaccination was recommended for girls aged 9–13 years. This recommendation was updated
in April 2014 [8], with the emphasis to include extended 2-doseHPV immunization for girls
aged 9–14 years, who were not immune compromised. With the recent licensing of the
9-valent vaccine and the introduction of variousHPV vaccination strategies, an update on the
current recommendations ofHPV vaccination are inevitable. The goals of the immunisation
program are to combat the acquisition and spread ofHPV infections, and achieving optimum
coverage through effective delivery systems. According to the underlying distribution ofHPV
infection types of CC, the 9vHPV vaccine builds population-level strong immunity against
HPV-6, 11, 16, 18, 31, 33, 45, 52, and 58 infections [5] that cumulatively contributed
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approximately 89% of all CCs globally [9]. With respect to the primary prevention ofHPV
infection, it is expected that the 9vHPV vaccine can reduce the lifetime risk of diagnosis with
CC by an additional 10% in immunised cohorts compared with the 4vHPV vaccine and by an
additional 52% in non-vaccinated cohorts [10].
This review aims to update the current evidence on the economic viability ofHPV vaccina-
tion. In addition, this study aims to examine the cost-effectiveness of the 9-valent vaccine
when boys are included and when age cohorts are varied, from the global context. This review
may be used as comprehensive evidence of general trends on the ongoing cost-effectiveness
evaluation ofHPV vaccine.
Materials and methods
Study design
Published original academic literature that examined the cost-effectiveness of 9vHPV vaccina-
tion were included in this systematic review. A wide type of study perspectives including socie-
tal and health systems perspectives were employed. A search strategy was adopted considering
all countries regardless of perspective or vaccine delivery strategy. A combinedWHO [11],
Drummond [12] and CHEERS [13] checklist was used to evaluate the quality of included
studies.
Search strategy and sources
A literature search for the period of January 2000 to 31 July 2019 was conducted using PubMed
and Scopus bibliographic databases. This study searched for articles with no language restric-
tions. The literature search was performed by searching Scopus and PubMed databases to
identify relevant articles following the inclusion criteria. Search inclusion terms included ‘eco-
nomic evaluation’, ‘cost-effectiveness’, ‘analysis’, ‘human papillomavirus’, ‘HPV’, ‘vaccine’,
‘vaccinated’, ‘vaccination’, ‘cervical cancer’, ‘non-valent’, ‘9 or nine-valent’ (Appendix A). Ref-
erence lists for selected studies were checked to identify relevant studies for inclusion.
Study selection
Three authors (RAM, SAK and GMO) of the review team independently examined the titles
and abstracts of the articles that met the selection criteria. The existing academic literature in
the cost-effectiveness of 9vHPV vaccination was searched. Language restrictions were not
applied. The eligibility of studies for inclusion was determined following a three-stage screen-
ing process. The first stage involved screening studies by title to eliminate duplicates. The sec-
ond stage required the reading of abstracts to determine their relevance to this study. The
third stage necessitated the reading of full texts of the retained studies as reflected in Fig 1.
RAM carried out and recorded the above process, and shared the record with SAK and GMO
for verification. Discrepancies were discussed and resolved by consensus.
Data checking
The study strategy followed a number of checks to ensure consistency of approach, including a
discussion about discrepancies within the study team. For each outcome and model input
parameters, the authors identified the proportion of missing observations. Datasets were com-
bined to form a new master dataset where model input assumptions and outcome-related
parameters used in the original studies were included. Further, three authors independently
assessed the analytical quality of the preliminary selected studies using appropriate tools for
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examining risk of bias. Disagreements on inclusions were resolved by discussion with a third
review author.
Data extraction (selection and coding)
The study selection process was conducted following the PRISMA guidelines [14]. Data were
extracted to develop a comprehensive data matrix which summarises the study characteristics
such as authors, settings, perspective, threshold, outcome-related parameters and other neces-
sary information.
Strategy for data synthesis
Three authors (RAM, SAK and GMO) independently reviewed the titles and abstract. Data
from all eligible studies were extracted by the same two authors using a standardized data col-
lection form. A matrix was developed to summarise the characteristics and findings of the
studies. Studies were characterized by incorporating four themes: (i) study used 9vHPV vac-
cine to examine the cost-effectiveness, (ii) target population demographic characteristics (e.g.,
gender-neutral and multiple age cohort immunisation), (iii) study perspectives, model and
economic level of each country, and (iv) model input and outcome-related parameters.
To compare findings across the selected studies, incremental cost-effectiveness ratios
(ICERs) and standardized cost-effectiveness were outlined. In terms of standardized cost-effec-
tiveness scenarios, these studies used the heuristic cost-effectiveness threshold guided by the
WHO [15], wherein an intervention or program was evaluated to be cost-effective if the ICER/
DALYs averted was less than three times a country’s annual per capita Gross Domestic Product
(GDP). Further, theWHO constructed three broad decision rules: (i) an intervention or pro-
gram was recommended as very cost-effective if ICER/DALYs averted<1 time GDP threshold;
(ii) cost-effective if ICER/DALYs averted� 1 time GDP threshold and� 3 times GDP thresh-
old; and (iii) not cost-effective if ICER/DALYs averted>3 times GDP threshold [16]. Examin-
ing whether an ICER offered by any strategy signifies value for money requires comparison to
a cost-effectiveness threshold (CET). The CET refers to the health effects foregone (i.e., oppor-
tunity costs) related to resources being devoted to an intervention and consequentially being
Fig 1. PRISMA flow-chart for systematic review of studies.
https://doi.org/10.1371/journal.pone.0233499.g001
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unavailable for other health-care priorities. Policy makers should be willing to invest their lim-
ited resources in the strategy offering the greatest health gains. The review may serve as an
important evidence with respect to methodological and current practices of cost-effectiveness
evaluation studies such as determination of study research questions; the study perspective
adopted, the duration of vaccine protection, time horizon and discount rate; explanation of
model performed for data analysis; model input assumptions behind the estimation of associ-
ated costs and outcome parameters; reporting of ICERs; most dominant parameters of sensi-
tivity analysis; examination of study conclusions and recommendations as well as financial
disclosure of the selected studies.
Study characteristics
Four hundred and eighty-one articles were yielded through the primary search, of which 78
articles were discarded because of duplication. Fifty-one articles were considered for full-text
review after screening by title and abstract. Of these, 12 articles were eligible for the final
review (Table 1). Three hundred fifty-two articles were excluded from this study following the
inclusion criteria. The reasons for exclusion were: conference abstract (n = 58), reviews or edi-
torials or commentary (n = 160), not cost-effectiveness evaluations (n = 60), did not use
9-valent vaccine (4v-HPV, 2v-HPV; n = 72) and insufficient information (n = 2). Finally, 12
articles were included in this review (Fig 1).
Settings and funding
Single country studies mostly focused on high-income settings [4,17,26–28,18–25] (Table 2).
However, a single study was found that covered two low-income countries (e.g., Kenya and
Uganda) [29]. Eight studies were funded by research organisations [4,17,19,21–24,29], while
two studies did not state funding sources [20,27]. The Bill and Melinda Gates Foundation was
the sole funder of one study [29] and three studies were funded by the Centre for Disease Con-
trol (CDC) [21,24,27]. Further, five studies were conducted in United States [20,22,24,27,28],
one study was conducted in each of Germany [23], Italy [4], China [18], Australia [25], Austria
[17], and Canada [19]. Low resource countries mostly depend on external funding agency for
HPV vaccine programs, hence these countries may have less impetus for cost-effectiveness
studies to inform local decision making as priorities are driven by external considerations.
Study questions
Most studies (8 out of 12 studies) investigated the cost-effectiveness of introducing 9vHPV vac-
cination to preadolescent girls aged 12 or younger [4,17–19,22,24–26,29]. Four studies assessed
vaccinating 12 years or older girls [20,23,27,28]. All studies investigated vaccination either as
an addition to existing screening programs or (more commonly) as opportunistic preventive
programs or none at all. Further, most studies considered a range of vaccination and screening
options to find the most cost-effective combination.
Analytical model
Nine studies used a dynamic economic model for examining the cost-effectiveness ofHPV
vaccination programs [4,17,27,28,18,20–26], two studies used a static model [19,29], and
one study used a Markov model for analytical exploration [18] (Table 2). However, some
studies did not explicitly account for the pathologic transition from HPV-acquisition to
HPV-associated disease [4,18,25,27,28], pathologic transition [4,23] and herd immunity
[17,19,20,24,27,28].
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Thresholds and perspectives
In terms of the cost-effectiveness scenario, four studies used the heuristic cost-effectiveness
threshold proposed by theWHO. These studies used either one or three times GDP per cap-
ita [18,19,24,29]. The majority of studies adopted local thresholds (e.g., willingness to pay)
while three studies considered both thresholds of GDP per capita and willingness to pay
[18,24,29]. Apart from these studies, seven studies undertook an evaluation from a societal
perspective [19,22–24,27–29], and four studies utilised the health system perspective
[4,18,20,25]. Several studies used the societal perspective and included all vaccination costs,
relevant direct medical costs, and gains in quality and length of life without considering who
incurred the costs or who received the benefits (Table 2). However, these selected studies
reported little about the indirect costs and productivity losses which are significant from the
societal perspective.
Table 1. Characteristics of twelve included cost-effectiveness studies of 9vHPV vaccination.
Characteristics Number of studies (n) Percentage (%)
Selected articles 12 100
Year of publication
2014 2 17
2016 7 58
2017 2 17
2018 1 8
Name of Journal
BMC Infectious Diseases 2 17
Cost Effectiveness and Resource Allocation 1 8
Expert Review of Pharmacoeconomics & Outcomes Research 1 8
Human Vaccines & Immunotherapeutics 1 8
International Journal of Cancer 1 8
The Lancet Public Health 1 8
PLoS ONE 1 8
The Journal of Infectious Diseases 2 17
Vaccine 1 8
Journal of the National Cancer Institute 1 8
Study setting
Australia 1 8
Austria 1 8
Canada 1 8
China 1 8
Germany 1 8
Italy 1 8
Kenya and Uganda 1 8
United States 5 42
Main location of first author
Research institute 8 67
Research group 1 8
Hospital or University 3 25
Conflict of interest
Yes 6 50
No 6 50
https://doi.org/10.1371/journal.pone.0233499.t001
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Table 2. Characteristics of the selected studies.
Author Study
settings
Economic
category
Target age
cohort
Sex of
cohort
Vaccine
delivery
route
No of
doses
Type of
model
Threshold Perspective Time
horizon
(year)
Discount
rate
Sensitivity
analysis
Most sensitive
parameter
Kiatpongsan
et al. [29]
Kenya and
Uganda
LMIC 9 years Female NIP 3 Static GDP and
WTP
Societal ns 3% One-way Discount rate
Laprise et al.
[22]
United
States
HI 9–14 years Female NIP 2 & 3 Dynamic WTP Societal 100 3% One-way Vaccine efficacy,
screening method,
and healthcare costs,
vaccine coverage
Largeron et al.
[23]
Germany HI 12–17 years Female SHI plans 2 Dynamic WTP Societal 100 3% One-way Discounted rate,
vaccine price
Mennini et al.
[4]
Italy HI 12 years Female NIP 2 Dynamic WTP Health
system
100 3% One-way Vaccine price
Mo et al. [18] China MI 12 years Female NIP 3 Markov GDP and
WTP
Health
system
3% One-way
Simms et al.
[25]
Australia HI 12 years Female NIP 2 Dynamic WTP Health
system
20 5% One-way Vaccine price and
vaccine duration of
protection
Boiron et al.
[17]
Austria HI 9 years Gender-
neutral
Universal 2 Dynamic WTP &
GDP
Health
system
100 3% One-way Discount rates and
duration of
protection
Brisson et al.
[24]
United
States
HI 9 years Gender-
neutral
Universal 3 Dynamic WTP Societal 70 3% One-way Vaccine price
Chesson et al.
[27]
United
States
HI Female: 12 to
26 years, and
male:12 to 21
years
Gender-
neutral
NIP 3 Dynamic WTP Societal 100 3% One-way Vaccine price, Time
horizon
Chesson et al.
[28]
United
States
HI Female:13-
18years
female NIP 3 Dynamic WTP Societal 100 3% One-way,
Multi-way
Vaccine price
Chesson et al.
[20]
United
States
HI Female: 12 to
26 years, and
male:12 to 21
years
Gender-
neutral
NIP 3 Dynamic WTP Health
system
100 3% One-way,
Multi-way
Vaccine price
Drolet et al.
[19]
Canada HI 10 years Female NIP 3 Static GDP Societal 70 3% One-way,
Multi-way
Duration of
protection, vaccine
efficacy, vaccine
price, discount rate
SHI = Statutory health insurance plans, NIP = National Immunisation Program, WTP =Willingness to pay
https://doi.org/10.1371/journal.pone.0233499.t002
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Vaccine coverage
The assumptions on vaccine coverage are significant in influencing the potential impact of
HPV vaccine onHPV related diseases. Four selected studies assumed a vaccination coverage
rate of 90% or above [18,22,23,29]. The vaccine coverage might be varied in terms of study set-
tings as well as from a gender point of view. Among the selected studies, three studies consid-
ered vaccine coverage rates of 26–60% for females and 25–40% for males [17,27,28], and three
studies considered a 46–80% vaccine coverage rate [19,20,25]. Three studies grouped vaccina-
tion coverage rate by gender, assumed 25–60% for females and 11–40% for males [24,27,28].
The remaining studies did not specify the vaccination coverage rate [24].
Vaccine efficacy
Most studies considered a vaccine efficacy rate ranged from 95–100% againstHPV infections
except the study of Simms et al. (2016) [25], which considered a vaccine efficacy rate of only
59%. The study conducted in two East African countries (Kenya and Uganda) used a 100%
vaccine efficacy rate in case of 9vHPV [29]. Most studies (n = 10/12) used a 95% vaccine effi-
cacy rate [4,17,27,28,18–24,26].
Number of vaccine dose and delivery route
Eight studies used a three-dose schedule of 9vHPV vaccine. Most studies were conducted in
developed countries [18–21,24,27–29] and the other two studies were conducted in low- and
middle-income countries (LMICs) [18,29]. Further, one study conducted in the United States
[21] used both 2- and 3-dose vaccines. Diverse vaccine delivery routes were evidenced across
the selected studies. Nine studies used the vaccine delivery route of a national immunisation
program for the target population [4,18–21,25,27–29]. Two studies conducted in Austria [17]
and United States [24], used a universal immunisation strategy to deliver the vaccine. Only
one cost-effectiveness exploration of 9vHPV vaccine was conducted in Germany [23] and it
used a vaccine delivery route through social health insurance.
Duration of vaccine protection, herd immunity effect, and discounting rate
Most studies (11/12) assumed lifelong vaccine protection while only one study assumed a
shorter duration of protection of 20 years [19]. Half of the studies specified herd immunity
due to vaccination [17,19,20,24,27,28]. The remaining six studies did not consider the indirect
effect of vaccination. Regarding the discount rate, majority of the studies (11/12) used 3% dis-
count rate, while one study considered a 5% discount rate to adjust for future values in terms
of economic value and health outcome [25].
Quality of included studies
The quality scores were assigned using the Consensus Health Economic Criteria (CHEC) list, a
checklist that can be used to critically evaluate published economic evaluations [30]. Table 3
showed the extent to which the reviewed studies followed the standards of reporting economic
evaluations based on theWHO guidance [11], Drummond [12] and the Consolidated Health Eco-
nomic Evaluation Reporting Standards (CHEERS) [13]. All studies clearly identified the study
question, intervention(s), comparator(s) perspectives, time horizon and discounting rates. Most
studies performed sensitivity analyses (11/12; 92%) to assess the robustness of concerned study
findings. Most studies clearly described the measurements and the assumptions for measuring the
costs (11/12, 92%). The choice of model used was justified in all studies, where dynamic transmis-
sion model was adopted to capture herd immunity. The currency and price data were also
PLOS ONE Cost-effectiveness evaluations of the 9vHPV vaccine
PLOSONE | https://doi.org/10.1371/journal.pone.0233499 June 2, 2020 8 / 15
147
reported in all studies. 10 (83%) out 12 studies disclosed the funding sources. However, only 8
studies (67%) reported the measurement of effectiveness from synthesis-based estimates, either
through the combination of several randomized trials or the use of systematic reviews.
Results
Ten studies concluded that their evaluation of 9vHPV vaccination was found to be cost-effec-
tive (Table 4) while the remaining two studies did not find cost-effectiveness [27,28]. Further,
five studies exhibited a ‘very cost-effective’ decision [4,18,19,23,29] and four studies found
‘cost-savings’ [17,22,24,27]. In the context of high-income countries (e.g., Canada and Aus-
tria), introduction of 9vHPV vaccination was a cost-effective decision to prevent cervical can-
cer in adolescent girls, as the incremental cost of vaccine was less than US$23-US$47.
However, in low and middle-income countries (e.g., Kenya and Uganda), the ICER of 9vHPV
vaccine must not be priced over US$8.40-US$9.80 [19,29]. Two US based studies concluded
that the cost-effectiveness exploration of 9vHPV vaccine was more likely to be ‘cost-saving’
regardless of cross-protection assumption [24,27]. Most studies used ‘quality-adjusted life
year’ (QALYs) as the unit of measurement. In addition, selected studies explored the cost-effec-
tiveness decision usingWTP thresholds that depend on country settings. Cost-effectiveness
decision differs with country specific vaccine prices. For example, two studies conducted in
the US, considered two different vaccine prices per dose, US$162.74 and US$174, respectively.
However, both studies confirmed that the introduction of 9vHPV vaccine was not cost-effec-
tive. Four studies reported cost-effectiveness of 9vHPV vaccine for gender-neutral approaches
[17,20,24,27] and three studies found it a ‘cost-effective’ or ‘cost-saving’ decision [17,24,27].
The remaining eight studies suggested vaccinating girls only. In terms of key drivers of cost-
effectiveness, this review identified duration of vaccine protection [17,19,25], time horizon
[28], vaccine price [4,19,20,23–25,27,28], healthcare costs [22], vaccine efficacy [19,22], vaccine
coverage [19,22] and discounting rates [17,19,23,29] as the most influential parameters.
Discussion
TheHPV vaccination is one of the cornerstones of CC prevention worldwide. This study
explored the cost-effectiveness of 9vHPV vaccination by reviewing 12 cost-effectiveness
Table 3. Extent to which included studies met standard reporting recommendations.
Explained recommendations Number of studies fulfilling Percentage (%)
Research question or objective clearly stated 10/12 83
Described intervention and comparator 10/12 83
Exploration of effectiveness reported 11/12 92
Single study-based estimates 8/12 67
Synthesis-based estimates 10/12 83
Assumption of costs and outcomes specified 11/12 92
Currency and price data reported 12 100
Choice of model justified 12 100
Perspective specified 12 100
Time horizon specified 12 100
Discounting rates specified 12 100
Calculated and reported ICER or cost-saving 12 100
Sensitivity analysis performed 11/12 92
Conclusions follow from the data reported 12 100
Disclosed funding source(s) 10/12 83
https://doi.org/10.1371/journal.pone.0233499.t003
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evaluations in order to inform and expand knowledge on the cost-effectiveness of 9vHPV vac-
cines. Most studies were conducted from a developed country perspective and two studies
were performed from a LMIC perspective. However, a higher incidence of cervical cancer in
LMICs is a serious public health concern, which warrants more evidence for effective decision
Table 4. Summary of the results of the selected studies.
Author Vaccine
efficacy
Vaccine
coverage
Duration of
vaccine
protection
Herd
effect
Vaccine
price per
dose
Unit of cost-
effectiveness
GDP per
capita
Incremental cost-
effectiveness
ration (ICER)
Conclusion or
recommendation
Study funder
Kiatpongsan
et al. [29]
100% 100% Lifetime No US$
90.25
QALYs Kenya =
$1,349.97,
Uganda = $
674.05
Very cost-
effective if
additional cost of
9vHPV vaccine
per course� $9.8
in Kenya &� 8.4
in Uganda
Very cost-effective
for both countries
(Kenya & Uganda)
The Bill and Melinda
Gates Foundation
Laprise et al.
[22]
95% 90% Lifetime No US$ 158 QALYs Cost saving to US
$ 500
Cost saving CDC
Largeron
et al. [23]
96% 90% Lifetime No € 140 QALYs £30,000 € 329 / QALY Highly cost-effective Sanofi Pasteur MSD
(SPMSD).
Mennini
et al. [4]
96% 90% lifelong No € 80.00 QALYs € 40,000 € 10,463 / QALY Highly cost-effective Sanofi Pasteur MSD
Mo et al. [18] 96.7% 20% lifetime No USD
149.03
QALYs USD
23,880
US$ 5,768 /
QALY
Highly cost-effective
with screening 1
+ 9vHPV,—Cost-
effective with
screening 2 + 9vHPV
The Japan Society
for the Promotion of
Sciences, the
National Centre for
Child Health and
Development, and
the Chinese Natural
Sciences Foundation
Simms et al.
[25]
59% 70% lifelong No ns QALYs AUD
30,000
Cost-
effectiveness if
the additional
cost per dose is
US$18–28
Cost-effective National Health and
Medical Research
Council, Australia
Boiron et al.
[17]
98% Female:
60%
Male:
40%
Lifelong Yes US$
147.15
QALYs US$
44,767.35
Cost-saving at
vaccine price up
to US$ 166.77
Cost-saving Sanofi Pasteur MSD
Brisson et al.
[24]
95.0% Not
stated
Lifelong Yes US$ 158 QALYs US$
48,373.88
Cost-saving
regardless of
cross-protection
assumptions
Cost-saving if
additional cost of
vaccine per
dose< US$ 13
CDC, Canadian
Research Chair
Program
Chesson
et al. [27]
95.0% Female:
25.8%
Male:
11.7%
Lifelong Yes US$
162.74
QALYs US$
52,787.03
Cost-saving
regardless of
cross-protection
assumptions
(<$0)
Cost-saving Not stated
Chesson
et al. [28]
95.0% Female:
46%
Male:
25%
Lifelong Yes US$
162.74
QALYs US$
52,787.03
US$ 111,446 /
QALY
Not cost-effective CDC, Canada
Research Chair
Program, Canadian
Institute for Health
Research
Chesson
et al. [20]
95.0% 46% Lifelong Yes US$ 174 QALYs US$
52,787.03
US$ 228,800 /
QALY
Not cost-effective Not stated
Drolet et al.
[19]
95.0% 80% 20years Yes US$
90.25
QALYs US$
50,440.44
US$ 11,593
/QALY
Very cost-effective if
additional cost of
vaccine per
dose� US$ 22.80
Canadian Research
Chair Program
https://doi.org/10.1371/journal.pone.0233499.t004
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making [31]. The economic viability of gender-neutral 9vHPV vaccination was confirmed by
three studies [17,24,27]. Cost-effectiveness exploration depends on the coverage of vaccination
from the perspective of gender. For example, if the vaccine coverage for female recipients is
80% or above, the majority of the anogenital CC including vulvar cancers, invasive vaginal car-
cinomas cancers in females could be prevented. As a result, introduction of 9vHPV vaccination
for boys is relatively less important compared with girls as high economic costs are involved
without additional benefits gained, both from the societal and health system perspectives.
Therefore, achieving optimal coverage of vaccination in females should remain a priority. This
is of primary significance for LMICs settings since it is more effective and economically viable
to prevent CC in females. However, it is also important to note that past studies paid little
attention to the broader benefits of vaccination among male cohorts to prevent penile, anal,
and oropharyngeal cancers. Exclusion of these diseases related to males may undermine the
effectiveness of reducing CC. Gender-neutral vaccination might have several benefits includ-
ing herd protection for boys. Moreover, it may provide indirect protection to unvaccinated
women and direct protection to homosexual men. Therefore, this vaccination strategy should
be further considered in country-level immunization programs by underlining other parame-
ters including disease burden, sexual behaviour in a country (e.g., homosexual intercourse),
equity, budget impact, and affordability.
Despite different methodologies and various assumptions, most studies were consistent in
their conclusion that multiple age cohort vaccination was economically viable. Nevertheless,
there was an upper age limit at which HPV vaccination was no longer cost-effective, and
should be interpreted cautiously as several studies evaluated the cost-effectiveness in a single
age range only and did not compare to the next age range in a progressive manner. Subse-
quently, this could result in an overestimation of the cut-off age range for vaccination. The
protection duration from vaccination has a large impact on the cost-effectiveness of multi-
cohort vaccination, with most studies assuming life-long protection. Therefore, the use of
ICERs based on the conventional evaluation of 10-year protection may be more representative
of real-life effectiveness rather than the use of ICER based on lifetime protection. The cost-
effectiveness ofHPV vaccination is also dependent upon the levels of vaccine coverage, com-
pliance, and vaccine price.
Most studies presumed a high rate of vaccination coverage, e.g., assumed that 70% of the
target population will receive full doses of vaccination. However, not everyone completed full
doses (i.e., two or three doses) within the recommended time frame. Therefore, cost-effective-
ness evaluation may underestimate or overestimate the actual costs and benefits. The analytical
model outcomes in terms of herd immunity is only hypothetical unless the coverage level
increases among the study cohort. Further, it is also indeterminate how non-compliance may
consequently influence vaccine efficacy, effectiveness and duration of protection. Model input
assumptions regarding the 9vHPV vaccine price also influence the observed cost-effectiveness
outcomes. Prices for 9vHPV vaccine are currently not specified, particularly, in lower-income
countries. Hence, the cost-effectiveness of 9vHPV vaccine is still indeterminate and there is no
exclusive evidence of greater cost-effectiveness than the older licensedHPV vaccines.
Therefore, once the 9-valent vaccine price is fixed, including support by the GAVI vaccine-
alliance, reassessment of cost-effectiveness of 9vHPV vaccine is necessary. Another model
input assumption that may influence the cost-effectiveness is the inclusion or exclusion of
herd immunity effects based on the type of model acceptance. Two studies [19,29] constituted
the static model as an analytical exploration which did not confirm herd immunity effects.
Generally, the cost-effectiveness evaluations ofHPV vaccine should use a dynamic model for
exploration because economic evaluations for primary prevention strategy should be deter-
mined by societal benefits (e.g., indirect impacts on population not immunised) rather than
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individual demands [32]. However, the application of a static model in these two studies may
underestimate or overestimate the benefits of vaccination. If anHPV vaccination program is
exhibited to be cost-effective considering a static model for analytical exploration, it is antici-
pated to be even very cost-effective when a dynamic model is considered [32].
There are several types of cost-effectiveness threshold. The majority of the studies used the
cost-effectiveness demand side-threshold (e.g. willingness-to-pay). In health-related explora-
tions, a willingness-to-pay threshold signifies an evaluation of what a consumer of health care
might be prepared to pay for the health benefit–given other competing demands on that con-
sumer’s resources. There are also supply-side thresholds that resource allocation mechanism
takes into account. For example, estimates of health status are predetermined since when an
insurance company or other provider spends some of its available budget on a new interven-
tion it is therefore required to decrease its funding of previous interventions. In considering
the choice of the type of cost-effectiveness threshold to use, the concept of opportunity cost
may be the one most relevant to providers who are primarily concerned with using available
resources to maximise improvements in health status. In response to the implementation of a
new intervention, decision-makers need estimates of both the health that might be gained else-
where through the alternative use of the resources needed for the new intervention and the
health that is likely to be lost if the new intervention is not used.
This review has some limitations. The cost-effectiveness evaluation based on GDP based
thresholds of 1–3 times of GDP per capita might be misleading for country-level decision mak-
ing due to a lack of country specific thresholds [33]. It is uncertain whether this threshold truly
reflects the country’s affordability or societal willingness to pay for additional health gains.
Additionally, GDP is originally intended to measure the experience of people residing in urban
areas and thus it may not actually reflect the experience of the entire population in a country,
especially those living in rural areas. Apart from an economic standpoint, other factors should
be considered for the national immunization program, such as budget availability, political
issues, cultural influences and availability of healthcare workforce.
Conclusions
There are a limited number of studies that showed conclusive evidence of cost-effectiveness of
the 9vHPV vaccine. The inclusion of adolescent males inHPV vaccination programs is cost-
effective subject to vaccine price or coverage of females being low and HPV-associated male
diseases are taken into account. Multiple age cohort vaccination strategy is likely to be cost-
effective in the age range of 9–14 years, but the upper age limit at whichHPV vaccination is no
longer cost-effective requires further investigation. Vaccine coverage, price, duration of pro-
tection and discount rates are important parameters for considering the uptake ofHPV vacci-
nation. Nonetheless, the present study findings may serve as useful evidence for health policy-
makers and healthcare providers in taking decision aboutHPV national immunization pro-
grams using the new 9vHPV vaccine or inclusion of adolescent boys’ for vaccination or
extending the age of immunization.
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Abstract
Introduction
Cervical cancer imposes a substantial health burden worldwide including in Australia and is
caused by persistent infection with one of 13 sexually transmitted high-risk human papillo-
mavirus (HPV) types. The objective of this study was to assess the cost-effectiveness of
adding a nonavalent new Gardasil-9® (9vHPV) vaccine to the national immunisation sched-
ule in Australia across three different delivery strategies.
Materials and methods
The Papillomavirus Rapid Interface for Modelling and Economics (PRIME) model was used
to examine the cost-effectiveness of 9vHPV vaccine introduction to prevent HPV infection.
Academic literature and anecdotal evidence were included on the demographic variables,
cervical cancer incidence and mortality, treatment costs, and vaccine delivery costs. The
incremental cost-effectiveness ratios (ICERs) were measured per disability-adjusted life
years (DALYs) averted, using the heuristic cost-effectiveness threshold defined by the
World Health Organisation (WHO). Analyses and data from international agencies were
used in scenario analysis from the health system and societal perspectives.
Results
The 9vHPV vaccination was estimated to prevent 113 new cases of cervical cancer (dis-
counted) during a 20-year period. From the health system and societal perspectives, the
9vHPV vaccination was very cost-effective in comparison with the status quo, with an ICER
of A$47,008 and A$44,678 per DALY averted, respectively, using the heuristic cost-
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effectiveness threshold level. Considering delivery strategies, the ICERs per DALY averted
were A$47,605, A$46,682, and A$46,738 for school, health facilities, and outreach-based
vaccination programs from the health system perspective, wherein, from the societal per-
spective, the ICERs per DALY averted were A$46,378, A$43,729, A$43,930, respectively.
All estimates of ICERs fell below the threshold level (A$73,267).
Conclusions
This cost-effectiveness evaluation suggests that the routine two-dose 9vHPV vaccination
strategy of preadolescent girls against HPV is very cost-effective in Australia from both the
health system and societal perspectives. If equally priced, the 9vHPV option is the most eco-
nomically viable vaccine. Overall, this analysis seeks to contribute to an evidence-based
recommendation about the new 9vHPV vaccination in the national immunisation program in
Australia.
Introduction
Cervical cancer is both a leading cancer and the leading cause of cancer deaths in women glob-
ally [1]. An estimated 570,000 new cases of cervical cancer were diagnosed in 2018, composing
6.6% of all cancers in women [1]. In Australia, over the last couple of years, the age-specific
cervical cancer incidence has slightly reduced to 7.1 cases per 100,000 females in 2018 from 7.4
cases per 100,000 females in 2014 [2]. However, the incidence is quite high among young adult
females at 15.0 cases per 100,000 females and was the most frequently diagnosed cancer
among women in 2018 [2]. Persistent infections with human papillomavirus (HPV) are a key
cause of cervical cancer and an established carcinogen of cervical cancer [3].HPV is predomi-
nantly transmitted to reproductive-aged women through sexual contact [4]. Most HPV infec-
tions are transient and can be cleared up within a short duration, usually a few months after
their acquisition. However,HPV infections can continue and evolve in cancer in some cases.
There are more than 100 types ofHPV infections that have been identified and divided into
low- and high-risk types develop into cervical cancer [5]. Thirteen high-risk HPV types are
known to be predominantly responsible for malignant and premalignant lesions of the ano-
genital area [6] and are the leading causes of most aggressive cervical cancers [7]. Further,
HPV is also responsible for the majority of anogenital cervical cancers such as anal cancers
(88%), vulvar cancers (43%), invasive vaginal carcinomas (70%), and all penile cancers (50%)
globally [5]. The incidence of neck and head cancers caused byHPV infection is low but not
negligible [8]. Cervical cancer is preventable through implementation of a primary prevention
strategy such as vaccination worldwide including Australia [9,10]. Therefore, a reduction in
cervical cancer incidence and associated cancer mortality along with the improvement of sur-
vival rates have the potential to reduce the burden of cervical cancer.
The high burden of cervical cancer in terms of incidence and associated mortality rates
across the world could be reduced by incorporating a comprehensive primary prevention
mechanism. Prevention mechanisms includes early vaccination, diagnosis, effective screening,
adequate referral and advanced course of treatment procedures. In this context,HPV vaccina-
tions (i.e., bivalent and quadrivalent) has been introduced in many countries in the past decade
[10]. Currently, availableHPV vaccines can promote herd immunity against cancer-causing
types ofHPV that helps to reduce the high-risk of cervical cancer burden. These vaccines have
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played a significant role in preventingHPV infection types 16 and 18 [10], which cause more
than 70% of cervical cancers in Australia [7].
Australia was the first country to implement a publicly-funded NationalHPV Immunisa-
tion Program (NHIP), starting with preadolescent girls in 2007, using the quadrivalent
Gardasil1 vaccine (4vHPV; Merck & Co., Kenilworth, NJ, USA) [11]. The goals of the immu-
nisation program were to reduce the acquisition and spread ofHPV infections and to achieve
optimum coverage through the school-based delivery system [12]. This program for adolescent
employed a three-dose schedule of the 4vHPV vaccine [13]. The 4vHPV vaccine provides pro-
tection againstHPV infection types 6, 11, 16, and 18 [14]. In the context of Australia, the
4vHPV vaccine was replaced by the two-dose nonavalent Gardasil1-9 vaccine (9vHPV;
Merck Sharp & Dohme) in 2018 [15]. According to the underlying distribution ofHPV infec-
tion types of cervical cancers, the 9vHPV vaccine builds population-level strong immunity
againstHPV-6, 11, 16, 18, 31, 33, 45, 52, and 58 infections [6] that cumulatively contribute to
approximately 89% of all cervical cancers globally [16] and 93% in Australia [17]. Considering
the primary prevention ofHPV infection, the 9vHPV vaccine is anticipated to reduce by 10%
more the lifetime risk of diagnosis of cervical cancer in immunised cohorts than the 4vHPV
vaccine and by 52% more compared to non-vaccinated cohorts [18].
With the availability of vaccines against the different HPV infection types, there are good
opportunities for primary prevention to add to continuing efforts on secondary prevention
strategies. However, the decision for any country to add a new vaccine to national immuniza-
tion programs requires careful assessment of the relative value of the vaccine compared with
alternative uses of the required resources (i.e., cost-effectiveness) and its affordability (i.e., bud-
getary impact). Cost-effectiveness analysis (CEA) is a pragmatic approach which aims to exam-
ine the outcomes and costs of interventions or programs designed to improve health. CEA
evolves measuring the net or incremental costs and effects of an intervention or program in
terms of costs and health outcomes as compared with some comparator. There is considerable
evidence of assessing the cost-effectiveness of the 9vHPV vaccine in different country settings.
In Canada, the 9vHPV was found to be highly cost-effective compared with the 4vHPV vaccine
taking into consideration the shorter duration of protection (9vHPV = 20 years vs. 4vHPV =
lifelong), along with a lower vaccine efficacy (85% vs. 95%) [19]. In other studies conducted in
the United States (US), the 9vHPV vaccine was also found to be very cost-effective compared
to the 4vHPV vaccine [20]. However, findings from cost-effective evaluations will differ based
on study settings, funding, perspectives and coverage of vaccination For example, in the US,
Chesson et al. (2016) found that the 9vHPV vaccine was not cost-effective, with an incremental
cost-effectiveness ratio (ICER) of $146,200 per quality-adjusted life year (QALY) gained that
exceeded the cost-effectiveness threshold ($100,000) [21]. Some cost-effective evaluations were
performed using the same vaccine (i.e., 9-valent) in the US to capture the different dimensions
of its economic viability [22–27]. These studies incorporated different study participants,
designs, perspectives, vaccine delivery routes and model specifications. Simms et al. (2016)
evaluated the 9vHPV vaccine in a primary HPV screening scenario in both Australia and Can-
ada [18]. They found that 9vHPV had a significant impact on reducing cervical cancer inci-
dence from the health system perspective. Further, they claimed that the incremental cost per
dose in girls should not exceed a median of A$35.99. However, this study emphasised the
impact of vaccines to prevent cervical cancer rather than their economic viability. Sufficient
evidence did not arise for health policymakers to use the findings to develop cost-effective
intervention strategies. In Germany, universal immunisation with 9vHPV was suggested as it
had an ICER of €22,987/QALY gained, which was below the threshold [28]. In Spain, a recent
study evaluated a vaccine program in adolescent girls, wherein the 9vHPV vaccine was found
to be more highly cost-effective, with an ICER of €7,718 per QALY compared to the 4vHPV
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vaccine [29]. In the African setting, in Kenya and Uganda, a study recommended that the
9vHPV vaccine was very cost-effective in both countries, wherein the additional cost of the
9vHPV vaccine did not exceed I$8.3 per immunised girl [30].
In Australia, the 9vHPV vaccine was introduced in 2018. There is limited current compre-
hensive evidence about the cost-effectiveness of the 9vHPV vaccine in Australia across delivery
strategies (e.g., school-based, health facility-based and outreach-based) from the health system
and societal perspectives. The present study evaluates the cost-effectiveness of the 9vHPV vac-
cine from both health system and societal perspectives across three delivery routes. However,
the previous cost-effective evaluation considered only one perspective nor health system or
societal, or both perspectives along with single vaccine delivery route. Further, the findings of
the present study will provide evidence about the cost-effectiveness of the 9vHPV vaccine to
policymakers. These cost-effectiveness findings will also be significant for determining the
optimal pricing of delivery strategies in the vaccination program in order to maximise the soci-
etal benefits of the introduction of the new 9vHPV vaccine to Australia.
The objectives of this study are (1) to examine the cost-effectiveness of the 9vHPV vaccine
by considering three different vaccine delivery strategies in the setting of Australia from the
health system and societal perspectives and (2) compare the ICER per case, disability-adjusted
life years (DALYs), and life-years saved across delivery strategies such as school-based, health
facility-based, and outreach-based programs.
Materials and methods
Study perspective
This study was designed from both the health system and societal perspectives. The societal per-
spective refers to all types of costs that can be identified, quantified, estimated, and valued no
matter who incurred them and it is considered to be the summation of both provider and house-
hold costs. This is the recommended standard for undertaking cost-effectiveness analysis [31].
Model overview
The study used the Papillomavirus Rapid Interface for Modelling and Economics (PRIME)
model. PRIME is a user-friendly model designed and developed by the World Health Organi-
sation (WHO) in collaboration with the Johns Hopkins Bloomberg School of Public Health in
Baltimore, the School of Hygiene and Tropical Medicine in London, and the Universite Laval
in Quebec [10]. PRIME is a Microsoft Excel based (Microsoft Corp., Armonk, NY, USA) static
model that measures the health and economic effects of the vaccination of adolescent girls
againstHPV infection. It is not designed to examine other dimensions, such as immunised
males or older women or the impact of cervical cancer screening services [10]. Several spread-
sheets are contained in this model to input different parameter-level data on demographics, an
age-dependent incidence of cervical cancer, associated mortality, vaccine efficacy, vaccine cov-
erage, and associated costs (e.g., vaccination costs, treatment costs). This model does not con-
sider indirect effects like herd immunity.
Methodological assumptions
Methodological assumptions follow theWHO guidelines for cost-effectiveness analysis [32].
The use of cost-effectiveness analysis is recommended when considering health system and
societal perspectives. In the context of the health system perspective, the average cost parame-
ters associated with treating a woman with cervical cancer (per episode, over the lifetime), and
the cost of theHPV vaccination program were both considered. From the societal viewpoint,
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both direct medical (e.g., drugs, diagnostics) and non-medical (e.g., transportation) costs as
well as indirect costs (e.g., productivity loses or income loss due to cervical cancer) were con-
sidered in the analysis. All future costs and health benefits were adjusted by a discount rate of
5% annually [5,29,32], which was validated in the sensitivity analysis. The primary outcome
measure is the ICERs per DALYs averted. DALY estimation was undertaken by summing up
the fatal burden (years of life lost; YLL) due to premature cervical cancer related mortality and
the non-fatal burden (years lost due to disability; YLD) for patients surviving the condition.
DALY ¼ YLLþ YLD ð1Þ
YLL ¼
N
r
1  e rLð Þ ð2Þ
YLD ¼ I � DW � L
1  e rL
r
� �
ð3Þ
where, N = number of deaths; L (YLL) = standard life expectancy at the age of death in that
year; I = number of people with cervical cancer cases; DW = disability weight; r = discount
rate; and L (YLD) = duration of disability in years.
Cost-effectiveness analysis
The performance of competing strategies was explained using the ICER which were calculated
by dividing the difference in cost with and without HPV vaccination by the difference in health
outcomes (e.g., the number of DALYs averted, the number of deaths and cases averted) with
and without vaccination in Australia. The ICER is used to examine whether the 9vHPV vaccine
is economically viable in Australia. In the context of Australia, no explicit cost-effectiveness
threshold has been approved [33,34], although research has confirmed that there is a correla-
tion between the incremental cost per health outcomes (e.g., QALY gained or DALY averted)
and the probability of rejection of a health intervention or a new medicine [35]. The pharma-
ceutical industry claim that an acceptable threshold was in the range of AUD 45,000 to AUD
60,000 per additional QALY gained [36]. Some studies also stated that “Pharmaceutical Bene-
fits Advisory Committee (PBAC) decisions in the past have shown that the ICER per QALY
gained was of the order of $50,000” [18,37]. The present study intended to evaluate the cost-
effectiveness of the 9vHPV vaccine in terms of the ICER per DALYs averted. Further, DALYs
and QALYs differ in concept and application. The concept of DALYs was used to measure the
disease burden using life lost due to premature death and the time spent in worse healthy
states. Empirical evidence in the Australian context is limited to the use of the willingness-to-
pay (WTP) threshold values for the ICER per DALYs averted. In reporting the cost-effective-
ness scenario, the present study used the heuristic cost-effectiveness threshold as defined by
theWHO Commission on Macroeconomics and Health (CMH) [38]. The gross domestic
product (GDP)-related cost-effectiveness thresholds were based on assumptions about leisure
time, non-health consumption, longevity and health-related quality of life. An intervention is
cost-effective if the ICER per DALY averted is less than three times of a country’s annual per
capita GDP. According to this guideline, the CMH recommended three broad decision rules,
as follows: (1) a program or intervention is defined as very cost-effective if the ICER per DALY
averted is less than one time the GDP per capita; (2) a program or intervention is cost-effective
if the ICER per DALY averted is one or more times the GDP per capita but less than or equal to
three times the GDP per capita; and (3) a program or intervention is not cost-effective if the
ICER per DALY averted is more than three times the GDP per capita [31].
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Vaccine and efficacy
The Australian Technical Advisory Group on Immunisation (ATAGI) in 2018 advised moving
from using the quadrivalent 4vHPV to using the nonavalent Gardasil-9 (9vHPV) vaccine [39].
The 9vHPV vaccine has been registered for use in Australia [40]. The vaccine is funded
through the national immunisation program (NIP) and delivered primarily by state and terri-
tory school-based immunisation programs in Australia [39]. This vaccine is manufactured
using a procedure similar to that of the 4vHPV vaccine, which contains 0.5mg of aluminium
hydroxyphosphate sulphate and a yeast expression system [40]. The 4vHPV vaccine contains
five more virus-like particles than the original vaccine, identical to those in the protective cap-
sule around the nine included strains (HPV-6, 11, 16, 18, 31, 33, 45, 52, and 58) with the aim to
further reduce theHPV disease burden. The high prophylactic efficacy of the 9vHPV vaccine
(93%) againstHPV infection is evident both in Australia (77% forHPV types 16, 18 and 16%
forHPV types 6, 31, 33, 45, 52, 58) [17] and globally (89%) [16]. However, no herd immunity
was considered. It was recommended for the target cohort of adolescents aged 12 years to
receive a two-dose 9vHPV vaccination for several reasons [39]. First, administering a vaccina-
tion at this age is more likely to ensure it is being given before their first sexual encounter (and
HPV exposure). Also, the immune response tends to be stronger and more long-lasting when
the vaccine is given to pre-adolescents. However, 9vHPV is not recommended for use during
pregnancy. Similarly, vaccination is delayed if the person is unwell or has a high temperature,
medical advice is recommended if the person is allergic to yeast or has had a severe reaction to
a previous vaccine, and anyone who receives the vaccine is recommended to sit for 15 minutes
thereafter to reduce the risk of fainting.
Vaccine delivery strategies
TheHPV vaccine delivery strategy is an important aspect that needs to be considered carefully
by each country. According to the country-specific context, the costs of vaccine delivery may
vary. TheWHO has recommended several types of common vaccine delivery strategies for dif-
ferent country settings. One example is vaccine delivery at healthcare facilities and via outreach
routes (e.g. school-based program) and campaigns. It may be required to use a combined vac-
cine delivery strategy to ensure access among the entire target population. The 9vHPV vaccine
has been delivered in Australia through school-based NIP in all states and territories to the tar-
get population cohort of school-going adolescents since January 2018. Two doses of 9vHPV
are recommended to be administered at a minimum interval of six to 12 months between
doses [39]. In some cases, general practitioner (GP) and other primary health care providers
are generally engaged to catch up doses missed in the routinely school-based NIP. All provid-
ers are proactively involved in delivering and ensuring the completion of all doses of the
9vHPV vaccine to those individuals with special requirements, vaccine hesitancy, or immuno-
compromise. However, individuals who have already been fully immunised with HPV vac-
cines are not eligible for free 9vHPV vaccination. The present study incorporated another two
hypothetical vaccine delivery strategies, as health facility-based and outreach-based, both from
the health system and societal perspectives.
Vaccine delivery costs
The present study considered vaccine delivery related costs across three delivery strategies
(e.g., school-based, health facility-based and outreach-based). Costs were derived from an
existing costing study [41]. This study captured both financial and economic costs according
to theWHO guidelines [42], included eight cost parameters, and focused on the investment
and recurrent cost impacts ofHPV vaccination on existing vaccination services. Furthermore,
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the investment costs were defined as microplanning (e.g., per diems and travel allowances,
venue rental, transport and personnel time spent), training (e.g., training materials, statio-
nery), social mobilisation (e.g., facilitator time in meetings, production of television/radio
spots, posters, leaflets, value of teacher and volunteer time), and cold chain supplement. In
addition, recurrent costs were covered including vaccines, service delivery, monitoring and
evaluation, and waste disposal.
Cervical cancer treatment costs
Direct medical costs. Cervical cancer treatment costs were derived from a previous cost-
of-illness study considering four treatment procedures: localised cancer treatment, regional
cancer treatment, distant cancer treatment and terminal care [43]. The treatment costs were
estimated based on different parameters such as surgical (e.g., conisation, hysterectomy, radi-
cal hysterectomy) and non-surgical (e.g., radiation therapy, adjuvant radiation therapy,
chemo-radiation) [43]. Different types of activities included in cancer diagnosis were the direct
medical costs such as colposcopy, chest X-ray, computerised tomography scan, positron-emis-
sion tomography scan, magnetic resonance imaging, bone scan and cystoscopy. Other costs
included those related to inpatient care, emergency care, medicine costs, rehab, complex con-
tinuing care, long-term care, home care services, physician consultations, and non-physician
provider costs.
Indirect costs. Indirect costs of cervical cancer patients and vaccine receivers were
restricted to the loss of labour productivity due to ill health. Absenteeism-related data were
obtained for a cervical cancer episode from elsewhere [32]. Other indirect costs were estimated
using the human capital approach (S1 Table). The production losses were measured in both
monetary and quantitative terms (e.g., days of productivity loss) [44]. The value of unpaid
time devoted to own care and family defined caregivers [45]. The value of daily productivity
was measured based on an age-specific average wage [46]. The average daily wage of cervical
cancer patients were used for adult patients, and one-half of that wage was applied to teenager
patients. Intangible costs related to pain, discomfort and grief were excluded [46]. All costs
were converted into 2018 Australian dollars using the Consumer Price Index of Health Care
[47].
Dynamic modelling of HPV transmission and the impact of vaccination. A dynamic
cancer disease model was introduced to cover HPV transmission, HPV vaccination and cervi-
cal pre-cancer (Fig 1). The model incorporates demographics, economics, HPV attributable
fractions in cervical cancer and vaccine uptake assumptions, as detailed in Table 1. When
modelling the impact ofHPV vaccination, the model captured the effects of herd protection
(i.e., naturally acquired immunity) on the unvaccinated cohort. It was assumed that 9vHPV
vaccine type-specific (HPV types) efficacy in girls was 100% and that the duration of protection
was 20 years [19,27].
Sensitivity analysis. A deterministic sensitivity analysis was performed to examine the
robustness of the results. The output estimates varied for each value of the input parameters.
These prices were derived from the academic and anecdotal literature and aimed to determine
the impact of uncertainty in input assumptions on the ICERs.
Results
Model input parameters
Table 1 shows several input parameters, including the population cohort at birth, coverage of
full dose vaccine, vaccine effectiveness versusHPV-9 types, the price of vaccine, and vaccine
delivery costs per fully immunised girl. Cervical cancer treatment related costs per episode
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included direct costs (e.g., medical and non-medical costs) and indirect costs (e.g., loss of
labour productivity for patients and caregivers during treatment).DALYs incurred for nonfatal
and fatal cervical cancer episodes, and epidemiological data related to cervical cancer inci-
dence were used. The sizes of the female birth cohort and the cohort at immunisation age were
191,340 and 118,679, respectively. Vaccination coverage was 86%, whereas vaccine effective-
ness againstHPV infections was 95%. The price of the vaccine and direct and indirect vaccine
delivery costs were A$280, A$31.77, and A$17.59, respectively. Cervical cancer treatment costs
were A$61,272, wherein 53.78% (A$32,952) were direct costs and 46.22% (A$28,322) indirect
costs. These varied depending on the types of treatment and stages of cancer. Cervical cancer
incidence and mortality-related data were extracted from national sources and the GLOBO-
CAN-2018 study [48]. Methodological assumptions such as disability weights (for cancer diag-
nosis, non-terminal and terminal) are shown in Table 1. Vaccine protection was considered to
be 20 years as suggested by an expert panel and earlier research [49].
Cost-effectiveness estimates
The model estimates in Table 2 show the cost-effectiveness of the 9vHPV vaccination in Aus-
tralia under various assumptions about the cost of cervical cancer treatment and the cost of
vaccination across delivery strategies. The 9vHPV vaccination in Australia would cost the pub-
lic approximately A$28.11 million for this target population cohort, although several types of
treatment procedures would be transferred from the health system perspective and the value
of A$26.72 million from a societal perspective across the various vaccine delivery strategies
(e.g., school-based, health facility-based, outreach-based) would result. State and territory
school-based immunisation programs primarily implement the 9vHPV vaccination through
the NIP in Australia. Another two possible delivery strategies (e.g., health facility-based and
outreach-based) were also included for comparison. Overall, the ICER per DALY averted was
A$47,008 from a health system perspective and A$44,678 from a societal perspective, respec-
tively. Considering delivery strategies, the ICERs per DALY averted were A$47,605, $46,682
and $46,738 for school-based, health facility-based and outreach-based programs, respectively,
from the health system perspective. Whereas, from the societal perspective, the values were A
$46,378, A$43,729, and A$43,930 respectively. Both perspectives for ICERs per DALY averted
fell below the 2018 fiscal year GDP per capita in Australia (A$73,267), which is used as a
Fig 1. Simplified diagram of the model of HPV transmission, human impact of vaccination and disease outcomes
in Australia.
https://doi.org/10.1371/journal.pone.0223658.g001
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threshold for examining the cost-effectiveness of an intervention. Similarly, consistent results
were presented for the ICERs per life-year saved for both perspectives across delivery strategies
(Table 2). This evaluation signifies the cost-effectiveness of the 9vHPV vaccination from both
perspectives in Australia.
Table 1. Input parameter assumptions and sensitivity analysis.
Input parameters Health system perspective Societal perspective
Sensitivity analysis and
potential sources
Overall School-
based
Health
facilities-
based
Outreach-
based
Overall School-
based
Health
facilities-
based
Outreach-
based
Population
Population cohort at birth
(female) (‘000)
191.34 191.34 191.34 191.34 191.34 191.34 191.34 191.34 [50]
Population cohort at
vaccination age (female)
(‘000)
118.68 118.68 118.68 118.68 118.68 118.68 118.68 118.68
[40,51]
Target age group (yrs) 12 12 12 12 12 12 12 12 [39]
Vaccination and vaccine delivery costs
Vaccination coverage (full
doses)
86% 86% 86% 86% 86% 86% 86% 86% 72.00% -90.1% [51–55]
Vaccine effectiveness vs
HPV types1
95% 95% 95% 95% 95% 95% 95% 95% 85% -100% [25,52,53,56]
Price of vaccine per fully
immunised girl (FIG) (A$)
280 280 280 280 280 280 280 280 270–320 [32,41,57]
Direct costs of vaccine
delivery per FIG (A$)
31.77 35.27 29.86 30.19 31.77 35.27 29.86 30.19 [5,32,41]
Indirect costs of vaccine
delivery per FIG (A$)
- - - - 17.59 24.05 13.93 14.79
Total cost of vaccine
delivery cost per FIG (A$)
31.77 35.27 29.86 30.19 49.36 59.32 43.80 44.98
Total costs of vaccination
per FIG (A$)
311.77 315.27 309.86 310.19 329.36 339.32 323.80 324.98 300–500 [5,32,41]
Treatment cost per episode
Direct costs A$ (‘000) 32.95 32.95 32.95 32.95 32.95 32.95 32.95 32.95 [32,43]
Indirect costs (including
caregiver costs) A$ (‘000)
- - - - 28.32 28.32 28.32 28.32 [32,43]
Total treatment costs A$
(‘000)
32.95 32.95 32.95 32.95 61.27 61.27 61.27 61.27 36.05–71.05 [32,43]
Methodological assumptions
Disability weight for cancer
diagnosis
0.09 0.09 0.09 0.09 0.07 0.09 0.09 0.09 0.061–0.095 [10,32,58,59]
Disability weight for non-
terminal (per year)
0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.065–0.091 [10,32]
Disability weight for
terminal cancer
0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.70–0.90 (assumption)
Vaccine protection (years) 20 yrs 20 yrs 20 yrs 20 yrs 20 yrs 20 yrs 20 yrs 20 yrs 20 years [19]
Discount rate 5.0% 5.0% 5.0% 5.0% 5.0% 5.0% 5.0% 5.0% 3.0% -5.0%
[23,24,30,32,58,60]
Proportion of cervical
cancer cases that are
due to 1HPV-types
90.3% 90.3% 90.3% 90.3% 90.3% 90.3% 90.3% 90.3% 70% -95.0% [9,15,17,39]
Economic growth
GDP per capita, A$ 73,267 73,267 73,267 73,267 73,267 73,267 73,267 73,267 73,267 [61]
1HPV-6, 11, 16,18,31,33,45,52,58
https://doi.org/10.1371/journal.pone.0223658.t001
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Table 2. Outcomes of the vaccination program�.
Scenario Scenario– 1 Scenario—2
Perspective Health system perspective Societal perspective
Vaccine delivery strategies Overall School-
based
Health facilities-
based
Outreach-
based
Overall School-
based
Health
facilities-
based
Outreach-
based
Output parameters
Cohort size at birth (female), (‘000) 191.34 191.34 191.34 191.34 191.34 191.34 191.34 191.34
Cohort size at vaccination age (female)
(‘000)
118.68 118.68 118.68 118.68 118.68 118.68 118.68 118.68
Total costs of vaccination, A$ (‘000) 31,820.48 32,177.70 31,625.53 31,659.21 33,615.78 34,632.34 33,048.30 33,168.74
Total treatment costs averted, A$ (‘000) 3,709.75 3,709.75 3,709.75 3,709.75 6,898.41 6,898.41 6,898.41 6,898.41
Net costs of the vaccination, A$ (‘000) 28,110.73 28,467.95 27,915.78 27,949.47 26,717.37 27,733.93 26,149.90 26,270.33
Number of averted-
- Cervical cancers case averted 113 113 113 113 113 113 113 113
- Deaths averted 23 23 23 23 23 23 23 23
- Life years saved 543 543 543 543 543 543 543 543
Nonfatal DALYs averted 55 55 55 55 55 55 55 55
Incremental cost-effectiveness ratio
(ICER) per-
- Cervical cancers case averted, A$ 248,767 251,929 247,042 247,340 236,437 245,433 231,415 232,481
- Life saved, A$ 1,222,205 1,237,737 1,213,730 1,215,194 1,161,625 1,205,823 1,136,952 1,142,188
- Life year saved1, A$ 51,769 52,427 51,410 51,472 49,203 51,075 48,158 48,380
- DALYs averted1, A$ 47,008 47,605 46,682 46,738 44,678 46,378 43,729 43,930
Cost-effectiveness threshold
GDP per capita, A$ 73,267 73,267 73,267 73,267 73,267 73,267 73,267 73,267
Decision rules
- Very cost-effective1 Yes Yes Yes Yes Yes Yes Yes Yes
- Cost-effective2
- No cost-effective3
1Very cost-effective if ICER per DALYs averted< 1 time GDP per capita
2cost-effective if ICER per DALYs averted� 1 times GDP per capita and� 3 times GDP per capita
3no cost-effective if ICER per DALYs averted> 3 times GDP per capita.
�Costs and DALYs were discounted at 5% per year.
https://doi.org/10.1371/journal.pone.0223658.t002
Fig 2. Changes in input model parameters on ICER per DALY averted from a health system perspective.
https://doi.org/10.1371/journal.pone.0223658.g002
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Sensitivity analysis
Model uncertainty was investigated by changing the values of input parameters in the cost-
effectiveness model from the health system (Fig 2) and societal perspectives (Fig 3). The output
of the deterministic sensitivity analysis showed that the price of vaccine, vaccine delivery costs,
the incidence of cervical cancer, vaccination coverage, vaccine efficacy, and cervical cancer
treatment costs were the dominating parameters that influence the ICERs per DALY averted.
These findings are conservative, as only a simple static model of 9vHPV vaccination was con-
sidered. According to theWHO-CHOICE threshold, the 9vHPV vaccination is a very cost-
effective and favourable option for introduction in Australia. This analysis indicates that the
model outputs are robust to variation in the values of all parameters; however, there is a neces-
sity to confirm that the pricing of the vaccine is appropriate in the context of Australia.
Discussion
The present study is a comprehensive cost-effectiveness evaluation of the introduction of a
NIP with the new 9vHPV vaccine to adolescent girls in Australia. The impact of 9vHPV vacci-
nation on health and economic outcomes was measured using various model scenarios allow-
ing for the testing of three different vaccine delivery strategies.
The findings show that the new 9-valent vaccination of 12-year-old adolescent girls is highly
cost-effective, with ICERs per DALY of A$47,008 and A$44,678, from the health system and
societal perspectives, respectively. Although the 9vHPV vaccination has been implemented as
part of the school-based delivery strategy, the present study has emphasised two other hypo-
thetical delivery strategies, namely health facility-based and outreach-based programs. If the
9vHPV vaccination program is extended to these delivery outlets, the ICER remains highly
cost-effective at A$46,682/DALY averted for health facility-based and A$46,738/DALY averted
for outreach-based vaccination programs compared with a school-based vaccination program
(ICER = A$47,605/DALY averted). Considering the societal perspective, the 9vHPV vaccina-
tion also reports a very cost-effective outcome, with an ICER of A$46,378/DALY averted, A
$43,729/DALY averted, and A$43,930/DALY averted for the school-based, health facility-
based and outreach-based vaccination programs, respectively. It is noteworthy that the ICERs
are comparatively lower from the societal perspective in terms of vaccine delivery strategies
compared with the health system perspective.
Immunisation would still be very cost-effective from both the health system and societal
perspectives if the program is extended to encompass other delivery strategies. However, no
herd immunity was considered in the context of these strategies. This evaluation provides a
piece of initial evidence for the value of money of investments in the 9vHPV vaccination and
protection against transient and persistent infections ofHPV. Under the input model
Fig 3. Changes in input model parameters on ICER per DALY averted from a societal perspective.
https://doi.org/10.1371/journal.pone.0223658.g003
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assumptions, the present evaluation of the two-dose 9vHPV vaccination would be very cost-
effective across delivery strategies. From the societal perspective, the ICER per DALYs averted
was comparatively lower than the health system perspective in terms of delivery strategies. The
cost-effectiveness evaluation is significant even allowing for different vaccine delivery strate-
gies and vaccination model assumptions.
This study findings are consistent with the conclusions from the evaluation of cost-effec-
tiveness of the 9vHPV vaccination in other country settings including Austria [62], Canada
[19], Germany [28], Italy [5], Kenya and Uganda [30], South Africa [52], and the US [21,63].
These studies estimated that an immunisation programs with the 9vHPV vaccine was likely to
belong within an acceptance heuristic threshold level of cost-effectiveness or even reach cost-
saving status in different country settings. In Canada, the 9vHPV vaccine was offered to
school-aged girls and evidenced to be cost-effective at a price increment lower than CAN$24
[19]. Further, 9vHPV was found to be cost-effective in the US, if the incremental cost per dose
of the 9vHPV was less than US$13 for a gender-neutral strategy (school-aged girls only) from a
health system perspective [64]. From a societal perspective, the 9vHPV vaccine would also be
considered very cost-effective at the national and state levels in the US if the vaccine price of
9vHPV was US$148 per dose (in 2016) [65], whereas two-dose schedules of the 9vHPV vaccine
were likely more cost-efficient compared with three-dose schedules considering the popula-
tion-level effectiveness [18]. Another recent study showed that introducing a universal 9vHPV
vaccination in Germany would yield noteworthy incremental public health benefits and be
highly cost-effective [28].
The present evaluation was performed among school-aged preadolescent girls (i.e., 12 years
of age). Previous studies confirmed that vaccination of girls only was commonly more effective
versus vaccination of both genders in different settings [28,32]. The two-dose 9vHPV vaccina-
tion approach is recommended for the target cohort of adolescent girls aged 12 to 14 years for
several reasons [39]. Giving the vaccination at this age is likely to ensure immunization before
their first sexual encounter and HPV exposure. As a result, the immune response tends to be
stronger and more long-lasting when the vaccine is present in preadolescent girls. A vaccina-
tion schedule againstHPV would allow for a more efficient primary strategy by protecting
females exposed to male partners and unvaccinated females to preventHPV transmission
[9,28,63]. Eventually it would provide additional benefits to potentially accomplish virus eradi-
cation [28].
Most previous studies pay little attention to comparing the cost-effectiveness from the
health system and societal point of views across vaccine delivery strategies. Thus, the evidence
produced is not sufficient for health policymakers to decide upon effective or conclusive strate-
gies. This study findings however provides effective and efficient empirical evidence of its eco-
nomic viability. Health policymakers can use this evidence for the allocation of health
resources and extend their vaccination program to other country settings to ensure optimal
health gains.
This study has some strengths that should be highlighted. This vaccination is justified over-
all by epidemiological and health and economic outcomes. Under the input model assump-
tions, this study demonstrates that the 9vHPV vaccination is economically viable from both
the health system and societal perspectives. A broader societal perspective calculates additional
benefits of the new vaccine that are mainly associated with reduced productivity losses.HPV-
related cervical lesions lead to a loss or reduction of women’s household income due to high
productivity loss (presenteeism) and absenteeism [66]. Ultimately, HPV related diseases lead
to a decrease in a victim’s socioeconomic position, which is costly for working women, their
employers, and the economy. The study findings show distinctly that three vaccine delivery
strategies (e.g., school-based, health facilities and outreach-based) are cost-effective. This is
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significant for health policymakers, strategic leaders, health scientists, cancer experts and pub-
lic health professionals to help promote further implementation and extension of vaccination
via a universal immunisation strategy.
This study also has some caveats. Little evidence is available on the health and economic
burden of cervical cancer in Australia. Some of the model parameters related to indirect costs
for cervical cancer treatment and costs of vaccination across vaccine delivery strategies (e.g.,
school-based, health facility-based, and outreach-based) are not available for Australia. Indi-
rect costs of patients (e.g., opportunity costs) in terms of absenteeism due to cervical cancer
and caregiver time were taken from the academic literature and anecdotal evidence in Austra-
lia and international sources. In this context, the cost-of-illness study would be appropriate for
measuring the productivity losses of patients and their caregivers. However, due to a limited
timeframe it was not able to conduct a cost-of-illness study among cervical cancer patients. It
was presumed that the 9vHPV vaccine would be delivered to both boys and girls, but that it
would only be cost-effective among girls, as the direct health impacts for 9vHPV is expected to
be small for boys. This study used the GDP per capita thresholds level as defined by CMH. The
GDP threshold might be a suitable screening method but should not be the only consideration
for vaccination investment as there are other issues such as feasibility, affordability, alternative
interventions and other local considerations which are not accounted for in the threshold level
decision rule. Finally, the study findings were generated for the national context in Australia
and might vary by state or regional settings, depending on cervical cancer outcomes (e.g., inci-
dence, mortality), treatment procedures, cancer stages, costs of vaccination, and coverage of
immunisation.
Conclusions
This study is an extensive cost-effectiveness analysis of 9vHPV vaccination in Australia from
both the health system and societal perspectives. The introduction of the 9vHPV immunisation
is assessed to be very cost-effective from both perspectives. It incorporated three delivery strat-
egies (school-based, health facility-based, and outreach-based). However, this high-value vac-
cination would need substantial upfront investments. Considering a two-dose schedule, the
9vHPV vaccination demonstrated ‘good value for money’, if the vaccination could accomplish
a high vaccination coverage and provide protection. The findings of this evaluation contribute
to decision-making about the incorporation of the 9vHPV vaccine into a universal cervical
cancer vaccination program in Australia. With continued assessment of the potential vaccine
properties as well as vaccine delivery and scale-up strategies, the two-dose 9vHPV vaccine
would provide significant health and economic benefits for preadolescents and society. Finally,
the success of 9vHPV vaccination will be contingent on several predominating factors includ-
ing value for money, feasibility, acceptability, and affordability.
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Chapter 3: Conclusions 
This chapter is an overview of the findings of the thesis, together with suggestions to 
strengthen healthcare services, improve educational materials and general 
information given to cancer survivors. Future research scope and questions are also 
suggested. The advantages of adopting longitudinal design and health economics 
approaches, using a quantitative approach are discussed.  
3.1 Introduction 
A longitudinal and health economics perspectives-based, quantitative study of the 
cancer burden and economic viability of cancer prevention strategy (cancer 
vaccination) has sought to investigate patient adverse experiences over extended 
periods of time. The findings from this thesis may assist medical/health and allied 
professionals and health policymakers to understand issues and concerns related to 
long-term cancer burden. Note also that these issues may not be static. Subsequent 
recommendations may help other individuals diagnosed with cancer in the future to 
make informed choices and to reduce the burdens they may suffer. The following 
discussion briefly highlights findings from each of the studies, presented in more 
detail in chapter 2, and then discusses them more generally.  
3.2 Overview of the key findings from chapter 2 (Studies 1-5).  
The major findings of the study are divided into three themes as follows:  
3.2.1 Understanding the challenges of cancer outcomes (Study 1) 
Cancer incidence (annual average percentage change, AAPC = 1.33%), 
hospitalisation (AAPC =1.27%), cancer-related mortality (AAPC = 0.76%), and 
burden of cancer (AAPC = 0.84%) all increased significantly over the period of 
1982-2014. The same-day (AAPC = 1.35%) and overnight (AAPC = 1.19%) 
hospitalisation rates also showed an increasing trend. Furthermore, the ratio (least-
most advantaged economic resources ratio, LMR of mortality) and (LMR of 
incidence) was especially high for cervix (M/I = 1.80), prostate (M/I = 1.51), 
melanoma (M/I = 1.33), Non-Hodgkin Lymphoma (M/I = 1.32) and breast (M/I = 
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1.31), suggesting that survival inequality was most pronounced for these cancers. In 
addition, people who lived in deprived socioeconomic status were more likely to 
bear an increasing cancer burden in terms of incidence, mortality and death.  
3.2.2 Long-term health status burden, chronic comorbid conditions, productivity-
related disability, and its consequences over the extended period (Studies 2-4) 
A longitudinal health status burden of cancer survivors was prominent among this 
Australian sample (Study 2). Approximately 36% of cancer survivors had an initial 
extreme health status burden in 2013, while this had declined significantly (21%) by 
2017. This was evidenced in significant improvements in body pain, social 
functioning, and mental health measures. Several individual-level factors, including 
an adequate level of physical activity, social support, and higher economic status, 
were significantly associated with improving health status. In contrast, factors that 
significantly determined increaseing health status burden included being 
unemployed, Indigenous, uninsured, and living in a regional location (Study 2, 
Article II).   
 
However, the majority of cancer patients suffer from chronic diseases or comorbid 
conditions. In the case of cancer, chronic comorbidity refers to the existence of one 
or more additional conditions in a person simultaneously. The risk of having 
comorbidity increases during treatment as well as oncology follow-up periods 
(AIHW, 2018, 2019; WHO, 2018), which then adversely influences treatment 
choices and outcomes. Understanding more about comorbidities among cancer 
patients can generate possible evidence as well as provide direction for prevention, 
management, and treatment of chronic diseases. Concerning chronic comorbid 
conditions, 61% of cancer patients experienced at least one chronic disease over the 
oncology follow-up period, and 21% of patients experienced three or more chronic 
diseases (Study 3, Article III). Furthermore, a higher risk of chronic comorbid 
conditions was greatly evidenced with cancer patients aged 65 years or over, 
inadequate levels of physical activity, patients who suffered from an extreme or 
moderate health burden, and patients living in the poorest households. The 
importance of comorbidities in cancer patients draws from an increasing awareness 
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of their impacts on cancer care and outcomes. Chronic comorbid conditions of 
cancer patients contribute to a major clinical challenge in terms of long-term health 
conditions or illness (e.g., disability) (Stairmand et al., 2015).  
Also, the burden of cancer imposes a long-term productivity-related disability that 
leads to an economic burden on the individual, family and society. Lost productivity, 
loss/reduction of household income, and increased expenditure due to illness 
resulting in reduced earnings and higher expenditure, which consequently lead to a 
decrease in their socioeconomic position. In Australia, 50% of cancer survivors 
suffer from a long-term productivity-related disability, amongst whom 18% of 
patients have experienced extreme level disability (Study 4, Article IV). In addition, 
the magnitude of disability levels increases significantly with the level of health 
burden. For instance, a cancer survivor who faces a severe health burden faces a 5.32 
times higher risk of having a productivity-related disability compared with patients 
who have reported no health burden. The disability level is extended among patients 
who engage in an unhealthy lifestyle (e.g., inadequate levels of physical activities, 
those who drink alcohol or smoke tobacco).  
3.2.3 Economic evaluation of cancer prevention program (cancer vaccination)     
        (Study 5) 
The World Health Organization (WHO) recommends that programs including cancer 
vaccination are recognised to be economically viable before implementation. With 
the availability of vaccines against the different HPV infection types, there are good 
opportunities for primary prevention to add to continuing efforts with secondary 
prevention strategies. However, the decision for any country to add a new vaccine to 
national immunization programs requires careful assessment of the relative value of 
the vaccine compared with alternative uses of the required resources (i.e., cost-
effectiveness) and its affordability (i.e., budgetary impact). The WHO has 
recommended several types of common vaccine delivery strategies for different 
country settings. One example is vaccine delivery at healthcare facilities and via 
outreach routes (e.g. school-based program) and campaigns. A combined vaccine 
delivery strategy may be required to ensure access amongst the entire target 
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population. However, previous cost-effectiveness evaluations have considered only a 
health system or societal perspective in isolation, or both perspectives along with a 
single vaccine delivery route. 
Despite some heterogeneity in approaches to measuring cost-effectiveness, ten 
studies concluded that 9vHPV vaccination was cost-effective while two studies 
concluded that they were not (Study 5; Article-V). The addition of adolescent boys 
into an immunisation program was cost-effective when the vaccine price and 
coverage was comparatively low. When vaccination coverage for females was 75% 
or more, gender-neutral HPV vaccination was less cost-effective than when targeting 
only girls aged 9–18 years. A multi-cohort immunization approach was cost-
effective in the age range of 9–14 years, but the upper age limit at which vaccination 
was no longer cost-effective needs to be further evaluated (Study 5; Article-V) within 
a global context.  
In Australia, the 9vHPV vaccination was estimated to prevent 113 new cases of 
cervical cancer (discounted) during a 20-year period (Study 5, Article VI). From 
health system and societal perspectives, the 9vHPV vaccination was very cost-
effective in comparison with the status quo, with an ICER of A$47,008 and 
A$44,678 per DALY averted, respectively, using the heuristic cost-effectiveness 
threshold level. Considering delivery strategies, the ICERs per DALY averted were 
A$47,605, A$46,682, and A$46,738 for school, health facilities, and outreach-based 
vaccination programs from the health system perspective, while from the societal 
perspective, the ICERs per DALY averted were A$46,378, A$43,729, A$43,930, 
respectively.  
3.3 Limitations 
Despite the compelling findings of this study, there are limitations. Due to the 
paucity of survival data, this study has not captured inequalities regarding cancer 
survivorship in detail (Study 1). However, there is limited understanding about what 
is driving the changes of cancer outcomes reported in this thesis, which may reflect 
random variation or changes in unknown risk factors, and therefore highlight the 
need for more research into the aetiology of cancer. 
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Study participants (Study 2-4) were derived from the HILDA survey, which covers 
the health, economic, employment, income and health characteristics of Australian 
household members aged 15 years and older. Children who suffered from cancer 
were not included in this study. This study considered the overall health status of 
cancer survivors, which might vary in terms of cancer stages and types of cancer. 
The authors were not able to measure the cancer-specific health status of cancer 
patients due to the paucity of available information. Examining the long-term health 
status burden, chronic comorbid conditions, and productivity-related disability is 
widely perceived to have substantial potential as an endpoint in health outcomes 
research; however, results are partially dependent upon study methods and outcome 
variables of interest. The participants of the present study (Study 2-4) were derived 
from the protocol “HILDA study” (Summerfield et al., 2018), and long-term health 
conditions of cancer patients might change for independent study designs as well as 
the application of survey instruments. 
In the HILDA survey waves, the length of the survey period may have introduced 
uncontrolled bias, as changes in health status are not instantaneous and might emerge 
only after time, which was not captured in this study. Due to funding restrictions and 
the study’s timeframe, this research did not consider cancer patients who registered 
for cancer surveillance as well as received health care services from health facilities 
(e.g., private clinics, community clinics, secondary or tertiary hospitals).  
Due to the paucity of cancer-related data in the HILDA study, the researcher was 
unable to perform cancer-specific or period of treatment related calculations. 
Furthermore, the study findings were based on self-reported information that might 
have been impacted by respondents’ prejudice (e.g., silence and over-response), or 
by problems in understanding and interpretation.  
In Study 5, the economic evaluation of cancer vaccination (cost-effectiveness 
analysis) based on GDP thresholds of 1–3 times the GDP per capita, lacks country 
specificity and has little meaning for other country-level decision making (Bertram 
et al., 2016). It is uncertain whether this threshold truly reflects the country’s 
affordability or societal willingness to pay for additional health gains. Additionally, 
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GDP  was originally intended to measure the experience of people residing in urban 
areas and thus, it may not actually reflect the experience of the entire population in a 
country, especially those living in rural areas. Apart from an economic standpoint, 
other factors should be considered for the national immunization program, such as 
budget availability, political issues, cultural influences and availability of a 
healthcare workforce. Some of the model parameters (Study 5, Article VI) related to 
indirect costs for cervical cancer treatment and costs of vaccination across vaccine 
delivery strategies (e.g., school-based, health facility-based, and outreach-based) 
were not available for Australia. Indirect costs of patients (e.g., opportunity costs) in 
terms of absenteeism due to cervical cancer and caregiver time were taken from the 
academic literature and anecdotal evidence from Australia and international sources. 
In this context, a cost-of-illness study would be appropriate for measuring the 
productivity losses of patients and their caregivers. However, due to a limited 
timeframe it was not  possible to conduct a cost-of-illness study among cervical 
cancer patients. It was presumed that the 9vHPV vaccine would be delivered to both 
boys and girls, but that it would only be cost-effective amongst girls, as the direct 
health impacts for 9vHPV is expected to be small for boys. This study used the GDP 
per capita thresholds level, as defined by the WHO Commission on Macroeconomics 
and Health. The GDP threshold might be a suitable screening method but should not 
be the only consideration for vaccination investment as there are other issues, such as 
feasibility, affordability, alternative interventions and other local considerations, 
which are not accounted for in the threshold level decision rule. Finally, the study’s 
findings were generated for the national context of Australia and might vary by state 
or regional settings, depending on cervical cancer outcomes (e.g., incidence, 
mortality), treatment procedures, cancer stages, costs of vaccination, and coverage of 
immunisation.   
3.4 Contribution of the thesis  
This thesis contributes to the existing literature by providing first-hand evidence on 
the trends, determinants and inequalities of incidence, mortality and burden of 
cancer, using Australian nationally representative population-based data (2,784,148 
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registered cancer cases) over the past 33 years (Study 1). The study’s findings also 
provide authorities with national evidence about the trends and magnitude of the 
inequalities in the cancer burden and hopefully assist in developing low-cost 
interventions to reduce this burden.  
Considering the longitudinal perspective, these studies (Study 2-4) have proposed the 
development of a better understanding of long term follow-ups, and the application 
of well-validated and reliable longitudinal wave measures of the impacts of a cancer 
diagnosis on the long-term health status burden, chronic comorbid conditions and 
productivity-related disability of individuals over the 2003-2017 period. This study 
thus complements and contributes to this strand of ongoing cancer research to 
increase awareness and improve public health practice among sufferers and 
survivors, and to measure impact.  
These findings will help to improve the understanding of potential employment 
opportunities after a cancer diagnosis. In addition, these findings may be considered 
from different perspectives in cancer policy discussions: the cancer survivor (e.g., 
health status burden, chronic comorbid conditions, productivity-related disability 
level and return to employment), the caregiver and the family (e.g., the health 
burden, reduction of socio-economic position and risk of poverty), the employer and 
co-workers (e.g., employment conditions, workload), the health care provider (e.g., 
supportive care needs, effective programs and interventions), and the community or 
society (e.g., economic and policy changes). The findings could contribute to the 
design of appropriate interventions and/or the provision of quality healthcare 
services and resources for ongoing surveillance of people living with, through and 
beyond cancer, and help determine what kinds of support survivors need. The study 
results could be used to better outline the management of a sequelae course of 
treatment for those who should undergo more intensive physical rehabilitation aimed 
at reducing the risk of adverse health outcomes, such as long-term health status 
burden, chronic comorbid conditions, and productivity-related disability levels.  
Given the clinical significance of comorbidity in cancer survivors, this study may 
play a significant role in providing comprehensive evidence for health care 
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providers, including physical therapists and oncologists, who should be aware of the 
unique problems that challenge this population and who should advocate for 
prevention and evidence-based interventions.  
This thesis has proposed new measurement levels of health status burden in terms of 
SF-36 scores. The levels of health status burden are proposed based on the 
magnitude of quality of life scores as follows: (1) high burden if the short form-36 
(SF-36) scores < 50.00, (2) moderate burden if 50.00 ≤ SF-36 scores < 90.00, and (3) 
no burden if SF-36 scores ≥ 90.00. The levels of health status burden have captured 
the severity of disease for cancer patients. This proposed levels of health status 
burden will play a significant role in measuring the patient-level health burden.   
Concerning the economic viewpoint, this study’s (Study 5) findings are anticipated 
to support policy-makers in extending immunization programs by either switching to 
the 9-valent vaccine or the inclusion of adolescent boys’ vaccination, or extending 
the age of vaccination. This study is an extensive cost-effectiveness analysis of 
9vHPV vaccination in Australia from both the health system and societal 
perspectives. The introduction of 9vHPV immunisation is assessed as being very 
cost-effective from both the health system and societal perspectives, by 
incorporating three delivery strategies (school-based, health facility-based, and 
outreach-based). Considering a two-dose schedule, the 9vHPV vaccination 
demonstrated ‘good value for money’, if the vaccination could accomplish a high 
vaccination coverage and provide protection. The findings of this evaluation 
contribute to decision-making about the incorporation of the 9vHPV vaccine into a 
universal cervical cancer vaccination program in Australia. With continued 
assessment of the potential vaccine properties, as well as vaccine delivery and scale-
up strategies, the two-dose 9vHPV vaccine would provide significant health and 
economic benefits for preadolescents and society. Finally, the success of 9vHPV 
vaccination will be contingent on several predominating factors including value for 
money, feasibility, acceptability, and affordability. 
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3.5 Future research directions  
This study’s findings have established a relationship between cancer burden and the 
long-term impacts on health status burden, chronic comorbid conditions, and 
productivity-related work disability among cancer survivors, which might vary in 
terms of cancer stages and types of cancer. However, the researcher was not able to 
estimate the cancer-specific health burden nor the work disability of cancer survivors 
due to the paucity of relevant data. A future study is required that will use a similar 
study design, perspective, and analytical methods in terms of cancer-specific 
exploration.  
 
3.6 Conclusions  
Resource scarcity is commonly recognised in healthcare provision worldwide, 
including Australia. This thesis has documented an understanding of the challenges 
of cancer outcomes and long-term consequences on health status burden, chronic 
comorbid conditions, and productivity-related work disability, and has provided an 
evaluation of cancer vaccination for preventing cancer-related infections, along with 
contributing to the ongoing debate of cancer research.  
From the findings, it can be concluded that policies for cancer prevention strategies 
should have a high priority in policy discussions. If equally priced, the cancer 
vaccination option is the most economically viable intervention. Overall, this 
analysis has sought to contribute to an evidence-based recommendation about the 
new 9vHPV vaccination in the national immunisation program in Australia. Apart 
from an economic standpoint, other factors should be considered for the national 
immunization program, such as budget availability, political issues, cultural 
influences and availability of a healthcare workforce. As cancer-related illness is 
life-threating for a high-risk population, the thesis argues that universal vaccination 
programs should be introduced as these early prevention programs could avert the 
number of cases, deaths, disability-adjusted life years, and hospitalisations. 
However, an optimum decision should be made by comparing vaccination programs 
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with alternative public health and healthcare low-cost interventions in Australia to 
reduce this burden (e.g., cancer case management strategies, other early cancer 
prevention programs, and increasing public health awareness about avoidable risks 
of cancer in the community). The findings have further implications for improving 
public health policy and reducing population-level unhealthy lifestyles, which should 
be recommended.     
The overall burden of cancer is substantial in Australia across all socio-economic 
strata and geographical regions. Compared with socio-economically advantaged 
people, disadvantaged people had a substantially higher risk of cancer incidence and 
cancer-related mortality. Those living in remote areas also bear a higher burden than 
those in urban areas who are closer to prevention and treatment services. The 
findings of this study can inform efforts by health care policymakers and those 
involved in healthcare systems to improve cancer survival in Australia. This work 
further suggests that the provision of universal cancer care can reduce the burden by 
ensuring that curable and preventive cancer care services are accessible to all people 
regardless of socio-economic status or location. It is also significant for health care 
providers, including physical therapists and oncologists, who must manage the 
unique problems that challenge this population and who should advocate for 
prevention and evidence-based interventions by incorporating comprehensive social 
supports. In this context, more research on this public health problem is required 
before any decision should be made. 
It is therefore anticipated that the present study will be useful for informing  
policymakers with the necessary knowledge to make rational investment choices in 
preventing cancer-related infections.  
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Appendix A1. Search strategies (study 5, article V) 
PubMed  
#1 
 (hpv[Title] OR papilloma⁄[Title] OR cervi⁄[Title]) AND (vaccine⁄ OR vaccinated OR 
vaccination OR vaccinated OR immune⁄) AND (non-valent/ OR 9 or nine-valent/) 
AND (cost[Title/Abstract] OR costs[Title/ Abstract] OR cost-effective⁄ OR cost-
utility⁄ OR cost-benefit⁄) AND (analysis OR economic evaluation⁄) AND (cervical 
cancer).  
 
OR  
#2 (((cost-effectiveness analysis OR cost-benefit analysis OR cost-utility analysis OR 
economic evaluation) AND (cervical cancer) AND (vaccine OR vaccination) AND 
(human papillomavirus OR HPV))) OR ((hpv[Title] OR papilloma⁄ [Title] OR 
cervi⁄[Title]) AND (vaccine⁄ OR vaccinated OR vaccination OR vaccinated OR 
immune⁄) AND (non-valent/ OR 9 or nine-valent/) AND (cost[Title/ Abstract] OR 
costs[Title/Abstract] OR cost-effective⁄ OR cost-utility⁄ OR cost-benefit⁄) AND 
(analysis OR economic evaluation⁄) AND cervical cancer) 
 
Scopus 
# 1 
TITLE-ABS-KEY ("Economic evaluation" OR "Cost-effectiveness" OR "Cost-
benefit analysis" OR "Cost-utility analysis" OR "Analysis" OR "Human 
papillomavirus" OR "HPV" OR "Vaccine" OR "Vaccinated" OR "Vaccination" OR 
"Cervical cancer" AND "non-valent" OR "9-Valent")) 
# 2 
TITLE-ABS-KEY("Economic evaluation" OR "Cost-effectiveness" OR "Cost-benefit 
analysis" OR "Cost-utility analysis" OR "Analysis" OR "Human papillomavirus" OR "HPV" 
OR "Vaccine" OR "Vaccinated" OR "Vaccination" OR "Cervical cancer" AND "non-valent" 
OR "9-Valent" ) AND ( LIMIT-TO ( PUBYEAR,2019) OR LIMIT-TO ( PUBYEAR,2018) OR 
LIMIT-TO (PUBYEAR,2017) OR LIMIT-TO (PUBYEAR,2016) OR LIMIT-TO ( PUBYEAR,2015) 
OR LIMIT-TO ( PUBYEAR,2014) OR LIMIT-TO ( PUBYEAR,2013) OR LIMIT-TO 
(PUBYEAR,2012) OR LIMIT-TO (PUBYEAR,2011) OR LIMIT-TO (PUBYEAR,2010) OR LIMIT-
TO ( PUBYEAR,2009) OR LIMIT-TO ( PUBYEAR,2008) OR LIMIT-TO (PUBYEAR,2007) OR 
LIMIT-TO (PUBYEAR,2006) OR LIMIT-TO (PUBYEAR,2005) OR LIMIT-TO ( PUBYEAR,2004) 
OR LIMIT-TO (PUBYEAR,2003) OR LIMIT-TO (PUBYEAR,2002) OR LIMIT-TO 
(PUBYEAR,2001) OR LIMIT-TO ( PUBYEAR,2000))  
 
 
 
185
Produced with a Trial Version of
  
 
# 3 
TITLE-ABS-KEY ("Economic evaluation"  OR  "Cost-effectiveness"  OR  "Cost-benefit 
analysis"  OR  "Cost-utility analysis"  OR  "Analysis"  OR  "Human 
papillomavirus"  OR  "HPV"  OR  "Vaccine"  OR  "Vaccinated"  OR  "Vaccination"  OR  "Cervical 
cancer"  AND  "non-valent"  OR  "9-Valent")  AND  (LIMIT  
TO (PUBYEAR ,  2019)  OR  LIMIT-TO (PUBYEAR ,  2018)  OR  LIMIT-
TO ( PUBYEAR ,  2017)  OR  LIMIT-TO (PUBYEAR ,  2016)  OR  LIMIT-
TO ( PUBYEAR ,  2015)  OR  LIMIT-TO (PUBYEAR ,  2014)  OR  LIMIT-
TO ( PUBYEAR ,  2013)  OR  LIMIT-TO (PUBYEAR ,  2012)  OR  LIMIT-
TO ( PUBYEAR ,  2011)  OR  LIMIT-TO (PUBYEAR ,  2010)  OR  LIMIT-
TO ( PUBYEAR ,  2009)  OR  LIMIT-TO (PUBYEAR ,  2008)  OR  LIMIT-
TO ( PUBYEAR ,  2007)  OR  LIMIT-TO (PUBYEAR ,  2006)  OR  LIMIT-
TO ( PUBYEAR ,  2005)  OR  LIMIT-TO (PUBYEAR ,  2004)  OR  LIMIT-
TO ( PUBYEAR ,  2003)  OR  LIMIT-TO (PUBYEAR ,  2002)  OR  LIMIT-
TO ( PUBYEAR ,  2001)  OR  LIMIT-TO (PUBYEAR ,  2000) )  AND  ( LIMIT-
TO ( DOCTYPE ,  "ar" ) ) 
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Systematic review
This record cannot be edited because it has been rejected
 
1. * Review title.
 
Give the working title of the review, for example the one used for obtaining funding. Ideally the title should
state succinctly the interventions or exposures being reviewed and the associated health or social problems.
Where appropriate, the title should use the PI(E)COS structure to contain information on the Participants,
Intervention (or Exposure) and Comparison groups, the Outcomes to be measured and Study designs to be
included.
Mapping of the 9-Valent human papillomavirus (HPV) vaccination to prevent cervical cancer: A systematic
review
2. Original language title.
 
For reviews in languages other than English, this field should be used to enter the title in the language of the
review. This will be displayed together with the English language title.
3. * Anticipated or actual start date.
 
Give the date when the systematic review commenced, or is expected to commence.
 
27/09/2018
4. * Anticipated completion date.
 
Give the date by which the review is expected to be completed.
 
31/07/2019
5. * Stage of review at time of this submission.
 
Indicate the stage of progress of the review by ticking the relevant Started and Completed boxes. Additional
information may be added in the free text box provided.
Please note: Reviews that have progressed beyond the point of completing data extraction at the time of
initial registration are not eligible for inclusion in PROSPERO. Should evidence of incorrect status and/or
completion date being supplied at the time of submission come to light, the content of the PROSPERO
record will be removed leaving only the title and named contact details and a statement that inaccuracies in
the stage of the review date had been identified.
This field should be updated when any amendments are made to a published record and on completion and
publication of the review. If this field was pre-populated from the initial screening questions then you are not
able to edit it until the record is published.
 
The review has not yet started: No
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Preliminary searches Yes Yes
Piloting of the study selection process Yes Yes
Formal screening of search results against eligibility criteria Yes Yes
Data extraction Yes No
Risk of bias (quality) assessment Yes No
Data analysis No No
Provide any other relevant information about the stage of the review here (e.g. Funded proposal, protocol not
yet finalised).
 
6. * Named contact.
 
The named contact acts as the guarantor for the accuracy of the information presented in the register record.
 
Rashidul Mahumud
Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence:
 
Mr Mahumud
7. * Named contact email.
 
Give the electronic mail address of the named contact. 
 
rashidul.icddrb@gmail.com
8. Named contact address
 
Give the full postal address for the named contact.
 
Health Economics Research, Health Systems and Population Studies Division, icddr,b, 68, Shaheed
Tajuddin Ahmed Sarani, Mohakhali, Dhaka-1212, Bangladesh
9. Named contact phone number.
 
Give the telephone number for the named contact, including international dialling code.
 
8801913684183
10. * Organisational affiliation of the review.
 
Full title of the organisational affiliations for this review and website address if available. This field may be
completed as 'None' if the review is not affiliated to any organisation.
 
icddr,b
Organisation web address:
 
www.icddrb.org
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11. * Review team members and their organisational affiliations.
 
Give the personal details and the organisational affiliations of each member of the review team. Affiliation
refers to groups or organisations to which review team members belong. NOTE: email and country are
now mandatory fields for each person.
 
Mr Rashidul Mahumud. icddr,b
Professor Khorshed Alam. Health Economics and Policy Research, University of Southern Queensland,
QLD, Australia
Syed Karamat. Health Economics and Policy Research, University of Southern Queensland, QLD, Australia
Professor Jeff Gow. Health Economics and Policy Research, UNiversity of Southern Queensland, QLD,
Australia
Professor Jeff Dunn. Cancer Council Queensland, Australia
Professor Khorshed Alam. Health Economics and Policy Research, University of Southern Queensland,
QLD, Australia
12. * Funding sources/sponsors.
 
Give details of the individuals, organizations, groups or other legal entities who take responsibility for
initiating, managing, sponsoring and/or financing the review. Include any unique identification numbers
assigned to the review by the individuals or bodies listed.
The study was conducted during the first author’s PhD research at the University of Southern Queensland,
Australia. This study was conducted without financial support from any institute or organization.
Grant number(s)
13. * Conflicts of interest.
 
List any conditions that could lead to actual or perceived undue influence on judgements concerning the
main topic investigated in the review.
 
None
 
14. Collaborators.
 
Give the name and affiliation of any individuals or organisations who are working on the review but who are
not listed as review team members. NOTE: email and country are now mandatory fields for each
person.
 
Dr Shariful Islam. Deakin University
15. * Review question.
 
State the question(s) to be addressed by the review, clearly and precisely. Review questions may be specific
or broad. It may be appropriate to break very broad questions down into a series of related more specific
questions. Questions may be framed or refined using PI(E)COS where relevant.
What is the magnitude of cost-effectiveness of HPV vaccine to prevent cervical cancer?
16. * Searches.
 
State the sources that will be searched. Give the search dates, and any restrictions (e.g. language or
publication period). Do NOT enter the full search strategy (it may be provided as a link or attachment.)
Scopus, PubMed, the Cochrane Library, Web of Science, Google Scholar, Academic Search, Global Health
and Embase databases will be searched systematically according to the eligibility criteria. The existing
literature in the cost-effectiveness of 9-valent HPV vaccination will be reviewed. Exclusion of articles will be
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done based on: ‘not cost-effectiveness analyses, ‘insufficient cost and cost-effectiveness related data’, or
‘not using nine-valent HPV vaccine’. Language restrictions will not be considered.
17. URL to search strategy.
 
Give a link to a published pdf/word document detailing either the search strategy or an example of a search
strategy for a specific database if available (including the keywords that will be used in the search
strategies), or upload your search strategy.Do NOT provide links to your search results.
 
 
 
Alternatively, upload your search strategy to CRD in pdf format. Please note that by doing so you are
consenting to the file being made publicly accessible.
 
 
Yes I give permission for this file to be made publicly available
18. * Condition or domain being studied.
 
Give a short description of the disease, condition or healthcare domain being studied. This could include
health and wellbeing outcomes.
Published original academic literature that had a quantitative nature to examine the cost-effectiveness of
9vHPV vaccination were included in the systematic review. This study was considered a wide type of study
perspectives including societal and health systems
19. * Participants/population.
 
Give summary criteria for the participants or populations being studied by the review. The preferred format
includes details of both inclusion and exclusion criteria.
Target population characteristics (e.g., gender-neutral, multiple age cohort immunization) will be considered
in this review. Inclusion: adolescents and adults (less than 26 years old) will be considered the age group.
Exclusion: adults with more than 26 years old for male and female. 
20. * Intervention(s), exposure(s).
 
Give full and clear descriptions or definitions of the nature of the interventions or the exposures to be
reviewed.
To introduce HPV vaccine to prevent cervical cancer
21. * Comparator(s)/control.
 
Where relevant, give details of the alternatives against which the main subject/topic of the review will be
compared (e.g. another intervention or a non-exposed control group). The preferred format includes details
of both inclusion and exclusion criteria. 
Vaccinated vs non-vaccinated
22. * Types of study to be included.
 
Give details of the types of study (study designs) eligible for inclusion in the review. If there are no
restrictions on the types of study design eligible for inclusion, or certain study types are excluded, this should
be stated. The preferred format includes details of both inclusion and exclusion criteria.
Published original academic literature that had a quantitative nature to examine the cost-effectiveness of
9-valent HPV vaccine were included in the systematic review
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23. Context.
 
Give summary details of the setting and other relevant characteristics which help define the inclusion or
exclusion criteria.
24. * Main outcome(s).
 
Give the pre-specified main (most important) outcomes of the review, including details of how the outcome is
defined and measured and when these measurement are made, if these are part of the review inclusion
criteria.
Incremental cost-effectiveness ratio (ICERs), DALY averted, QALY gained
* Measures of effect
 
Please specify the effect measure(s) for you main outcome(s) e.g. relative risks, odds ratios, risk difference,
and/or 'number needed to treat.
To introduce nine-valent HPV vaccine to prevent cervical cancer
25. * Additional outcome(s).
 
List the pre-specified additional outcomes of the review, with a similar level of detail to that required for main
outcomes. Where there are no additional outcomes please state ‘None’ or ‘Not applicable’ as appropriate
to the review
None
* Measures of effect
 
Please specify the effect measure(s) for you additional outcome(s) e.g. relative risks, odds ratios, risk
difference, and/or 'number needed to treat.
None
26. * Data extraction (selection and coding).
 
Describe how studies will be selected for inclusion. State what data will be extracted or obtained. State how
this will be done and recorded.
The study selection process will be conducted in line with the PRISMA guidelines. Data extraction will be
performed to develop a comprehensive data matrix which accurately summarises the study characteristics
(e.g., authors, settings, perspective, threshold, outcome-related parameters and other necessary
information), data needed for quality assessment.
Three authors of the review team independently examined the titles and abstracts identified by the search
strategy and which meet the inclusion criteria. The remaining articles will be rechecked="checked" value="1"
according to the inclusion criteria. The academic literature situated in the cost-effectiveness of 9-valent HPV
vaccination will be reviewed. Exclusion of articles will be based on: ‘not a cost-effectiveness analyses,
‘insufficient cost and cost-effectiveness related data’, or ‘not using nine-valent HPV vaccine’. No language
restrictions will not be applied. 
27. * Risk of bias (quality) assessment.
 
Describe the method of assessing risk of bias or quality assessment. State which characteristics of the
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studies will be assessed and any formal risk of bias tools that will be used.
Two authors independently assess the analytical quality of the preliminary selected studies using appropriate
tools for examining risk of bias. Disagreements on a study inclusion will be resolved by discussion with a
third review author. This study will follow the recommendations set out by research scholar to examine the
likelihood of publication and data availability bias. It will describe the study-level and patient-level
characteristics of the included studies. It will also report the systematic review from the selected papers that
combines the aggregate data.
28. * Strategy for data synthesis.
 
Provide details of the planned synthesis including a rationale for the methods selected. This must not be
generic text but should be specific to your review and describe how the proposed analysis will be applied
to your data.
Two authors (RAM and SAK) independently will be reviewed the titles and abstract. Data from all eligible
studies will be extracted by the same two authors using a standardized data collection form. A matrix will be
developed to summarise the characteristics findings of the studies. Studies will be characterized by
incorporating four themes: (i) study used 9-valent HPV vaccine to examine the cost-effectiveness, (ii) target
population demographic characteristics (e.g., gender-neutral, multiple age cohort immunisation), (iii) study
perspectives, model and economic level of each country, and (iii) model input and outcome-related
parameters. To compare findings across selected studies, incremental cost-effectiveness ratios (ICERs) and
standardized cost-effectiveness will be presented. 
29. * Analysis of subgroups or subsets.
 
State any planned investigation of ‘subgroups’. Be clear and specific about which type of study or
participant will be included in each group or covariate investigated. State the planned analytic approach.
Settings and funding
Study questions and comparator 
Analytical model
Thresholds and perspectives
Vaccine coverage
Vaccine efficacy
Number of vaccine dose and delivery route
Duration of vaccine protection, herd effect and discounting rate
Incremental cost-effectiveness ratio per DALY averted or QALY gained
30. * Type and method of review.
 
Select the type of review and the review method from the lists below. Select the health area(s) of interest for
your review. 
 
Type of review
Cost effectiveness
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Yes
Diagnostic
 No
Epidemiologic
 No
Individual patient data (IPD) meta-analysis
 No
Intervention
 No
Meta-analysis
 No
Methodology
 No
Narrative synthesis
 No
Network meta-analysis
 No
Pre-clinical
 No
Prevention
 No
Prognostic
 No
Prospective meta-analysis (PMA)
 No
Review of reviews
 No
Service delivery
 No
Synthesis of qualitative studies
 No
Systematic review
 Yes
Other
 No
 
 
Health area of the review
Alcohol/substance misuse/abuse
 No
Blood and immune system
 No
Cancer
 Yes
Cardiovascular
 No
Care of the elderly
 No
Child health
 No
Complementary therapies
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No
COVID-19
 No
Crime and justice
 No
Dental
 No
Digestive system
 No
Ear, nose and throat
 No
Education
 No
Endocrine and metabolic disorders
 No
Eye disorders
 No
General interest
 No
Genetics
 No
Health inequalities/health equity
 No
Infections and infestations
 No
International development
 No
Mental health and behavioural conditions
 No
Musculoskeletal
 No
Neurological
 No
Nursing
 No
Obstetrics and gynaecology
 No
Oral health
 No
Palliative care
 No
Perioperative care
 No
Physiotherapy
 No
Pregnancy and childbirth
 No
Public health (including social determinants of health)
 No
Rehabilitation
 No
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Respiratory disorders
 No
Service delivery
 No
Skin disorders
 No
Social care
 No
Surgery
 No
Tropical Medicine
 No
Urological
 No
Wounds, injuries and accidents
 No
Violence and abuse
 No
31. Language.
 
Select each language individually to add it to the list below, use the bin icon  to remove any added in error.
 English
 
There is an English language summary.
32. * Country.
 
Select the country in which the review is being carried out from the drop down list. For multi-national
collaborations select all the countries involved.
 
 Australia
33. Other registration details.
 
Give the name of any organisation where the systematic review title or protocol is registered (such as with
The Campbell Collaboration, or The Joanna Briggs Institute) together with any unique identification number
assigned. (N.B. Registration details for Cochrane protocols will be automatically entered). If extracted data
will be stored and made available through a repository such as the Systematic Review Data Repository
(SRDR), details and a link should be included here. If none, leave blank.
34. Reference and/or URL for published protocol.
 
Give the citation and link for the published protocol, if there is one
 
 
Give the link to the published protocol. 
 
 
Alternatively, upload your published protocol to CRD in pdf format. Please note that by doing so you are
consenting to the file being made publicly accessible.
 
Yes I give permission for this file to be made publicly available
 
Please note that the information required in the PROSPERO registration form must be completed in full even
if access to a protocol is given.
35. Dissemination plans.
 
Give brief details of plans for communicating essential messages from the review to the appropriate
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audiences.
 
Do you intend to publish the review on completion?
 
Yes
36. Keywords.
 
Give words or phrases that best describe the review. Separate keywords with a semicolon or new line.
Keywords will help users find the review in the Register (the words do not appear in the public record but are
included in searches). Be as specific and precise as possible. Avoid acronyms and abbreviations unless
these are in wide use.
 
Cost-effectiveness analysis, 9 or nine-valent HPV vaccine, Cervical Cancer, 
37. Details of any existing review of the same topic by the same authors.
 
Give details of earlier versions of the systematic review if an update of an existing review is being registered,
including full bibliographic reference if possible.
38. * Current review status.
 
Review status should be updated when the review is completed and when it is published. For
newregistrations the review must be Ongoing.
Please provide anticipated publication date
 
Review_Ongoing
39. Any additional information.
 
Provide any other information the review team feel is relevant to the registration of the review.
 
40. Details of final report/publication(s) or preprints if available.
 
This field should be left empty until details of the completed review are available OR you have a link to a
preprint. 
 
 
Give the link to the published review.
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Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Mapping of cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence 
from a systematic review 
1 
ABSTRACT   
Structured summary  2 Introduction 
The World Health Organization (WHO) recommends that programs for human papillomavirus (HPV) vaccination are 
established to be cost-effective before implementation. HPV vaccination is WHO recommended for girls aged 9–13 
years old due to the high burden of cervical cancer. This review examined evidence of the cost-effectiveness 
evaluation of the 9-valent HPV vaccine within a global context.  
Methods 
Searches were performed until 31 July 2019 using two databases: PubMed and Scopus. A combined checklist (i.e., 
WHO, Drummond and CHEERS) was used to examine the quality of eligible studies. A total of 12 studies were 
eligible for review and nearly all were conducted in developed countries. 
Results 
Despite some heterogeneity in approaches to measuring cost-effectiveness, ten studies concluded that 9vHPV 
vaccination was cost-effective while two studies were not. The addition of adolescent boys into immunisation 
program was cost effective when vaccine price and coverage was comparatively low. When vaccination coverage for 
female was more than 75%, gender neutral HPV vaccination was less cost-effective than when targeting only girls 
aged 9–18 years. Multi cohort immunization approach was cost-effective in the age range of 9–14 years but the upper 
age limit at which vaccination was no longer cost-effective requires to be further evaluated. Most dominating 
parameters determined were duration of vaccine protection, time horizon, vaccine price, coverage, healthcare costs, 
efficacy and discounting rates. 
Conclusions 
These findings are anticipated to support policy-makers in extending HPV immunization programs on either 
switching to the 9-valent vaccine or inclusion of adolescent boys’ vaccination or extending the age of vaccination. 
Further, this review also supports extending vaccination to low-resource settings where vaccine prices are 
competitive, donor funding is offered, cervical cancer burden is high and screening options are limited. 
1 
INTRODUCTION   
Rationale  3 Cervical cancer (CC) is both a leading cancer and the leading cause of cancer deaths in women globally [1]. 
Approximately 570,000 new cases of CC were diagnosed in 2018, composing 6.6% of all cancers in women [1]. The 
burden of CC is an alarming issue worldwide, especially in low- and middle-income countries (LMICs). 
Approximately 85% of CC cases and 90% of deaths from CC occur in LMICs [1]. Persistent infections with human 
papillomavirus (HPV) are a key cause of CC and is an established carcinogen of CC [2]. HPV is predominantly 
transmitted to reproductive-aged women through sexual contact [3]. Most HPV infections are transient and can be 
cleared up within a short duration, usually a few months after their acquisition. However, untreated HPV infections 
can continue and evolve into cancer in some cases. There are more than 100 types of HPV infections, and high-risk 
2-3 
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types develop into CC [4]. Thirteen high-risk HPV genotypes are known to be predominantly responsible for 
malignant and premalignant lesions of the anogenital area [5], and these are the leading causes of most aggressive CC 
[6]. Further, HPV is also responsible for the majority of anogenital cervical cancers, including anal cancers (88%), 
vulvar cancers (43%), invasive vaginal carcinomas (70%), and all penile cancers (50%) globally [4].  
 
The burden of CC (i.e., high incidence and mortality rates) globally is preventable through the implementation of a 
primary prevention strategy such as vaccination [1]. There are vaccines that can protect common cancer-causing 
types of HPV and reduce the risk of CC significantly. Three types of HPV vaccines, namely bivalent (Cervarix), 
quadrivalent (Gardasil) and 9-valent vaccine (Gardasil-9), are currently available in the market. Unfortunately, as of 
March 2017, only 71 countries (37% of all countries) have introduced HPV vaccines in their national immunization 
programs for girls, and 11 countries (6%) for both sexes [2]. The first global recommendation on HPV vaccination 
was proposed by the World Health Organization’s Strategic Advisory Group of Experts on Immunization in October 
2008 [7], whereby HPV vaccination was recommended for girls aged 9–13 years old. This recommendation was 
updated in April 2014 [8], with the emphasis to include extended 2-dose HPV immunization for girls aged 9–14 
years, who were not immunocompromised. With the recent licensing of the 9-valent vaccine and the introduction of 
various HPV vaccination strategies, an update on the current recommendations of HPV vaccination are inevitable. 
The goals of the immunisation program are to reduce the acquisition and spread of HPV infections and to achieve 
optimum coverage through effective delivery systems. According to the underlying distribution of HPV infection 
types of CC, the 9vHPV vaccine builds population-level strong immunity against HPV-6, 11, 16, 18, 31, 33, 45, 52, 
and 58 infections [5] that cumulatively contribute approximately 89% of all CCs globally [9]. Considering the 
primary prevention of HPV infection, the 9vHPV vaccine is expected to reduce by an additional 10% the lifetime risk 
of diagnosis with CC in immunised cohorts compared with the 4vHPV vaccine and reduce CC by an additional 52% 
in non-vaccinated cohorts [10]. 
Objectives  4 This review aims to update current evidence on the economic viability of HPV vaccination. In addition, this study 
aims to examine the cost-effectiveness of the 9-valent vaccine when boys are included and when age cohorts are 
varied, all within a global context. This review may be used as comprehensive evidence of general trends on the 
ongoing cost-effectiveness evaluation of HPV vaccine.   
3 
METHODS   
Protocol and registration  5 The protocol has been submitted to PROSPERO, Centre for Reviews and Dissemination, University of 
York. https://www.crd.york.ac.uk/PROSPERO/#recordDetails. This protocol is under review that it is being 
assessed by the editorial team. 
Under 
Review 
Eligibility criteria  6 Three authors of the review team independently examined the titles and abstracts of the articles that met the selection 
criteria. The existing academic literature in the cost-effectiveness of 9-valent HPV vaccination was searched. 
Exclusion of articles was based on: ‘not cost-effectiveness analyses, ‘insufficient cost and cost-effectiveness related 
data’, or ‘not using nine-valent HPV vaccine’. Language restrictions were not applied.  
4 
Information sources  7 The literature search was performed by searching Scopus and PubMed to identify relevant articles following the 
inclusion criteria.  
4 
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Search  8 Search inclusion terms included ‘economic evaluation’, ‘cost-effectiveness’, ‘analysis’, ‘human papillomavirus’, 
‘HPV’, ‘vaccine’, ‘vaccinated’, ‘vaccination’, ‘cervical cancer’, ‘non-valent’, ‘9 or nine-valent’. 
4 
Study selection  9 Three authors of the review team independently examined the titles and abstracts of the articles that met the selection 
criteria (e.g., screening, eligibility), included in systematic review. The existing academic literature in the cost-
effectiveness of 9-valent HPV vaccination was searched. Exclusion of articles was based on: ‘not cost-effectiveness 
analyses, ‘insufficient cost and cost-effectiveness related data’, or ‘not using nine-valent HPV vaccine’. Language 
restrictions were not applied. Four hundred and eighty one articles were yielded through the primary search, 
of which 78 articles were discarded because of duplication. Fifty one articles were considered for full-text 
review after screening by title and abstract. Of these, 12 articles were eligible for the final review. Three 
hundred fifty-two articles were excluded from this study following the inclusion criteria. The reasons for 
exclusion were: conference abstract (n = 58), reviews or editorials or commentary (n = 160), not cost-
effectiveness evaluations (n = 60), did not use 9-valent vaccine (4v-HPV, 2v-HPV; n = 72) and insufficient 
information (n = 2). Finally, 12 articles were included in this review. 
4-5 
Data collection process  10 The study strategy followed a number of checks to ensure consistency of approach, including a discussion about 
discrepancies within the study team. For each outcome and model input parameters, the authors identified the 
proportion of missing observations and compare them with data in the original publication. In addition, a range of 
checks was carried out for all included studies to ensure that all values were reasonable. Datasets were combined to 
form a new master dataset where model input assumptions and outcome-related parameters used in the original 
studies were included. Further, two authors independently assessed the analytical quality of the preliminary selected 
studies using appropriate tools for examining risk of bias. Disagreements on inclusions were resolved by discussion 
with a third review author. 
4 
Data items  11 The study selection process was conducted in line with the PRISMA guidelines [11]. Data extraction was performed 
to develop a comprehensive data matrix which summarises the study characteristics such as authors, settings, 
perspective, threshold, outcome-related parameters and other necessary information. Two authors (RAM and SAK) 
independently reviewed the titles and abstract. Data from all eligible studies were extracted by the same two authors 
using a standardized data collection form. A matrix was developed to summarise the characteristics and findings of 
the studies. Studies were characterized by incorporating four themes: (i) study used 9-valent HPV vaccine to examine 
the cost-effectiveness, (ii) target population demographic characteristics (e.g., gender-neutral and multiple age cohort 
immunisation), (iii) study perspectives, model and economic level of each country, and (iv) model input and 
outcome-related parameters. The review showed evidence in terms of methodological and current practices of cost-
effectiveness evaluation studies such as determination of study research questions; the study perspective adopted, the 
duration of vaccine protection, time horizon and discount rate; explanation of model performed for data analysis; 
model input assumptions behind the estimation of associated costs and outcome parameters; reporting of ICERs; 
most dominant parameters of sensitivity analysis; examination of study conclusions and recommendations as well as 
financial disclosure of the selected studies.       
4-6 
Risk of bias in individual 
studies  
12 The study strategy followed a number of checks to ensure consistency of approach, including a discussion about 
discrepancies within the study team. For each outcome and model input parameters, the authors identified the 
proportion of missing observations and compare them with data in the original publication. In addition, a range of 
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checks was carried out for all included studies to ensure that all values were reasonable. Datasets were combined to 
form a new master dataset where model input assumptions and outcome-related parameters used in the original 
studies were included. Further, two authors independently assessed the analytical quality of the preliminary selected 
studies using appropriate tools for examining risk of bias. Disagreements on inclusions were resolved by discussion 
with a third review author. 
Summary measures  13 Incremental cost-effectiveness ratio (ICERs), DALY averted, QALY gained, case averted, death averted 5 
Synthesis of results  14 Two authors (RAM and SAK) independently reviewed the titles and abstract. Data from all eligible studies were 
extracted by the same two authors using a standardized data collection form. A matrix was developed to summarise 
the characteristics and findings of the studies. Studies were characterized by incorporating four themes: (i) study used 
9-valent HPV vaccine to examine the cost-effectiveness, (ii) target population demographic characteristics (e.g., 
gender-neutral and multiple age cohort immunisation), (iii) study perspectives, model and economic level of each 
country, and (iv) model input and outcome-related parameters.  
To compare findings across the selected studies, incremental cost-effectiveness ratios (ICERs) and standardized cost-
effectiveness were outlined. In terms of standardized cost-effectiveness scenarios, these studies used the heuristic 
cost-effectiveness threshold guided by the WHO [15], wherein an intervention or program was evaluated to be cost-
effective if the ICER/DALYs averted was less than three times a country’s annual per capita Gross Domestic Product 
(GDP). Further, the WHO constructed three broad decision rules: (i) an intervention or program was recommended as 
very cost-effective if ICER/DALYs averted <1 time GDP threshold; (ii) cost-effective if  ICER/DALYs averted ≥ 1 
time GDP threshold and ≤ 3 times GDP threshold; and (iii) not cost-effective if ICER/DALYs averted >3 times GDP 
threshold [16]. Examining whether an ICER offered by any strategy signifies value for money requires comparison to 
a cost-effectiveness threshold (CET). The CET refers to the health effects foregone (i.e., opportunity costs) related to 
resources being devoted to an intervention and consequentially being unavailable for other health-care priorities. 
Policy makers should be willing to invest their limited resources in the strategy offering the greatest health gains. 
CETs for the country with the lowest income in the world, borderline low/low-middle income, borderline low-
middle/upper-middle income, and borderline high-middle/high income were estimated to be 1% to 51% GDP per 
capita, 4% to 51%, 11% to 51%, and 32% to 59%, respectively [17].  
The review showed evidence in terms of methodological and current practices of cost-effectiveness evaluation 
studies such as determination of study research questions; the study perspective adopted, the duration of vaccine 
protection, time horizon and discount rate; explanation of model performed for data analysis; model input 
assumptions behind the estimation of associated costs and outcome parameters; reporting of ICERs; most dominant 
parameters of sensitivity analysis; examination of study conclusions and recommendations as well as financial 
disclosure of the selected studies.       
5 
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Risk of bias across studies  15 The study strategy followed a number of checks to ensure consistency of approach, including a discussion about 
discrepancies within the study team. For each outcome and model input parameters, the authors identified the 
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proportion of missing observations and compare them with data in the original publication. In addition, a range of 
checks was carried out for all included studies to ensure that all values were reasonable. Datasets were combined to 
form a new master dataset where model input assumptions and outcome-related parameters used in the original 
studies were included. Further, three authors independently assessed the analytical quality of the preliminary selected 
studies using appropriate tools for examining risk of bias. Disagreements on inclusions were resolved by discussion 
with a third review author. 
Additional analyses  16 Not applicable  Not 
applicable 
RESULTS   
Study selection  17 Four hundred and eighty one articles were yielded through the primary search, of which 78 articles were 
discarded because of duplication. Fifty one articles were considered for full-text review after screening by 
title and abstract. Of these, 12 articles were eligible for the final review. Three hundred fifty-two articles 
were excluded from this study following the inclusion criteria. The reasons for exclusion were: conference 
abstract (n = 58), reviews or editorials or commentary (n = 160), not cost-effectiveness evaluations (n = 
60), did not use 9-valent vaccine (4v-HPV, 2v-HPV; n = 72) and insufficient information (n = 2). Finally, 
12 articles were included in this review. 
6 
Study characteristics  18 Please see Table 1-3.  Please 
see 
Table 1-3 
Risk of bias within studies  19 Not applicable  Not 
applicable 
Results of individual studies  20 For all outcomes considered as economically viable of 9-valent vaccine across the countries.  8-9 
Synthesis of results  21 Please see Table 3 Table 3 
Risk of bias across studies  22 Not applicable  
Additional analysis  23 Not applicable  
DISCUSSION   
Summary of evidence  24 The HPV vaccination is one of the cornerstones of CC prevention worldwide. This study explored the cost-
effectiveness of 9-valent HPV vaccination, drawing on 12 cost-effectiveness evaluations in order to inform and 
expand knowledge of the potential influence of the next generation of HPV vaccines. Most studies were conducted in 
developed countries while one study was performed in an LMIC. However, in the context of LMICs, the incidence of 
cervical cancer is an alarming public health concern, which warrants an increase in studies which can be extremely 
useful to influence local decision making  [23].  The economic viability of gender-neutral 9-valent HPV vaccination 
was confirmed by three of the selected studies [13, 19, 20]. Cost-effectiveness exploration depends on the coverage 
of vaccination from the perspective of gender. For example, if the vaccine coverage for female recipients is 80% or 
above, the majority of the anogenital CC include vulvar cancers, invasive vaginal carcinomas cancers in female could 
9-10 
201
be prevented. As a result, introduction of 9-valent vaccination for boys is relatively less important compared with girls 
due to the high economic costs involved without the additional benefits gained as per the female population reduction 
in CC, both from the societal and health system perspectives. Therefore, achieving optimal coverage of vaccination in 
females should remain a priority. This is of primary significance for LMICs settings since it is more effective and 
economically viable to prevent CC in females. However, it is also important to note that past studies paid little 
attention to the broader benefits of vaccination among male cohorts to prevent penile, anal, and oropharyngeal 
cancers. Exclusion of these diseases related to males may undermine the effectiveness of reducing CC. Gender-
neutral vaccination might have several benefits including herd protection for boys. Moreover, it may provide indirect 
protection to unvaccinated women and direct protection to homosexual men. Therefore, this vaccination strategy 
should be further considerated in country-level immunization programs by underlining other parameters including 
disease burden, sexual behaviour in a country (e.g., homosexual intercourse), equity, budget impact, and 
affordability.  
Limitations  25 This review has some limitations. The cost-effectiveness evaluation based on GDP based thresholds of 1–3 times of 
GDP per capita lacks country specificity and has little meaning for country-level decision making [24]. It is uncertain 
whether this threshold truly reflects the country’s affordability or societal willingness to pay for additional health gains. 
Additionally, GDP is originally intended to measure the experience of people residing in urban areas and thus, it may 
not actually reflect the experience of the entire population in a country, especially those living in rural areas. Apart 
from an economic standpoint, other factors should be considered for the national immunization program, such as 
budget availability, political issues, cultural influences and availability of healthcare workforce. 
12 
Conclusions  26 Current evidence does not show conclusive proof of greater cost-effectiveness of the new 9-valent vaccine. The 
inclusion of adolescent males in HPV vaccination programs is cost-effective if vaccine price or coverage of females is 
low and if the HPV-associated male diseases are also considered. Multiple age cohort vaccination strategy is likely to 
be cost-effective in the age range of 9–14 years, but the upper age limit at which HPV vaccination is no longer cost-
effective needs to be further evaluated. Vaccine coverage, price, duration of protection and discount rates are 
important parameters for consideration in the uptake of HPV vaccination. Nonetheless, present study findings may be 
used as an evidence to policy-makers and healthcare providers in making recommendations for HPV national 
immunization programs on the new 9-valent vaccine or inclusion of adolescent boys’ vaccination or extending the age 
of immunization, but it should not divert resources from vaccinating the primary target population of girls aged 12 
years or from effective cervical cancer screening programs. 
12 
FUNDING   
Funding  27 This study was conducted without any financial supports.  
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Appendix A4. Media coverage of the PhD research findings  
 
 
This PhD research finding has been shared in the Australian Science Media 
Centre as the following sub-title:  
 
Sub-title of media articles:  
Additional diseases can affect cancer burden in Aussie 
patients 
 
Embargoed until: Publicly released: Thu 13 Feb 2020 at 0600 AEDT | 0800 
NZDT2020-02-13 06:00  
 
Around 63 percent of Aussie cancer patients suffer from at least one chronic 
disease, according to an observational study of over 2,000 cancer patients, and 
this can influence their cancer burden too. The researchers found the most 
prevalent comorbid conditions - relating to a medical condition that happens at 
the same time as another - were arthritis, osteoporosis, high blood pressure, 
hypertension, obesity, depression or anxiety, heart disease and asthma. Age, 
physical activity, nutrition, additional health issues and household income all 
contributed to how well patients were able to manage their diseases, and 
researchers say these risks should be taken into account during cancer treatment 
to help patients get through their treatment as smoothly as possible. 
 
Link to website: 
https://www.scimex.org/newsfeed/additional-diseases-can-affect-cancer-
burden-in-
aussiepatients?fbclid=IwAR0jbr2RxQ7BCT3KmwjFJzyVgxhvYTNMXBHT
VQvyEf_mFFK10SfVTRihs-s 
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